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Summary	
	
Hearing	loss	in	France	affects	about	10%	of	the	population,	namely	over	6	million	people	have	
to	face	hearing	difficulties	in	daily	life.	Older	adults	(over	50	years	old)	are	the	most	concerned	
–	one	third	of	 this	population	–	as	hearing	 loss	arises	during	the	course	of	 life	 (for	88%	of	
French	 people),	 through	 a	 natural	 and	 progressive	 phenomenon	 (presbycusis)	 or	 after	
exposure	to	noise.	In	Europe,	Japan	and	the	United	States,	prevalence	rates	are	comparable	
to	those	in	France.	The	WHO	estimates	this	burden	of	illness	to	currently	concern	more	than	
5%	 of	 the	 global	 population,	 representing	 360	 billion	 people.	 Nowadays,	 hearing	 loss	 is	
considered	as	a	major	public	health	issue	in	the	scientific	literature	and	by	international	health	
agencies.		
	
Not	only	 is	 hearing	 loss	 apparent	 through	direct	 functional	 limitations	 (understanding	and	
communication	difficulties),	but	hearing	impairment	is	also	associated	with	a	higher	frequency	
of	 mental	 disorders,	 cognitive	 decline,	 falls	 and	 even	 mortality,	 independently	 of	 ageing	
effects.	 Hearing	 loss	 could	 precipitate	 the	 elderly	 into	 dependency.	Hearing	 aids	 (‘medical	
devices	 for	 individual	 use’)	 compensate,	 to	 a	 certain	 extent,	 for	 hearing	 impairment	 and,	
furthermore,	ensure	some	individual	rehabilitation:	in	2015,	more	than	2	million	French	people	
owned	hearing	aids	out	of	3	million	eligible	people.	This	technical	solution	should	be	further	
encouraged,	since	1	million	French	people	declare	a	need	for	hearing	aids	but	don’t	get	them.	
	
As	a	result,	improving	access	to	hearing	aids	represents	a	decisive	issue,	not	only	in	terms	of	
financial	accessibility	and	fairness,	but	also	 in	terms	of	efficiency:	hearing	aid	equipment	 is	
presumed	to	reduce	the	significant	implications	of	hearing	loss	on	health	state	and	healthcare	
expenditure	and,	thus,	improve	the	patient’s	quality	of	life.	Yet,	the	hearing	aid	sector	in	France	
has	been	long	characterized	by	a	wait-and-see	public	policy:	the	regulatory	rules	have	been	
frozen	for	several	decades,	due	to	a	lack	of	reliable	information	on	the	expected	added	value	
of	hearing	aids	(in	economic	terms	of	utility).	This	lack	of	information	and	stalled	regulations	
have	resulted	in	several	recent	reports,	released	by	the	Court	of	Accounts	(Cour	des	comptes)	
and	 the	 General	 Inspectorate	 for	 Social	 Affairs	 (Inspection	 générale	 des	 affaires	 sociales),	
which	both	underline	the	urgent	need	to	re-examine	the	access	rules	to	hearing	aids	and	to	
provide,	at	the	same	time	an	economic	assessment	of	this	equipment.		
	
The	main	obstacle	to	hearing	aid	access	in	France	(financial	barrier)	concerns	current	financing	
rules,	and	particularly	the	public	trade-offs	that	have	led	hearing	aids	to	be	classified	in	the	
‘low	 risk’	 category	 and	 practically	 excluded	 from	 socialised	 health	 care.	 This	 classification	
implicitly	indicates	that	the	hearing	aid	is	a	luxury	product	whose	medical	added-value	is	very	
low:	 in	comparison	to	the	trade-offs	 for	drug	classification,	 the	hearing	aid	medical	added-
value	ranges	between	‘low’	and	‘insufficient’,	since	its	observed	reimbursement	rate	is	under	
15%.		Yet,	wide	access	to	hearing	aids	(2/3	in	terms	of	‘real	access’	of	the	eligible	population)	
shows	clearly	that	demand	elasticity	is	low:	they	are	a	necessary	item.	In	general,	the	public	
choice	of	coinsurance	depends	on	the	combination	of	‘low	risk’	and	‘commitment’.	There	is	
only	partial	reimbursement	in	relation	to	‘low	risk’,	or	even	totally	exclusion	from	the	social	
health	care	basket	when	it	does	not	depend	on	the	collective	responsibility	and	implies	an	
individual	judgement	on	the	trade-off	consumption-price	(in	order	to	avoid	over-consumption	
or,	in	economics,	the	‘moral	hazard’	risk).	Yet,	not	only	is	access	significant	despite	the	out-of-
pocket	payment,	but	moreover	 its	health	consequences	as	well	as	 its	economic	 impact	are	
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likely	to	be	major.	The	cost	to	society	of	hearing	aid	renunciation,	in	terms	of	quality	of	life,	
expenditure	 and	 social	 inequalities	 is	 in	 total	 opposition	 to	 the	 objectives	 assigned	 to	 the	
French	health	system.		
	
Hearing	loss:	outline	data		
	
Disabling	hearing	loss	prevalence	is	estimated	today	to	range	between	8.6%	and	11.2%	of	the	
overall	French	population.	The	analysis	of	hearing	aid	access	shows	that	30%	to	35%	of	hearing	
impaired	people	are	equipped,	namely	2	million	out	of	6	million	people.	This	gap	is	reduced	
when	considering	people	being	equipped	and	people	eligible	for	hearing	aids:	whatever	the	
expert	assessments,	survey	data	or	empirical	statements	(monographs	by	country),	only	half	
of	hearing	impaired	people	would	be	eligible	for	hearing	aids,	thus	3	million	people	in	France.	
Thus,	 65%	of	 eligible	 French	people	are	hearing	aid	owners	whereas	35%	of	 them	 remain	
unequipped.			
	
There	are	 two	main	 reasons	which	 can	explain	 this	 renunciation:	 a	 low	public	 and	private	
coverage	(provision),	and	a	lack	of	information.	Indeed,	the	average	price	for	one	hearing	aid	
comes	 to	1,535	euros,	and	3,070	euros	 for	binaural	equipment.	But	 this	expense	 is	poorly	
covered	by	the	National	Health	Insurance	(8%)	and	poorly	reinsured	by	complementary	health	
insurances	(30%),	leaving	a	high	out-of-pocket	payment	for	the	adult	insured	(62%),	namely	
950	euros	per	apparatus.	The	price	for	hearing	aid	equipment	comprises	both	the	device	and	
the	hearing	aid	professional’s	counselling	and	follow-up	services.		
	
For	the	hearing	aid	owners,	the	equipment	has	an	average	duration	of	5	to	6	years,	during	
which	 a	 qualified	 check-up	 is	 ensured	 by	 the	 hearing	 aid	 professional.	 The	 quality	 of	 the	
equipment	as	well	as	the	quality	of	the	follow-up	should	influence	hearing	aid	efficiency,	user	
satisfaction	and	beneficial	 compliance.	 This	hypothesis	 seems	 to	be	 confirmed	 throughout	
international	comparisons:	in	countries	where	the	access	rate	to	hearing	aids	is	higher,	the	
social	 coverage	 is	 better	 for	 downmarket	 or	 middle	 market	 equipment.	 However,	 these	
countries	don’t	necessarily	have	greater	rates	of	real	HAs	users	(i.e.	rates	considering	effective	
eligible	 people	 for	 hearing	 aids	 and	effective	wearing	 of	 hearing	 aids).	 Taken	 thus,	 France	
would	present	a	real	rate	of	use	close	to	those	of	the	United	Kingdom,	Germany	and	Norway	
and	starting	from	very	different	situations	in	terms	of	financial	access	to	equipment.	If	there	
is	room	for	improvement	in	France	regarding	the	need	for	hearing	aid	equipment	–	due	to	
financial	 impediment	 -	 there	 is	 also	 room	 for	 growth	 in	 countries	where	 hearing	 aids	 are	
(almost)	freely	delivered	but	where	the	compliance	isn’t	sufficiently	performant.	A	review	of	
financial	rules	relating	to	hearing	aids	has	to	consider	the	compliance	factors	determining	the	
effective	use	of	equipment	and,	thus,	the	level	of	satisfaction	for	hearing	aid	users.		
	
As	 concerns	 the	 payment	 schemes	 for	 hearing	 aid	 professionals,	 an	 economic	 analysis	 is	
necessary,	taking	into	account	their	incentive	properties.	In	order	to	regulate	the	hearing	aid	
sector	and	to	design	an	incentive	payment	for	hearing	aids,	a	trade-off	is	necessary	between	
the	 objectives	 of	 expenditure	 control,	 health	 care	 quality	 and	 freedom	 of	 choice,	 in	 a	
hypothetic	 framework	 assuming	 a	 higher	 coverage	 of	 hearing	 aids.	 There	 are	many	 tools	
allowing	us	to	realise	the	optimal	trade-off	 for	public	 financing,	but	a	cautious	approach	 is	
required	 regarding	 the	 issue	 of	 a	 possible	 decoupling	 of	 the	 device	 and	 the	 service.	 This	
decoupling	model	brings	up	adverse	effects	which	are	similar	to	those	of	‘cost-plus’	payment,	
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leading	 to	 increasing	 prices	 and	 putting	 patients’	 compliance	 at	 stake,	 i.e.	 affecting	 the	
therapeutic	efficiency	of	hearing	aids	for	some	of	them.	At	the	same	time	that	recourse	to	
prospective	payment	systems	is	increasingly	implemented	for	pricing	in	health	systems,	and	
as	 growing	 attention	 is	 paid	 to	 patients’	 empowerment,	 this	 concept	 of	 divisibility	
device/service	 falls	within	a	backwards	economic	approach	 in	 terms	of	optimal	 incentives.	
International	comparisons	highlight	the	impact	of	coverage	and	health	care	organisation	on	
hearing	aid	access,	equipment	renewal	and	patients’	compliance.	They	show	also	that	French	
prices	for	one	hearing	aid	are	very	similar	to	those	of	other	European	countries.		
	
Health	and	economic	consequences	of	hearing	loss:	impact	study	
	
International	medical	 scientific	 literature	as	well	as	French	survey	data	are	profuse	on	 the	
burden	 of	 illness	 topics	 and	 these	 start	 to	 provide	 evidence-based	 studies	 on	 the	 causal	
alleged	connection	between	hearing	loss	and	health	state	degradation.	Disabling	hearing	loss	
(or	moderate	to	total	auditive	functional	limitations),	by	reducing	the	person’s	communication	
capacities,	 rebounds	 significantly	 onto	 the	 whole	 dimensions	 of	 health	 state	 (mobility,	
autonomy,	daily	activities,	pain/discomfort,	anxiety/depression)	through	a	succession	of	chain	
reactions,	the	main	ones	being	social	 isolation,	cognitive	decline,	suffering	at	work,	mental	
troubles	and	falls.	Hearing	loss	represents	a	major	impairment	which,	by	affecting	more	than	
six	million	(often	older)	French	people,	not	only	has	deleterious	effects	on	quality	of	life	but	
also	leads	to	additional	health	and	social	care	expenditure	for	society	as	a	whole.		
The	scientific	literature	unambiguously	reports	the	negative	waterfall	effects	of	hearing	loss,	
but	also	shows	the	beneficial	effects	of	hearing	aid	wearing:	reduced	mortality	risk;	improved	
psycho-social	health	state;	and	a	normalising	effect	on	cognitive	decline	risk.	Publications	also	
point	out	that	this	favourable	impact	on	mental	health	is	appreciable	starting	from	the	first	3	
months	of	 equipment.	 In	 the	 same	perspective,	 some	 studies	 show	 the	 reliability	 and	 the	
efficiency	of	earlier	screening	for	people	at	the	end	of	their	working	lives,	screening	those	who	
are	old	enough	to	justify	secondary	prevention,	but	who	are	still	young	enough	to	benefit	from	
it	since	their	hearing	loss	level	is	moderate	to	severe.	Earlier	screening	appears	to	be	a	very	
efficient	strategy	regarding	cost	and	quality	of	life.	It	should	be	implemented	over	the	course	
of	medical	consultations,	in	the	form	of	two	short	questions	without	additional	costs	to	general	
practice.		
	
Starting	from	this	literature	and	the	survey	data,	two	scenarios	for	economic	assessment	of	
hearing	loss	are	proposed.	The	first	one	gives	rough	estimates	for	intangible	costs	related	to	
quality	of	life	degradation	in	France.	The	aim	is	to	assess	the	monetary	value	of	lost	healthy	
years	 by	 valuing	 them	 in	 terms	 of	 the	 implicit	 price	 of	 human	 life.	 Based	 on	 realistic	
assumptions,	this	estimation	draws	an	image	of	saved	costs	thanks	to	hearing	aid	equipment	
or	 compliance,	 as	 well	 as	 the	 economic	 burden	 of	 hearing	 loss	 related	 to	 its	 prevalence:	
without	 equipment,	 this	 burden	 would	 amount	 to	 23.4	 billion	 euros.	 The	 real	 rate	 of	
equipment	(effective	access	and	effective	use	of	hearing	aids)	reduces	this	burden	by	30%,	
whereas	 the	 target	 equipment	 rate	 (i.e.	 50%	of	hearing	 impaired	people	 related	 to	 actual	
compliance)	would	lighten	the	burden	by	40%.			
	
The	 second	scenario	 relies	on	 several	assumptions	 in	order	 to	estimate,	on	 the	one	hand,	
medical	 costs	 related	 to	hearing	 loss	without	equipment	 and,	on	 the	other	hand,	 average	
scores	of	 lost	utility	 related	 to	quality	of	 life.	Both	dimensions	are	graduated	according	 to	
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French	 hearing	 loss	 prevalence	 rates	 by	 age	 groups	 and	 by	 severity	 levels,	 then	 they	 are	
connected	with	the	rate	of	eligible	people	for	hearing	aids	but	who	are	not	being	equipped.	
For	this	specific	population,	we	assume	that	a	gain	should	be	expected	in	quality	of	life	and	in	
cost	 savings,	 if	 equipment	were	delivered	 for	 6	 years.	Assessing	 these	 values	 allows	us	 to	
roughly	estimate	a	range	for	the	incremental	cost-utility	ratio,	expressing	the	cost	to	pay	in	
order	to	gain	one	additional	healthy	year	for	the	period.	Yet,	through	this	simple	simulation,	
the	target	strategy	(i.e.	equipment	for	eligible	population	not	accessing	hearing	aids)	would	
be	dominant,	even	taking	into	account	the	compliance	rate	that	reduces	quality	of	life	gains	
and	costs	savings:	the	overall	cost	of	this	additional	equipment	would	be	1.5	billion	euros,	with	
48,000	QALYs	gained	and	with	cost	savings	worth	1.7	billion	euros,	namely	a	 ICER	of	 -	830	
euros/QALY.	In	other	words,	the	target	strategy	of	‘all	eligible	people	are	equipped’	saves	costs	
and	provides	an	increased	quality	of	life,	and	is	thus	the	dominant	strategy.	This	entire	case	
study,	which	relies	on	acceptable	assumptions,	underlines	the	requirement	for	a	substantial	
economic	assessment	that	would	corroborate	these	results,	that	is	the	highly	efficient	target	
strategy	 that	 ‘all	 eligible	 hearing	 impaired	 people	 are	 equipped’,	 since	 the	 annual	 overall	
expenditure	of	the	hearing	aid	sector	comes	close	to	1	billion	euros.	However,	it	remains	to	
solve	 the	 touchy	 question	 of	 hearing	 aid	 financing	 likely	 to	 support	 access	 to	 them,	 and	
especially	 the	question	of	 the	relative	financial	contributions	of	payers,	as	seen	 in	the	first	
section	of	the	report.	Moreover,	 if	 the	National	Health	 Insurance	could	greatly	 increase	 its	
financial	role	in	hearing	aid	reimbursement,	we	would	anticipate	a	bounce	effect	for	people	
being	 equipped	 but	 having	 postponed	 hearing	 aid	 renewing.	 This	 effect	 would	 inevitably	
increase	the	budget	impact	of	hearing	aid	access.	That’s	why	an	overall	scenario	has	to	be	set	
up,	through	prospective	cost-efficiency	assessments,	by	collecting	useful	data	in	sequential	or	
regular	surveys	based	on	the	working	and	older	population,	in	order	to	infer	the	differential	
cost-utility	ratio	between	strategies.	This	overall	scenario	would	be	completed	by	estimating	
the	budget	impact	of	hearing	aid	equipment	depending	on	several	coverage	scenarios	from	
the	National	Health	Insurance’s	point	of	view.		
	
Coming	out	of	this	overview,	the	health	policy	for	secondary	prevention,	that	could	consist	of	
screening	and	equipping	hearing	impaired	people	with	hearing	aids,	is	non-existent	regarding	
public	reimbursement.	National	Health	Insurance,	by	covering	only	8%	of	hearing	aid	price	for	
adults,	has	almost	excluded	hearing	loss	from	its	management	policy	for	health	risk,	leaving	
the	out-of-pocket	payment	to	complementary	insurance	bodies	and	above	all	to	patients.	In	
fine,	families,	close	relatives	and	the	whole	society	bears	the	costs	of	this	impairment,	as	well	
as	for	the	loss	of	autonomy	since	one	third	of	the	eligible	population	for	hearing	aids	don’t	get	
to	them.	Moreover,	inequalities	relating	to	the	rights	of	those	insured	with	complementary	
health	bodies,	their	revenue	and	ability	to	pay	for	equipment	contribute	to	maintain	these	
social	inequalities	in	health,	by	the	renouncement	effect.	These	statements	would	impose	the	
need	for	an	urgent	examination	of	the	regulatory	rules	for	the	hearing	aid	sector	in	France,	at	
a	moment	where	ageing,	and	listening	to	amplified	music	among	the	young	risks	contributing	
to	aggravated	hearing	loss	prevalence	in	France.		
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Introduction	
	
In	France,	over	6	million	people	have	disabling	hearing	loss,	leading	to	difficulties	in	daily	life.	
Older	adults	(over	50	years	old)	are	the	most	concerned	–	one	third	of	this	population	–	as	
hearing	 loss	 arises	 during	 life	 course	 (for	 88%	 of	 French	 people),	 through	 a	 natural	 and	
progressive	phenomenon	(presbycusis)	or	after	exposure	to	noise.		
	
Not	only	 is	 hearing	 loss	 apparent	 through	direct	 functional	 limitations	 (understanding	and	
communication	difficulties),	but	hearing	impairment	is	also	associated	with	a	higher	frequency	
of	 mental	 disorders,	 cognitive	 decline,	 falls	 and	 even	 mortality,	 independently	 of	 ageing	
effects.	 Hearing	 loss	 could	 precipitate	 the	 elderly	 into	 dependency.	 Medical	 scientific	
literature	is	profuse	on	this	topic	and	starts	to	provide	evidence-based	studies	on	the	causal	
alleged	connection	between	hearing	loss	and	health	state	degradation.	Moreover,	it	highlights	
the	burden	of	illness	and	its	impact	on	healthcare	consumption	and	expenditure.	Therefore,	
hearing	loss	is	a	major	topic	for	public	health.		
	
Hearing	aids	compensate,	to	a	certain	extent,	for	hearing	loss	and,	furthermore,	ensure	some	
individual	 rehabilitation:	 in	 2015,	more	 than	 2	million	 French	 people	 owned	 hearing	 aids.	
However,	this	technical	solution	should	be	further	encouraged,	since	1	million	French	people	
are	eligible	for	hearing	aids	but	don’t	get	them.	There	are	two	main	reasons	which	can	explain	
this	 renunciation:	a	 low	public	and	private	coverage	 (provision),	and	a	 lack	of	 information.	
Indeed,	 the	 average	 price	 for	 one	 hearing	 aid	 comes	 to	 1,535	 euros,	 and	 3,070	 euros	 for	
binaural	equipment.	But	this	expense	is	poorly	covered	by	the	National	Health	Insurance	and	
poorly	reinsured	by	complementary	health	insurances,	leaving	a	high	out-of-pocket	payment	
for	the	insured.		
As	a	result,	improving	access	to	hearing	aids	represents	a	decisive	issue,	not	only	in	terms	of	
financial	accessibility	and	fairness,	but	also	 in	terms	of	efficiency:	hearing	aid	equipment	 is	
presumed	to	reduce	the	significant	implications	of	hearing	loss	on	health	state	and	healthcare	
expenditure	 and,	 thus,	 improve	 the	 patient’s	 quality	 of	 life.	 Yet,	 the	 hearing	 aid	 sector	 in	
France	has	been	long	characterized	by	a	wait-and-see	public	policy:	the	regulatory	rules	have	
been	frozen	for	several	decades,	due	to	a	lack	of	reliable	information	on	the	expected	added	
value	 of	 hearing	 aids	 (in	 economic	 terms	 of	 utility).	 This	 lack	 of	 information	 and	 stalled	
regulations	have	resulted	in	several	recent	reports,	released	by	the	Court	of	Accounts	(Cour	
des	comptes)	and	the	General	Inspectorate	for	Social	Affairs	(Inspection	générale	des	affaires	
sociales),	which	both	underline	the	urgent	need	to	re-examine	the	access	rules	to	hearing	aids	
and	to	provide,	at	the	same	time,	an	economic	assessment	of	this	equipment.		
	
Economic	 assessment	 of	 hearing	 aids	 should	 corroborate	 their	 efficiency	 and,	 if	 relevant,	
should	lead	to	a	correction	of	the	scope	for	social	reimbursement,	as	far	as	the	budget	impact	
on	National	Health	Insurance	is	affordable.	Such	an	assessment	requires	thinking	in	terms	of	
utility	and	quality	of	life	for	people	wearing	hearing	aids	and	to	compare	the	cost-utility	ratio	
of	equipment	with	respect	to	non-equipment.	In	line	with	these	questions,	another	issue	is	
the	reliability	of	hearing	loss	screening	in	order	to	prevent	early	loss	of	autonomy.	Should	a	
generalised	 screening	 program	 be	 considered	 appropriate	 for	 people	 at	 the	 end	 of	 their	
working	lives?	If	so,	under	which	conditions	and	for	what	efficiency?		
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The	purpose	of	the	present	study	is	to	gather	and	review	the	major	papers	in	the	scientific	
literature	as	well	as	the	grey	literature	released	on	this	topic	over	the	period	2005-2015.	We	
put	 this	 literature	 into	 perspective	 using	 some	 economic	 tools	 in	 order	 to	 propose	 an	
economical	 framework	 for	 regulatory	 analysis	 of	 the	 hearing	 aid	 sector.	 Then,	 we	 bring	
forward	rough	estimates	for	the	cost	and	the	utility	of	hearing	aids.		
	
This	 report	 is	 structured	 in	 two	main	 sections	 as	 follows:	 section	 1	 focuses	 specifically	 on	
hearing	loss	in	France	and	presents	the	rules	which	organise	access	and	delivery	of	hearing	aid	
equipment.	An	international	comparison	for	key	countries	in	Europe	is	addressed	when	similar	
collection	of	data	is	available.	Section	2	outlines	the	global	burden	of	hearing	loss,	on	the	basis	
of	key	papers	released	in	the	medical	scientific	 literature.	As	an	extension	of	this	survey,	a	
hypothetical	scenario	for	economic	assessment	 is	set	out	on	the	basis	of	available	data	for	
France.		
	 	
	 11	
1 Hearing	loss:	outline	data	
	
Hearing	loss	prevalence	in	France	and	its	consequences	on	health	state	emphasize	this	public	
health	issue,	even	though	there	are	differing	definitions:	approximately	16%	of	French	people	
report	some	difficulties	with	hearing	(in	the	broadest	sense,	defined	by	‘auditive	functional	
limitations’)	whereas	disabling	hearing	loss	affects	8.6%	to	11.2%	of	French	people	(defined	
by	‘disabling	hearing	loss’)	(Haeusler	and	al.,	2014	;	EHIMA,	2015)1.	Hearing	loss	affects	mostly	
adults	aged	50	years	and	over	(progressive	hearing	impairment	with	older	age	or	presbycusis).		
	
In	the	general	case,	hearing	loss	alleviation	relies	on	the	use	of	hearing	aids	(HAs),	which	are	
a	 ‘medical	 device	 for	 individual-use’	 in	 the	 French	 classification.	 The	 analysis	 of	 access	 to	
hearing	 aids	 is	 tricky	 because	 not	 only	 is	 available	 data	 lacking,	 but	 values	 are	 variable	
between	 sources,	 surveys	 or	 databases.	 There	 is	 an	 obvious	 and	 important	 gap	 between	
people	being	 fitted	with	 a	prosthesis	 (in	 the	 study,	 ‘hearing	 aid	owners’)	 and	people	with	
disabling	hearing	loss:	only	30%	to	35%	of	the	latter	are	hearing	aid	owners2.		
	
The	average	price	 for	one	hearing	aid	 (HA)	 is	around	1,535	euros,	while	 social	 coverage	 is	
particularly	low	(120	euros	for	one	ear,	that	is	a	basis	for	social	reimbursement	of	200	euros	
associated	with	a	coinsurance	rate	of	60%).	Hence,	the	gross	out-of-pocket	sum	is	 likely	to	
represent	a	high	barrier	to	access,	in	that	complementary	insurance	covers	a	minor	part	of	it.	
There	 is	 also	 significant	 inequality	between	beneficiaries	due	 to	 the	diversity	of	 contracts.	
Indeed,	the	net	out-of-pocket	sum	is	estimated	to	be	62%	of	the	total	price	(i.e.	958	euros	
apiece)	 and	 is	 associated	 with	 healthcare	 renunciation.	 For	 the	 hearing	 aid	 owners,	 the	
equipment	has	an	average	duration	of	5	years,	during	which	a	qualified	check-up	is	ensured	
by	 the	hearing	 aid	 professional:	 the	 price	 comprises	 both	 the	device	 and	 the	 service.	 The	
quality	 of	 the	 equipment	 as	 well	 as	 the	 quality	 of	 the	 follow-up	 should	 influence	 user	
satisfaction	and	beneficial	compliance.		
	
This	hypothesis	seems	to	be	confirmed	throughout	international	comparisons:	starting	from	
the	data	of	the	EHIMA	(2015)	and	on	the	basis	of	the	methodology	of	Alcimed-CNSA	(2009),	
we	can	state	the	fact	that	in	countries	where	access	rate	to	hearing	aids	is	higher,	the	social	
coverage	is	better	for	downmarket	or	middle	market	equipment.	However,	these	countries	
don’t	necessarily	have	greater	rates	of	real	HAs	users	(i.e.	rates	considering	effective	wearing	
of	hearing	aids).	Taken	thus,	France	would	present	a	real	rate	of	use	close	to	61%	(combining	
the	rate	of	eligible	people	for	hearing	aids	and	the	rate	of	effective	use),	a	rate	similar	to	those	
of	the	United-Kingdom,	Germany	and	Norway	and	starting	from	very	different	situations	in	
terms	of	financial	access	to	equipment.	If	there	is	room	for	improvement	in	France	regarding	
the	need	for	hearing	aid	equipment	–	due	to	financial	 impediment	-	there	 is	also	room	for	
growth	 in	 countries	 where	 hearing	 aids	 are	 (almost)	 freely	 delivered	 but	 where	 the	
																																																								
	
1	There	is	some	variability	in	estimations	of	the	number	of	people	affected	by	hearing	loss,	depending	on	the	
fields	of	surveys	and	their	methodology.	In	this	study,	we	qualify	hearing	loss	in	the	broad	sense	when	it	includes	
slight	limitations	not	associated	with	a	need	for	hearing	aids,	and	disabling	hearing	loss	(or	hearing	loss	in	the	
strict	sense	of	the	term)	when	the	impairment	has	an	impact	upon	the	daily	activities.		
2	As	 shown	 further,	 these	estimations	are	widely	 variable	 in	 surveys.	Moreover,	 the	 report	will	 focus	on	 the	
difference	between	people	able	to	be	equipped	and	people	with	disabling	hearing	loss.	Hence,	these	estimations	
have	to	be	taken	as	approximations.		
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compliance	 isn’t	sufficiently	performant.	A	review	of	financial	rules	relating	to	hearing	aids	
has	to	consider	the	compliance	factors	determining	the	effective	use	of	equipment	and,	thus,	
the	level	of	satisfaction	for	hearing	aid	users.	A	trade-off	has	to	be	undertaken	between,	on	
the	one	hand,	financial	access	and,	on	the	other	hand,	suppliers’	and	users’	commitment	to	
hearing	aid	use.		
	
1.1 Prevalence	of	hearing	loss	and	auditive	functional	limitations	in	France		
	
From	a	technical	and	medical	perspective,	hearing	loss	refers	to	ranges	of	decibels	(dB)	that	
cannot	be	heard	by	a	person:	ranging	between	0	to	20	dB,	audition	is	normal	or	sub-normal;	
21-40	dB,	impairment	is	slight;	41-70	dB,	impairment	is	moderate;	71-90	dB,	impairment	is	
severe;	91-119,	impairment	is	profound	and	beyond	120	dB	impairment	is	total	(deafness)3.		
	
The	Worldwide	Health	Organisation	(WHO)	suggests	a	categorisation	of	hearing	impairment	
into	five	grades	(table	1):	
	
Table	1	–	Grades	of	impairment	in	WHO	classification	
	
Source:	Shield,	2006.	Always	reference	values	on	www.who.int	(8	March	2016)	
	
	
Shield	(2006)	underlined	the	variability	of	definitions	and	levels	of	hearing	impairment	severity	
between	 health	 organisations,	 as	 shown	 in	 table	 2.	 This	 variability	 is	 one	 of	 the	 factors	
explaining	the	differences	of	hearing	loss	prevalence	in	the	same	country,	according	to	the	
national	and	international	sources.		
	
	
	
	
	 	
																																																								
	
3	Classification	of	 the	 international	committee	of	audio-phonology	–	BIAP	 (cf.	www.biap.org	on	8th	of	March	
2016).	Leusie’s	study	(2015)	brings	up	the	idea	of	“very	slight	hearing	loss”	or	“subclinical	hearing	loss”,	a	grade	
of	hearing	loss	being	between	15	and	25	dB,	from	which	it	would	be	appropriate	to	take	action.	Cf.	p123-124.						
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Table	2	–	Variability	of	reference	values	in	hearing	impairment	classifications	
	
WHO:	Worldwide	Health	Organisation	;	ANSI:	American	National	Standards	Institute	;	RNID	:	Royal	National	Institute	of	Deaf	
and	 hard	 of	 hearing	 people	;	 BSI	:	 British	 Society	 of	 Audiology	;	 NIDCD	:	 National	 Institute	 of	 Deafness	 and	 other	
Communication	Disorders.		
Source:	Shield,	2006	
	
The	 quantitative	measure	 of	 hearing	 levels	 in	 dB,	 performed	 by	 the	 ear,	 nose	 and	 throat	
specialist	(ENT	specialist)	or	the	hearing	aid	professional,	doesn’t	allow	for	a	direct	estimation	
of	the	hearing	loss	prevalence	in	the	general	population,	as	far	as	this	measure	occurs	when	a	
consultation	 is	 effective	 (in	others	words,	 there	 is	 a	 long	 time	between	 the	occurrence	of	
disabling	 hearing	 loss	 and	 healthcare	 access	 and	 the	 needs	 for	 hearing	 aids	 cannot	 be	
appreciated	only	through	health	care	consumption).	The	estimation	of	hearing	loss	prevalence	
relies	 in	 general	 on	 population	 studies	 and	 self-reported	 qualitative	 data.	 The	 ten-yearly	
French	 survey	 ‘Handicap-Santé’	 (i.e.	 ‘Impairment-Health’)	 2008,	 carried-out	by	 two	French	
national	 institutes	of	statistics,	the	INSEE	and	the	DREES,	and	released	in	2014,	is	the	main	
declarative	French	survey	allowing	an	estimation	of	hearing	loss	prevalence	and	an	appraisal	
of	 auditive	 functional	 limitations	 (Haeusler,	 Mordier,	 2014;	 Haeusler	 and	 al.,	 2014;	 InVS,	
2015)4.		However,	given	that	the	data	were	collected	in	2008,	it	is	advisable	to	bring	them	up	
to	date,	on	the	basis	of	a	few	hypotheses	and	on	other	recent	data	sources,	as	follows.		
	
1.1.1 Estimations	of	hearing	loss	prevalence	in	“Handicap-Santé”	French	survey	2008	
	
Following	the	“Handicap-Santé”	survey	2008,	hearing	impairment	is	recognised	either	through	
individual	statements	of	using	hearing	aids	or	statements	of	a	need	for	hearing	aid	equipment.	
In	this	way,	1,112,000	people	were	hearing	aid	owners	 in	2008,	whereas	2,043,000	people	
declared	a	need	for	hearing	aid	equipment	(that	is	35%	of	equipment	for	the	whole	population	
eligible	for	hearing	aids).	This	population	represented	more	than	3	million	people	affected	by	
a	level	of	hearing	loss	significantly	damaging	their	health	status	(table	3).		
	
	
	
	
	
																																																								
	
4 	Data	 are	 gathered	 from	 several	 surveys,	 of	 which	 the	 latest	 in	 France	 is	 the	 “Handicap-Santé”	 survey,	
implemented	in	2008.	Estimated	statistics	reported	by	Haeusler	and	Mordier	(2014)	rely	on	a	panel	sample	of	
28,500	people	and	are	extrapolated	to	the	French	whole	population.	Estimated	statistics	reported	by	Haeusler	
and	al.	(2014)	are	based	on	qualitative	statements	of	30,000	people	in	ordinary	households	and	9,000	people	in	
institutions.	
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Table	3	–	Number	of	people	who	are	hearing	aid	users	or	declaring	a	need	for	hearing	aids	in	2008	
	
Source:	DREES,	2014		
	
Moreover,	the	number	of	people	declaring	at	least	one	hearing	impairment	rises	to	more	than	
7	million	–	being	11.2%	of	the	French	population	–	provided	that	every	type	of	disability	 is	
included	in	the	survey	(table	4).	Therefore,	from	deductions	based	on	the	data	in	table	3	and	
table	4,	the	rate	of	equipment	relative	to	disabling	hearing	people	is	close	to	15.8%	in	2008.		
	
Table	4	–	Number	of	people	declaring	hearing	impairments		
	
Source:	DREES,	2014		
	
In	the	2008	survey,	disabling	hearing	loss,	on	the	one	hand,	is	estimated	directly	by	‘hearing	
impairment’	(hearing	aids	users/declared	need	for	a	hearing	aid,	hearing	disability)	and,	on	
the	other	hand,	is	assessed	indirectly	by	‘auditive	functional	limitations’	(for	instance,	difficulty	
to	hear	in	a	conversation	with	several	participants).	The	prevalence	data	are	then	reckoned	
by	the	authors	on	this	double	source	(hearing	impairment	and	auditive	functional	limitations).	
Auditive	 functional	 limitations	 (AFL)	 are	 classified	 into	 four	 levels	 of	 severity	 in	 order	 to	
identify	them	in	the	survey	(table	5).		
	
Table	5	–	Reference	groups	of	severity	for	auditive	functional	limitations	(AFL)	
	
Source:	DREES,	2014		
	
Are you a hearing aids user ? Number of people % of total population
Yes 1 112 000 1.8%
No, but I would need to use them 2 043 000 3.2%
No and I don't need them 59 875 000 94.9%
Doesn't know, withdraws from answer 54 000 0.1%
Total population 63 084 000 100%
Hearing loss : do you have some hearing troubles ? (hard of 
hearing, tinnitus). If yes, which ones ?
Number of 
people
% of the total 
population
Deafness 182 000 0.3%
Hard of hearing 1 062 000 1.7%
Single-sided deafness 974 000 1.5%
Other hearing loss but neither hard of hearing, nor deaf 3 153 000 0,05
Other hearing trouble (tinnitus, buzzing, ringing in the ears…) 2 012 000 3.2%
At least one hearing impairment 7 056 000 11.2%
Level of AFL Rule for findings
Very severe or total
Cannot hear at all a conversation with several participants and declares him/herself to be
deaf (single-sided or double-sided) or hard of hearing
Severe
Has a lot of difficulties to hear a conversation with several participants or cannot hear at
all a conversation with several people and declares a hearing impairment other than
deafness (single-sided or double-sided) or hard of hearing
Moderate
Has some difficulties to hear a conversation with several participants or being a person
equipped with hearing aids and able to follow a conversation without any difficulty or
being a person hard of hearing or being a person single-sided deaf having declared a
need for hearing aids and following a conversation without any difficulty
Slight
Has some difficulties to hear a conversation, but hasn't a declared hearing impairment or
hasn't difficulties to hear a conversation and declares a hearing impairment such as tinnitus
or ringing in the ears and doesn't use hearing aids
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In	2008,	10	million	people	were	affected	by	AFL:	this	was	16.1%	of	the	main	population.		
	
Moderate	to	severe	AFL	(three	levels	of	severity	higher)	affect	5.4	million	people	(8.6%	of	the	
general	population)	and	16%	of	them	have	a	social	recognition	of	invalidity	or	disability	for	
their	 impairment	 (amongst	 people	 younger	 than	 60	 years).	 Among	 this	 social	 recognition	
group,	only	2%	are	found	in	an	institution	(whereas	10%	of	people	with	very	severe	or	total	
AFL	live	in	an	institution)5.		
	
Table	6	–	Whole	prevalence	of	auditive	functional	limitations	(AFL)	due	to	hearing	loss	in	France	
	
Source:	DREES,	2014		
	
The	overall	AFL	concern	15.9	%	of	people	living	at	home,	18%	of	people	living	in	institutions	
for	disabled	persons	and	42%	of	people	living	in	institutions	for	the	elderly6.	In	other	words,	
people	living	in	institutions	are	more	frequently	affected	by	AFL.		
	
1.1.2 Estimated	data	for	hearing	loss	prevalence	in	2015	
	
The	Eurotrak	data	2015	released	by	the	EHIMA	(European	Hearing	Instrument	Manufacturers	
Association)	are	based	on	a	qualitative	survey	relying	on	a	representative	sample	of	14,824	
French	 people.	 Hearing	 loss	 prevalence	 was	 stated	 to	 be	 around	 9.3%	 of	 the	 general	
population	(11.4%	for	people	older	than	18),	and	this	estimation	has	been	steady	since	2009	
(2009:	10.4%;	2012:	9.4%)7.		
	
																																																								
	
5	As	underlined	by	the	DREES	(Haeusler	and	al.,	2014),	the	“Handicaps-Incapacités-Dépendances”	(‘Impairments-
Incapacities-Dependencies’)	 1998	 survey	 assessed	 5.2	 million	 people	 affected	 by	 moderate	 to	 total	 hearing	
difficulties,	 including	303,000	people	 concerned	by	very	 severe	 to	 total	AFL.	These	estimations	appear	 to	be	
steady	over	time,	despite	some	differences	in	the	assessment	method.		
6	Thus,	36.2%	of	people	 in	 institutions	are	affected	by	slight	 to	total	AFL.	However,	 the	DREES	considers	 that	
there	is	probably	an	understatement	of	hearing	loss	among	the	elderly	in	institutions,	because	hearing	loss	might	
be	judged	as	“normal”	in	relation	to	other	impairments	which	are	likely	to	be	more	marked	(Haeusler	and	al.,	
2014,	p.20).	
7	Since	2009	the	EHIMA	association	has	conducted	a	triennial	survey	into	the	major	European	markets	(France,	
Germany,	United	Kingdom),	which	has	extended	since	2012	to	Switzerland,	Denmark,	Norway	and	Italy	as	well	
as	 to	 Japan.	The	methodology	 for	 the	survey	reproduces	that	of	one	of	 the	American	models,	Marketrak.	 Its	
conception,	 design	 and	 conduction	 are	 operated	 by	 a	 Swiss	 company	 (Anovum).	 Thus,	 because	 of	 a	 similar	
methodology	for	surveys	on	significant	panels	of	the	national	population	(on	average	14,000	people	in	samples),	
the	data	allow	some	international	comparisons.	Moreover,	it	should	be	underlined	that	these	EHIMA	data	are	
put	into	perspective	in	the	DREES	report	2014	and	are	consistent	with	French	data	released	in	national	surveys.	
Auditive limitation scale Number Confidence interval 95% %
Not any problem* 52 931 000 52438000-53424000 82,50%
Slight 4 730 000 4471000-4989000 8%
Moderate 3 474 000 3264000-3684000 5,90%
Severe 1 600 000 1477000-1723000 2,70%
Profound or total 359 000 311000-406000 0,60%
Whole population 63 094 000 100%
Total with auditive limitations 10 163 000 9822000-10503000 16,10%
Including moderate to profound 5 433 000 5190000-5675000 8,61%
Field : People living at home or in institution
Sources : Disability-health survey 2008 ('enquête Handicap-Santé 2008')
*including 1 353 000 people not able to answer the question about conversation (young people or having heavy impairments)
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Chart	1	–		Prevalence	of	hearing	loss	in	France	2009,	2012	and	2015	(Eurotrak	2015)	
	
	
Source:	EHIMA,	2015	
	
In	 the	 last	 section	 of	 this	 study	 (cf.	 section	 2.2),	 an	 estimation	 of	 the	 2014	 hearing	 loss	
prevalence	by	adult	age	group	will	be	carried	out	on	the	basis	of	INSEE	demographic	data	and	
hearing	 loss	 rates	 available	 in	 the	 1998	 survey	 “Handicap-Incapacité-Dépendance”	
(‘Impairment	–	Disability	–	Dependency’).	These	rates	were	also	considered	as	steady	over	
time.		
	
1.1.3 Main	features	of	the	population	affected	by	auditive	functional	limitations	
	
AFL	concerned	more	men	than	women	(17.2%	and	15.1%),	and	are	derived	from	professional	
status	(exposure	to	noisy	environments)	or	leisure	habits	(sound	injury	due	to	loud	music	or	
headphones).	In	the	group	of	moderate	to	total	AFL,	the	gap	between	men	and	women	was	
more	pronounced	(10,4%	and	7%)8.	This	gap	appeared	from	the	age	of	40	years	(whereas	it	
appeared	at	an	age	of	50	years	in	the	1998	survey).		
	
The	link	between	the	prevalence	of	AFL	and	age	is	very	close:	10%	of	people	aged	50	years	
and	over	were	affected	by	moderate	to	total	AFL,	as	shown	in	chart	2.		
	
	
	
																																																								
	
8	This	estimation	is	standardised	by	age,	meaning	that	it	relies	on	the	hypothesis	of	a	similar	structure	of	male	
and	female	populations	by	age	group.		
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Chart	2	–		Prevalence	of	auditive	functional	limitations	by	age	and	severity		
	
Interpretation:	“moins	de	10	ans”	:	younger	than	10	years	old;	“entre	10	et	19	ans”	:	age	ranging	between	10	and	19	years	–	
“LFA	légères”:	slight	AFL	;	“LFA	moyennes”	:	moderate	AFL	;	“LFA	graves”	:	severe	AFL	;	“LFA	très	graves	ou	totales”	:	very	
severe	to	total	AFL	
Source:	DREES,	2014	
	
Not	only	does	the	prevalence	of	AFL	increase	with	age,	but	from	60	years	onwards	the	relative	
size	of	moderate	to	total	AFL	overtakes	slight	AFL:	59%	of	people	suffering	from	moderate	to	
total	AFL	were	aged	60	years	and	older9.	Moreover,	starting	from	80	years,	AFL	–	all	levels	of	
severity	inclusive	–	affects	more	than	one	out	of	every	two	individuals.	If	the	age	of	occurrence	
for	very	severe	to	total	AFL	is	always	known,	it	remains	unknown	in	the	general	case	for	the	
group	of	moderate	to	total	AFL,	as	well	as	the	causes	of	hearing	loss,	which	are	not	specified	
in	most	cases.	An	advanced	age	 is	 likely	 to	be	associated	with	more	difficulties	with	social	
integration.		
	
As	 regards	 the	 professional	 category	 (actual	 or	 former	 occupation),	 the	 prevalence	 of	
moderate	 to	 total	 AFL	 is	 variable:	 workers	 and	 farmers	 were	more	 affected	 (+13%)	 than	
craftspeople,	 shopkeepers	 and	 company	 heads	 (+9%)	 or	 senior	 managers	 (+10%).	
Nevertheless,	 it	 isn’t	 possible	 to	 interpret	 the	 direction	 of	 causality	 (impact	 of	 AFL	 on	
occupation	or	impact	of	occupation	on	AFL	occurrence,	except	for	farmers	for	whom	an	excess	
of	risk	due	to	working	conditions	is	demonstrated)10.	The	presence	of	AFL	seems	to	have	an	
impact	 on	 qualification	 level	 or	 job	 occupation	 (InVS,	 2015).	 However,	 job	 rates	 and	
unemployment	rates	are	similar	to	national	average	rates,	except	when	AFL	is	very	severe	or	
total.	Moreover,	 for	 the	working	population,	 the	 search	 for	multivariate	demographic	 and	
socio-economic	factors	likely	to	explain	the	prevalence	of	moderate	to	total	AFL	only	brings	
out	the	age,	the	sex	and	the	level	of	qualification	(particularly	when	the	qualification	is	higher	
than	a	bachelor’s	degree)11.		
	
																																																								
	
9	This	study	most	often	focuses	on	the	elderly	category,	given	the	greater	severity	of	hearing	troubles	and	the	
significant	size	of	this	population	in	hearing	loss	prevalence.		
10	Odds-ratio	1.49*	(1.08-2.06):	all	age	and	sex	being	equal,	the	likelihood	of	being	affected	by	moderate	to	total	
AFL	for	a	worker	or	a	farmer	is	1.5	times	greater	than	for	managers	and	self-employed	professionals.		
11	Cf.	Haeusler	and	al.	(2014),	p.22	and	following.		
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Compensation	of	hearing	loss	leads	to	hearing	aid	equipment	(even	to	cochlear	implants	in	
some	severe	cases).	However,	the	rate	of	people	being	equipped	is	substantially	lower	than	
the	rate	of	prevalence	for	moderate	to	total	AFL.	It	is	convenient	to	analyse	the	main	triggers	
of	access	to	hearing	aids,	in	order	to	later	question	the	economic	impact	of	hearing	loss.		
	
1.2 Access	to	hearing	aids	in	France:	an	overview		
	
Hearing	 aids	 (“audioprothèses”)	 are	 a	 device	 allowing	 the	wearer	 to	 receive,	 process	 and	
amplify	sounds,	which	have	to	be	adapted	to	the	user’s	ability	of	understanding	(perception)	
and	tolerance.	Thus,	they	are	a	medical	device	for	individual	use.		
	
In	 order	 to	 highlight	 some	 approximations	 relating	 to	 the	 expenditure	 of	 the	 hearing	 aid	
sector,	to	the	average	price	of	a	piece	of	equipment	and	to	hearing	aid	access,	several	data	
sources	have	been	cross-referenced.	Moreover,	the	rules	for	social	financing	of	hearing	aids	
are	featured,	where	public	and	private	insurance	coverage	is	associated	with	a	large	net	out-
of-pocket	expense	for	adult	HAs	users.	Finally,	the	provision	of	the	equipment,	combining	the	
device	and	the	service,	is	addressed	in	its	specificity.		
	
1.2.1 Public	and	private	hearing	aids	expenditure	in	France	
	
Hearing	aid	expenditure	is	neither	directly	estimated,	nor	at	least	released	in	published	French	
health	accounts	or	in	the	open	database	‘Eco-santé	OCDE’.	Indeed,	the	expenditure	for	this	
item	is	comprises	within	the	overall	range	of	prosthesis	(including	hearing	aids,	orthopaedic	
braces	and	vehicles	for	impaired	persons)12.	Hence,	an	estimation	is	proposed	on	the	basis	of	
some	available	trend	data,	and	then	the	expenditure	is	split	up	into	both	a	volume	effect	–	
depending	on	the	number	of	hearing	aid	users	–	and	an	average	price	effect.	
	
1.2.1.1 Overall	hearing	aids	expenditure	
	
Overall	hearing	aid	expenditure	ranged	around	one	billion	euros	in	2015,	an	estimation	based	
on	the	previous	data	combined	with	the	growth	rate	of	sales,	as	well	as	the	figures	in	the	IGF-
IGAS	report	(2015)13.		
	
Estimation	of	the	overall	expenditure	for	2011	
	
In	2011,	overall	hearing	aid	expenditure	was	estimated	to	be	around	800	million	euros	by	the	
“Haut	Conseil	pour	 l’avenir	de	 l’assurance	maladie”	 (‘High	Council	 for	 the	Future	of	Health	
Insurance’)	HCAAM	(2013b)	and	the	Court	of	Accounts	(2013)14,	with	:	
- 114	 million	 euros	 funded	 by	 National	 Health	 Insurance	 (“Assurance	 maladie	
obligatoire”,	AMO)	(around	14%	of	the	overall	expenditure);	
																																																								
	
12	A	difficulty	which	is	underlined	by	the	Court	of	Accounts	(2013).	As	for	the	field	of	‘other	medical	devices’	for	
individual	use,	it	depicts	80000	different	products	(Court	of	Accounts,	2014).		
13	IGF:	General	Inspection	of	Finances.	Cf.	volume	2,	form	8,	p.59.		
14	Cf.	p.	395,	by	deducting	optics.		
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- 246	million	euros	funded	by	complementary	health	 insurances	(“Assurance	maladie	
complémentaire”,	AMC)	(around	31%	of	the	overall	expenditure).		
Social	expenditure	presented	a	sustained	average	annual	growth	rate	that	was	sustained	at	a	
rate	of	11%	between	1997	and	2009	(IGAS,	2010).		
	
Estimation	of	the	overall	expenditure	for	2012	
	
In	2012	(IGAS,	2014),	overall	hearing	aid	expenditure	rose	to	824	million	euros,	including:	
- a	reimbursable	amount	of	169	million	euros	(cf.	infra);	
- a	 reimbursable	 amount	 of	 112	million	 euros	 covered	by	National	Health	 Insurance	
(AMO)	(a	base	rate	for	reimbursement	of	65.5%,	and	a	real	rate	of	reimbursement	of	
13,6%);	
- a	gross	out-of-pocket	amount	(including	coverage	of	complementary	health	insurance	
AMC)	of	711	million	euros.		
	
In	addition	to	these	overall	estimates,	the	National	Health	Insurance	data	(database	‘SNIIRAM)	
used	by	the	French	trade	union	of	hearing	aid	professionals	(UNSAF	-	“Union	nationale	des	
syndicats	 d’audiprothésistes	 français”),	 and	 members	 of	 the	 National	 Union	 of	 Health	
Professionals	 (UNPS,	“Union	nationale	des	professionnels	de	santé”),	enable	us	to	highlight	
the	distribution	by	age	of	the	hearing	aid	expenditure	for	2012,	then	estimated	to	be	822	877	
925	euros15.	This	distribution	illustrates	the	strong	concentration	of	expenditure	for	people	
aged	54	to	95	(chart	3).		
	
	 	
																																																								
	
15	The	gap	between	estimations	–	on	the	one	hand	IGAS	(2014)	and	on	the	other	hand	UNSAF	(Godinho,	2015a)	
–	 for	 2012	 data	 should	 be	 explained	 either	 by	 the	 different	 areas	 of	 inclusion	 for	 social	 expenditure	 in	 the	
SNIIRAM	database	(a	non-exhaustive	field	at	100%	depending	on	the	inclusion	or	not	of	the	different	health	care	
insurance	 funds)	 or	 else	 by	 the	 portion	 of	 hearing	 aid	 expenditure	 not	 presented	 for	 reimbursement.	 The	
Competitions	Authority	assess	the	amount	of	revenue	to	be	927	million	euros	in	its	2016	public	notice	(without	
specifying	a	year	of	reference,	which	was	probably	2014	or	2015).		
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Chart	3	–	Distribution	of	the	item	“electronic	devices	for	hearing	loss”	by	age	in	SNIIRAM	database		
	(2012)	
	
Source:	Sniiram	–	data	and	chart	UNSAF	(2015).	
	
Two	shortages	are	visible	in	this	distribution,	interpreted	by	UNSAF	as	threshold	effects	due	
to	coverage	rules:	the	end	of	specific	rights	for	younger	people	when	they	reach	the	age	of	20	
years;	and	the	end	of	eligibility	to	collective	contracts,	well-known	to	be	more	generous,	from	
the	age	of	65	years	(cf.	infra).	The	highest	expenditure	is	observable	at	81	years	(around	31	
million	euros).		
	
The	cumulated	expenditure	clearly	brings	about	delayed	access	to	hearing	aids,	regarding	the	
AFL	prevalence	data	released	by	DREES	(Haeusler	et	al.,	2014).	Indeed,	older	people	over	65	
represent	three-quarters	of	the	expenditure	whereas	people	over	75	comprise	more	than	half	
of	the	expenditure	(54%)16	(chart	4).		
	
	 	
																																																								
	
16	As	for	UNSAF	(2015),	the	noteworthy	cumulated	percentages	are:	3.1%	<	age	20,	9.1%	<	age	50,	24.9%	<	age	
65,	45.9	%	<	age	75.		
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Chart	4	–		Cumulated	expenditure	by	age,	on	item	“electronic	device	for	hearing	loss”	in	2012	
	
Source:	SNIIRAM	–	data	and	chart	UNSAF	(2015).	
	
Finally,	the	main	data	relating	to	overall	hearing	aid	expenditure	are	shown	in	table	7.		
	
	
Table	7	–	Summary	table:	overall	hearing	aids	expenditure	in	euros	depending	on	data	sources	
		
	
Source:	Authors	on	basis	on	available	data	
	
	
1.2.1.2 Estimations	of	the	number	of	hearing	aid	users		
	
Estimations	of	the	number	of	hearing	aid	users	in	France	vary	according	to	the	extrapolated	
data	of	surveys	(decennial	survey	‘Handicap	Santé’	2008;	Alcimed/DSS,	2011;	biennial	survey	
ESPS	2012;	Eurotrak	2015).		
	
	
0	€
100 000 000	€
200 000 000	€
300 000 000	€
400 000 000	€
500 000 000	€
600 000 000	€
700 000 000	€
800 000 000	€
900 000 000	€
0… 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 87 90 93 96 99 10
2
Cumulated	expenditure	depending	on	age	(in	%)	
75 years	and	over	:	54%	of	HA	expenditure
65	years	and	over	:	75%	of	HA	expenditure
Year Source 
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expenditure in 
euros
AMO (National 
Health Insurance)
AMC 
(Complementary 
health insurances)
Gross OOP
2011 HCAAM (2013b) 800 million 114 million (14%) 246 million (31%)
2012 IGAS (2014) 824 million
112 million 
(13,6%)
711 million
2012
SNIIRAM (UNSAF 
2015)
822,877,925
2015 IGF-IGAS (2015) 1 billion
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Estimations	of	the	‘Handicap-Santé’	survey	2008	
	
Following	 the	 ‘Handicap-Santé’	 survey	 of	 2008	 (Haeusler	 et	 al.,	 2014),	 in	 2008	 access	 to	
hearing	aids	concerned	1,112,000	people	(1.8%	of	the	whole	population,	given	that	only	20%	
of	people	affected	by	moderate	to	total	AFL	wore	hearing	aid(s)	–	and	were	more	frequently	
women	 and	 senior	 executives,	 all	 sex	 and	 severity	 levels	 of	 hearing	 loss	 being	 equal)17 .	
However,	the	rate	of	hearing	aid	owners	had	increased	by	7	points	between	1998	(13%)	–	the	
year	of	the	previous	survey	–	and	2008:	this	could	be	explained	by	a	better	quality	of	hearing	
aid	equipment.		
 
Table	8	–	Hearing	aid	equipment	rate	for	people	affected	by	moderate	to	total	AFL	
	
Source:	DREES,	2014	
 
Younger	people	aged	under	20	(37%)	are	more	often	equipped	with	hearing	aids	than	those	
aged	75	and	over	(32%	against	21%	in	1998),	which	can	be	explained,	simultaneously,	by	a	
better	social	coverage	of	the	former	group	and	a	better	response	to	equipment	in	terms	of	its	
effectiveness	(cf.	infra).	Also,	it	should	be	underlined	that:		
- Women	are	more	often	equipped	than	men	among	people	aged	over	60;	
- Senior	executives	are	more	often	equipped	than	workers,	all	levels	of	severity	being	
equal	(they	are	twice	as	likely	to	be	equipped)	and	independent	of	any	income	effect	
(not	significant	in	the	survey);	
- Impaired	people	are	more	often	equipped	than	other	people	in	the	age	group	60-74	
years,	due	to	French	social	coverage	rules	which	distinguish	impairment	and	old	age	
(cf.	infra);	
- In	 the	 labour	 force,	 there	 is	 no	 significant	 difference	 between	 employed	 and	
unemployed	people	(despite	the	fact	that	the	latter	have	lower	incomes).		
As	far	as	the	income	effect	is	not	perceptible	on	hearing	aid	access	in	the	survey,	this	access	
seems	to	depend	more	largely	on	a	socio-psychological	effect	(hearing	aids	are	more	discreet	
for	 women	 than	 for	 men),	 on	 a	 socio-cultural	 effect	 probably	 due	 to	 information	 (socio-
economic	class	effect)	and	on	the	level	of	public	and	(above	all)	private	coverage.		
	
Estimations	of	Alcimed-DSS	(2011)	for	the	year	2009	
	
The	Alcimed-DSS	survey	established	the	following	observations:	
- 	1.25	million	French	people	are	hearing	aid(s)	users	(estimation	based	on	trade	union	
data),	being	31.7%	of	the	population	eligible	for	hearing	aids;	
																																																								
	
17	The	rate	would	be	of	10.7%	if	the	whole	AFL	had	been	taken	into	account.		
Age Under 20 20-44 45-59 60-74 75 and over Overall
Moderate AFL 13% 8% 17% 31% 18,4%
Severe AFL 9% 8% 20% 30% 21,8%
Very severe to total AFL 25% 19% 26% 41% 33,5%
Moderate to total AFL 37% 14% 8% 15% 32% 20,4%
Moderate AFL 22% 28% 32% 41% 32%
Severe AFL 35% 45% 51% 51% 47%
Very severe to total AFL 32% 51% 63% 49% 51%
Moderate to total AFL 9% 26% 34% 38% 45% 37%
Equipment rate
Need for an equipment
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- among	hard	of	hearing	people	(6,300,000	people),	half	were	eligible	for	hearing	aid	
equipment;	
- hence,	 there	 is	notable	 room	for	 improvement	given	 the	 target	of	3	million	people	
(being	1,75	million	people	who	need	at	least	one	hearing	aid);	
- the	 average	 age	 at	 first	 equipment	 is	 estimated	 to	 be	 71,	 thus	 at	 a	 late	 age,	 as	 a	
consequence	of	a	delay	in	the	diagnosis	followed	by	a	delay	in	access.	The	gap	between	
the	perception	of	a	decline	 in	hearing	and	the	purchase	of	a	device	 is	estimated	 in	
years18.			
	
Estimations	of	the	biennial	survey	ESPS	for	the	period	1992-2012	
	
The	biennial	surveys	“Santé	et	protection	sociale”	ESPS	(‘Health	and	Social	Welfare	Survey’)	
show	a	remarkable	evolution	in	hearing	aid	access	between	1992	and	201219	(table	9):	
	
Table	9	–		Evolution	of	the	number	of	hearing	aids	owners	from	1992	to	2012		
	
Source:	Biennial	survey	ESPS,	data	Eco-Santé	OCDE		
(available	online	February	2016).	
	
	
																																																								
	
18 	According	 to	 Le	 Monde	 29	 September	 2009,	 access	 to	 hearing	 aids	 requires	 “seven	 years	 of	 reflection”	
(estimation	 based	 on	 the	 ‘Ipsos’	 survey,	 June	 2009).	 The	 Eurotrak	 survey	 for	 France	 2015	 estimates	 more	
precisely	that	84%	of	people	being	equipped	waited	 just	under	6	years	before	accessing	equipment	and	43%	
waited	between	3	to	6	years.		
19 	The	 ESPS	 survey	 collects	 data	 from	 a	 panel	 sample	 of	 8000	 ordinary	 households	 (20,000	 people)	 and	 is	
considered	as	representative	of	97%	of	the	French	metropolitan	population.		
A B C D
Hearing aids 
owners
Hearing aids 
owners aged 65 
and over
Inhabitants Hearing owners
In % of total 
population
In % of total 
population
Number Estimated number
1992 1,0 6,0 56 975 597 569 756
1993 1,1 7,0 57 239 847 629 638
1994 0,9 6,0 57 467 085 517 204
1995 0,9 5,5 57 658 772 518 929
1996 1,0 5,0 57 844 247 578 442
1997 1,2 5,8 58 025 989 696 312
1998 1,0 5,7 58 207 490 582 075
1999 nd nd 58 397 788 nd
2000 1,0 4,9 58 677 406 586 774
2001 nd nd 59 062 385 nd
2002 1,9 7,8 59 476 236 1 130 048
2003 nd nd 59 893 870 nd
2004 1,5 7,1 60 303 631 904 554
2005 nd nd 60 734 343 nd
2006 2,2 9,1 61 181 499 1 345 993
2007 nd nd 61 597 486 nd
2008 2,3 8,6 61 965 052 1 425 196
2009 nd nd 62 615 472 nd
2010 2,3 8,6 62 917 790 1 447 109
2011 nd nd 63 223 158 nd
2012 3,7 11,4 63 514 003 2 350 018
AAGR 6,8% 3,3% 0,5% 7,3%
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- The	proportion	of	hearing	aid	users	has	 risen	 from	1%	to	3.7%,	namely	an	average	
annual	growth	rate	of	6.8%;		
- The	proportion	of	hearing	aid	users	older	than	65	years	has	grown	from	6%	to	11.4%,	
namely	an	average	annual	growth	rate	of	3.3%.	At	the	same	time,	the	rate	of	these	
people	declaring	hearing	trouble	rises	to	23%;			
- Taking	into	account	these	latter	observations,	the	rise	in	access	to	hearing	aids	appears	
to	be	pushed	upwards	by	people	younger	than	65	years,	rather	than	by	those	over	65,	
indicating	earlier	access	to	hearing	aids;		
- The	estimated	number	of	hearing	aid	users	has	increased	by	7.3%	per	annum	over	the	
entire	period,	growing	from	569,756	people	in	1992	to	2,350,018	people	in	2012.	This	
average	annual	growth	rate	is	due	to	a	combination	in	the	growing	number	of	people	
being	equipped	and	demographic	growth	of	7.6%	in	the	period	2002	to	2012;	
- In	 2012,	 there	 is	 probably	 an	 overestimation	 in	 the	 number	 of	 hearing	 aid	 users’	
numbers	 (2.35	 million	 people	 according	 to	 the	 survey).	 This	 presumption	 of	
overestimation	is	reinforced	when	compared	to	other	available	recent	data	(cf.	infra	
table	18).	According	to	our	estimation,	the	number	of	hearing	aid	users	ought	to	be	
about	1.	8	million	people	in	2012.	 
	
Estimations	Eurotrak	2015	
	
The	Eurotrak	survey	estimates	the	rate	of	hearing	aid	access	at	34.1%	of	the	hearing	impaired	
population	 in	 2015	 and	 shows	 also	 that	 older	 people	 aged	 over	 65,	 affected	 by	 hearing	
impairment,	 are	 equipped	 at	 42%	 (23.2%	 for	 the	 age	 group	 45-64	 and	 29.5%	 for	 people	
younger	than	45	years).	
	
Chart	5	–		Evolution	of	the	rate	of	hearing	aid	access	relative	to	hearing	loss	prevalence	(2009,	2012,	2015)	
Eurotrak	data	
	
	
Source:	EHIMA,	2015	
	
70%	of	people	being	equipped	have	got	a	binaural	device	(both	ears).	Moreover,	access	is	as	
great	as	hearing	loss	severity	is	severe	(chart	6)20.		
																																																								
	
20	Severity	 is	assessed	on	the	basis	of	a	hearing	 loss	 level	 that	depends	on:	monaural	or	binaural	equipment,	
grade	 of	 hearing	 loss	 (moderate	 to	 severe),	 score	 on	 APHAB	 scale,	 and	 degree	 of	 difficulty	 to	 follow	 a	
9,3% 9,4% 10,4% 
3,2% 2,8% 3,1% 
34,1% 
30,4% 29,8% 
0% 
5% 
10% 
15% 
20% 
25% 
30% 
35% 
40% 
45% 
50% 
EuroTrak 2015 EuroTrak 2012  EuroTrak 2009 
Hearing impaired (stated) Adoption (% of population) Adoption (% of stated impaired) 
	 25	
Chart	6	–	Rate	of	hearing	aids	access	relative	on	hearing	loss	severity	
(Eurotrak)	
	
Source:	EHIMA,	2015	
	
	
Reference	values	
	
According	to	the	variability	of	estimations	(cf.	table	10),	it	seems	to	be	relevant	to	take	on	an	
access	rate	ranging	between	30%	to	35%	of	the	population	affected	by	disabling	hearing	loss21.	
Reader’s	attention	should	be	drawn	to	 the	meaning	of	 the	difference	between	the	rate	of	
hearing	 loss	 prevalence	 and	 the	 rate	 of	 people	 being	 equipped	 with	 hearing	 aids:	 this	
difference	doesn’t	fit	with	the	population	that	would	be	both	not	equipped	and	able	to	be	
equipped.	 For	 different	 reasons	 relative	 to	 feasibility	 of	 equipment,	 to	 the	 relevance	 of	 a	
hearing	compensation,	to	possible	therapeutic	options	for	severe	cases	(i.e.	cochlear	implant),	
or	else	to	social	and	psychological	factors	(rejection	of	hearing	aids),	the	access	to	hearing	aids	
is	foreseeable	only	for	a	fraction	of	hearing	impaired	people.	It	is	usually	considered	that	the	
population	eligible	for	hearing	aid	equipment	represents	half	of	the	impaired	population.	This	
reference	target,	central	in	this	report,	is	highlighted	further	(cf.	1.2.2.3).			
	
	 	
																																																								
	
conversation	in	a	noisy	background	without	hearing	aid	equipment.	This	estimation	leads	to	6	groups	of	identical	
size	(16,67%).		
21	The	IGAS	(2014)	estimates	the	number	of	impaired	people	to	be	7	million,	of	whom	15%	are	equipped.	The	
“UFC-Que	choisir”	(French	Consumers	Association	–	periodical	‘What	to	Choose’)	(2015)	estimates	this	number	
at	6	million,	with	25%	equipped.	These	 rates	of	equipment	are	among	 the	 lowest	values	 in	 the	whole	set	of	
surveys.		
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Table	10	–		Summary	of	estimated	rates	of	hearing	aids	access	in	the	literature	and	surveys		
	
Source:	Authors	on	basis	of	different	survey	data.	
		
Another	way	to	estimate	this	rate	of	hearing	aid	access	is	to	base	numbers	on	the	quantity	of	
devices	sold	(according	to	the	“Syndicat	national	de	l’industrie	et	des	technologies	médicales”	
SNITEM	–	‘National	Union	of	Medical	Industry	and	Technologies’)	during	the	last	6	years	(the	
median	lifespan	for	equipment	is	6	years	according	to	the	Eurotrak	survey	2015	for	France),	
and	then	to	consider	the	share	for	binaural	equipment	(70%,	same	source).	Thus,	it	is	possible	
to	estimate	the	number	of	wearers	of	hearing	aids,	by	assuming	that	the	devices	bought	in	
the	last	six	years	have	as	yet	to	be	renewed,	giving	2,041,075	hearing	aid	owners.	Given	a	rate	
of	hearing	loss	prevalence	of	10%	in	2012,	the	access	rate	would	then	be	about	32,6%22.		
	
Hence,	this	study	is	based	on	a	reference	rate	for	hearing	aid	access	ranging	between	30	to	
35%	of	the	hearing	impaired	population.		
	
1.2.1.3 Estimations	of	the	average	price	of	a	hearing	aid	
	
According	to	the	SNITEM	(2015),	hearing	aid	sales	have	followed	a	dynamic	trend	for	the	20	
years	from	1994	to	2014:		
	
	
	
																																																								
	
22	It	would	be	interesting	to	estimate	retrospectively	and	prospectively	the	progression	of	the	rate	of	hearing	
aids	owners	on	the	basis	of	SNITEM	sales	data,	on	the	demographic	structure	of	population	and	life	expectancy,	
on	the	rate	of	device	renewal	(median	of	6	years)	and	the	rate	of	new	purchasers	and	on	the	binaural	rate	of	
equipment.	However,	this	estimation	would	be	dependent	on	several	assumptions	(stability	of	device	duration	
and	of	 rate	of	binaural	equipment	and,	 for	 the	 forecasting,	 stability	of	average	annual	growth	rate	 for	 sales,	
stability	of	the	renewal	time	occurrence,	stability	of	the	rate	of	diffusion	related	to	acceptance,	forecast	of	the	
noise	exposure	 impact	 for	 young	generations).	 This	 longitudinal	 analysis	would	 require	 the	design	of	 several	
scenarios	that	goes	beyond	the	scope	of	this	study.		
Year Survey and HL criteria Access rate to equipment
Prevalence rate of 
hearing loss
2008
Handicap Santé (disabling 
hearing loss)
15,8% 11,2%
2008
Handicap santé (moderate to 
total AFL)
20,4% 8,6%
2008 ESPS 23,0% 10,0%
2009 Eurotrak 29,8% 10,4%
2009 Alcimed-DSS 31,7% 10%*
2010 ESPS 23,0% 10%*
2012 Eurotrak 30,4% 9,4%
2012 ESPS 37,0% 10%*
2015 Eurotrak 34,1% 9,3%
* Assumption
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Table	11	–		Estimation	of	sales	for	hearing	aids	between	1994	and	2014	
	
Source:	UNSAF-SNITEM,	2015		
	
If	we	consider	the	previously	estimated	overall	expenditure,	which	ranged	from	822,877,925	
euros	to	824	million	euros	in	2012,	and	the	number	of	hearing	aids	that	were	sold	in	the	same	
year	-	519,994	-,	the	average	price	per	unit	ranges	from	1	582.5	to	1584.6	euros	including	VAT	
in	201223.		
	
Estimations	of	UNSAF	(2015)	
	
Based	on	the	SNIIRAM	database	for	the	year	2013,	UNSAF’s	estimations	amount	to	an	average	
price	of	1456.35	euros	inc.	VAT	for	people	aged	over	20.	They	also	highlight	the	fact	that	the	
price	level	depends	closely	on	age	and	that	this	price	is	above	the	average	value	after	the	age	
of	55	 (and	 the	 threshold	effects	previously	underlined	remain	visible,	due	 to	 the	 financing	
rules	for	the	device).		
	
	 	
																																																								
	
23	The	value	added	tax	(“taxe	sur	la	valeur	ajoutée”,	TVA’)	applied	on	the	device	and	batteries	is	of	5.5%.		
Year
Number of sold 
devices
Rate of growth
1994 179 956 nd
1995 181 693 1,0%
1996 193 481 6,5%
1997 203 442 5,1%
1998 227 610 11,9%
1999 238 815 4,9%
2000 268 248 12,3%
2001 275 297 2,6%
2002 290 090 5,4%
2003 321 998 11,0%
2004 351 773 9,2%
2005 364 647 3,7%
2006 381 934 4,7%
2007 407 796 6,8%
2008 435 884 6,9%
2009 463 118 6,2%
2010 482 155 4,1%
2011 518 045 7,4%
2012 519 994 0,4%
2013 559 260 7,6%
2014 597 543 6,8%
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Chart	7	–		Average	price	as	a	function	of	age	in	2013	
	
	
Source	:	Sniiram	–	data	and	chart	UNSAF	(2015).	
	
The	distribution	of	average	prices	by	age	shows	that	a	hearing	aid	is	more	expensive	for	older	
people	aged	65	and	over	(1,560.83	euros	inc.	VAT),	then	for	younger	people	under	20	years	
old	(1,503.60	euros	VAT)	and	for	people	aged	between	20	and	64	(1,349.51	euros	VAT).		
	
Table	12	–		Average	VAT	price	for	a	hearing	aid	by	age	groups	in	2013	
	
Source:	SNIIRAM	–	data	and	table	UNSAF	(2015).	
		
Other	estimations	in	the	grey	literature	
	
The	grey	literature	captures	in	general	an	average	unit	price	of	1,600	euros	inc.	VAT	in	2009	
(Alcimed-DSS,	2011),	or	1,550	euros	inc.	VAT	in	2014	(Autorité	de	la	concurrence,	2016)	or	
1,535	euros	inc.	VAT	in	2011	(estimation	of	the	National	Health	Insurance	CNAMTS	that	has	
been	used	by	the	Court	of	Accounts	(Cour	des	comptes,	2013),	the	IGAS	(2014)	and	the	IGF-
IGAS	(2015)),	being	around	3,070	euros	inc.	VAT	for	both	ears24.		
	
																																																								
	
24	These	estimations	don’t	include	the	technical	cost	of	maintenance	(batteries	etc.).	
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These	estimations	do	not	depend	on	the	year	of	the	study,	since	it	must	be	noted	that	prices	
have	remained	quite	steady	over	time,	or	have	even	contracted,	given	the	evolution	of	both	
general	inflation	and	revenues.	Indeed,	the	average	price	of	a	digital	hearing	aid	has	stayed	
very	steady	between	1998-2000	and	2012,	according	to	the	National	Council	of	Consumption	
(“Conseil	national	de	la	consommation”,	2000	):	at	this	date,	the	price	of	a	digital	hearing	aid	
ranged	 from	 about	 9,000	 francs	 VAT	 (1,372	 euros)	 to	 10,000	 francs	 VAT	 (1,525	 euros)	
(including	 the	device	 and	 the	 service)25.	 Thus,	 if	 the	 level	 of	 the	price	 is	 certainly	 a	 factor	
hindering	access	to	equipment,	the	evolution	of	the	price	in	itself	cannot	be	supposed	to	add	
as	a	cumulative	factor.			
	
The	 French	 sales	 structure	 is	 characterised	 by	 a	 concentration	 on	middle-market	 and	 up-
market	hearing	 aids26.	According	 to	Alcimed-DSS	 (2011),	 80%	of	 sales	 are	 concentrated	 in	
these	two	market	sectors	(table	13)27.		
	
Table	13	–		Average	price	as	a	function	of	the	hearing	aid’s	market	sector	in	2009	
	
Source:	Authors	on	basis	of	Alcimed-DSS	(2011)	–	Prices	VAT	
	
The	dynamism	of	the	hearing	aid	market	(average	annual	growth	rate:	6.2%	between	1994	to	
2014)	 is	 largely	 sustained	 by	 the	 growth	 in	 users	 aged	 over	 60.	 Given	 that	 hearing	 loss	
prevalence	due	to	presbycusis	becomes	marked	from	55	years	and	 it	would	then	generate	
95%	of	hearing	loss	(Alcimed,	2011).	The	French	market	is	often	considered	opaque	and	not	
greatly	competitive	with	regards	to	manufacturers	or	distributors28.	According	to	the	Court	of	
Accounts	 (Cour	 des	 comptes,	 2013),	 this	 opacity	 is	 largely	 due	 to	 a	 failure	 in	 collecting	
information	within	public	authorities	(the	“Comité	économique	des	produits	de	santé”	CEPS	or	
																																																								
	
25	Le	Monde,	16	May	1996,	stated	that	innovative	digital	hearing	aids	entering	the	market	were	sold	at	a	price	of	
12,000	francs	(1,830	euros)	per	unit,	while	other	models	were	being	sold	at	an	average	price	of	between	6,000	
francs	(914	euros)	to	7,000	francs	(1,067	euros).	Four	year	later,	Le	Monde,	12	March	2000	related	an	average	
scale	of	prices	for	digital	hearing	aids	from	9,000	francs	(1,372	euros)	to	12,000	francs	(1,830	euros)	with	a	market	
penetration	of	30%.	At	this	time,	the	reimbursement	base	was	still	fixed	at	1,310	francs	(199.7	euros),	linked	to	
a	coinsurance	rate	of	65%	for	each	reimbursed	ear.	
26	There	are	four	main	lines	of	device,	A,	B,	C	and	D.	If	these	ranges	and	classifications	made	sense	when	designed	
(a	higher	range	corresponding	to	more	complex	and	advanced	technology,	referred	to	as	D	devices),	the	fast	rate	
of	 innovation	has	pushed	highly	technological	devices	 into	the	downmarket	or	middle	market	range,	without	
reclassification.	Incidentally,	more	than	94%	of	2014	sales	are	classified	in	the	D	range.			
27	Following	estimations	of	the	IGAS	(2014),	the	average	price	of	downmarket	devices	ranged	from	700	to	800	
euros.	90%	of	purchases	were	made	on	upmarket	devices	at	an	average	price	of	1,900	euros.		
28	There	 is	an	 international	oligopoly	of	 six	manufacturers	comprising	80%	of	worldwide	market	 share,	being	
Sonova	 (24%),	 Siemens	 (22%),	William	 Demant	 (22%),	 Starkey	 (24%),	 GN	 Resound	 (12%),	 and	Widex	 (10%)	
(According	to	several	sources,	see	for	example	Cour	des	comptes	,	2013,	p.	397).	The	oligopolous	market	can	be	
explained	by	both	a	high	value	technological	investment	and	a	relatively	reduced	market	for	sales.	The	factory	
price	excluding	tax	varies	between	200	euros	and	800	euros,	hence	a	net	margin	for	manufacturers	from	5%	to	
13%.		
Device Line CMU-C
Downmarket 
device
Middle market 
device
Upmarket device
Price inc. VAT in euros (one ear) 700*
600-1100 
(average 1000)
1100-1700 
(average 1500)
1600-2200 
(average 1950)
Market share (2009) 2-3% 15% 50% 30%
CMU-C in March 2016
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‘Economic	committee	of	health	products’	itself	not	having	available	sales	statistics	for	medical	
devices).	The	topics	of	competition,	market	characteristics,	product	differentiation	strategies,	
hearing	aid	distribution	networks	and	 sector	 regulations	go	beyond	 the	 framework	of	 this	
study	but	the	interested	reader	should	refer	to	recent	studies	by	the	Court	of	Accounts	(Cour	
des	comptes,	2013	and	2014),	by	the	Directorate	of	Social	Security	(“Direction	de	la	sécurité	
sociale”	-	DSS,	2011),	the	IGAS	(2013	and	2014),	the	IGF-IGAS	(2015),	and	by	the	Competition	
Authority	(Autorité	de	la	concurrence,	2016)29.		
	
Table	14	–		Estimations	summary	of	the	average	price	for	a	hearing	aid	in	the	literature	
	
Source:	Authors	on	basis	of	available	data	
	
If	valuations	of	the	average	price	for	one	hearing	aid	vary	between	sources,	they	converge	to	
1,535	euros	inc.	VAT	per	unit,	which	is	the	French	reference	value	in	this	study.			
	
1.2.1 Financing	hearing	aids		
	
For	the	most	part,	access	to	hearing	aids	concerns	older	people	and	impaired	people.	If	social	
financing	 is	 quite	 ‘generous’	 in	 some	 particular	 cases	 (people	 younger	 than	 20,	 the	 blind,	
beneficiaries	of	complementary	universal	health	insurance	(“couverture	maladie	universelle	
complémentaire”-	CMUC),	and	some	impaired	persons,	it	is	usually	very	low	in	relation	to	the	
price	level	of	hearing	aid	equipment.	According	to	the	HCAAM	(2008),	87.5%	of	hearing	aid	
owners	request	the	social	coverage	offered	by	the	National	Health	Insurance30.		
	
1.2.1.1 Financing	rules	for	hearing	aids	as	either	technical	support	or	medical	devices		
	
Hearing	aids	belong	to	the	‘technical	support'	category,	which	is	defined	for	beneficiaries	of	
impairment	compensation	allowance	(“prestation	de	compensation	du	handicap”	-	PCH)	as	
“all	technical	apparatus	or	systems	adapted	or	specially	designed	to	compensate	an	activity	
limitation	met	by	the	person	because	of	impairment,	and	acquired	or	rented	by	the	impaired	
person	for	his	own	use”31.	This	definition	is	retained	more	largely	by	the	IGAS	(2013),	for	lack	
																																																								
	
29	The	Competition	Authority	has	proceeded	to	Public	Inquiry	in	February	2016	in	order	to	highlight	the	presumed	
failures	of	 the	market,	not	 least	because	of	 the	survey	by	 the	UFC-Que	choisir	«	Audioprothèses	:	un	marché	
verrouillé	au	détriment	des	malentendants	»	(‘Hearing	aids	:	a	closed	market	to	the	detriment	of	hard	of	hearing	
people’,	released	in	September	2015.		
30	At	 this	 time,	 for	 400,000	 sold	devices,	 350,000	would	have	 led	 to	 a	 reimbursement	 request.	However,	 no	
further	estimation	of	this	share	was	available	for	recent	years.		
31	See	appendix	2-5	of	the	Social	Action	and	Family	Code	(“Code	de	l’action	sociale	et	de	la	famille”	(CASF)).		
Year Source 
Estimated average price for a 
hearing aid in euros
2009 Alcimed-DSS (2011) 1600
2012 SNIIRAM UNSAF (2015) and SNITEM (2015) 1583
2012-2013
CNAMTS (Court of Accounts, 2013; IGAS 
2014; IGF-IGAS 2015)
1535
2013 Non exhaustive SNIIRAM UNSAF (2015) 1465
2014 Competition Authority (2015) 1550
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of	 a	 similar	 definition	 for	 beneficiaries	 of	 the	 personalised	 autonomy	 subsidy	 (“allocation	
personnalisée	d’autonomie”,	APA).		
Such	a	pitfall	is	revealing	–	as	underlined	by	the	IGAS	–	of	the	great	confusion	surrounding	the	
rights	and	waiting	periods	involved	in	financing	technical	support,	depending	on	recipients’	
classification	into	illness,	impairment	or	old	age	(this	differentiation	of	needs,	rights	or	status	
–	 illness,	 invalidity,	 impairment,	 dependency	 -	 is	 particular	 to	 France).	 This	 confusion	 is	
reinforced	by	the	multiple	financing	bodies	in	case	of	impairment	and	by	the	variation	in	rights	
depending	on	the	area	of	residence.		
	
Furthermore,	 hearing	 aids	 are	 not	 only	 technical	 supports	 but	 are	 also	 medical	 devices	
(“dispositifs	médicaux”,	DM),	and	thus	relate	to	healthcare,	and	to	the	 list	of	reimbursable	
products	 and	 service	 provision	 (“Liste	 des	 produits	 et	 prestations	 remboursables”	 -	 LPPR)	
defined	by	the	National	Health	Insurance32.	However,	registration	in	the	LPPR	is	not	linked	to	
an	upper	price	limit	(unlike	most	medical	devices)	and	the	gap	between	prices	and	tariffs	is	
remarkably	wide	(CEPS,	2015)33.	The	juxtaposition	of	definitions,	public	bodies	and	rights	has	
finally	resulted	in	a	lack	of	management	of	the	access	to	technical	supports,	to	high	costs	due	
to	organisation	and	the	risk	of	errors,	and	to	inequalities	between	customers	whose	level	of	
information	about	accessibility	varies	greatly.		
	
1.2.1.2 Public	and	private	financing	rules	for	hearing	aid	equipment		
	
Coverage	by	the	National	Health	Insurance		
	
As	of	February	2016,	 the	National	Health	 Insurance	covers,	 for	 standard	cases	 (i.e.	people	
older	than	20	years	and/or	no	blindness	impairment34),	60%	of	the	LPPR	tariff	for	a	hearing	
aid,	fixed	at	199.71	euros,	that	is	119.83	euros	per	unit35.	This	reference	tariff	 includes	not	
only	the	device	itself,	but	also	the	accessories,	the	adaptation	and	prosthetic	education	by	the	
																																																								
	
32	Article	L.	5211-1	of	the	Public	Health	Code	which	imposes	norms,	such	as	the	CE	mark	by	the	manufacturer	
(article	L.	5211-3).		
33	“Fixing	a	ceiling	price	for	sales	implies,	however,	if	need	be,	the	resolution	of	the	question	of	any	surcharge	
billed	in	return	for/against	services	or	accessories	exceeding	the	definition	of	the	reimbursable	product	or	service	
specified	by	the	list.	In	particular,	this	is	the	case	in	the	external	prosthesis	or	orthotics	sectors,	where	patients	
ought	to	ask	for,	and	suppliers	ought	to	offer,	technical	or	aesthetic	accessories,	but	not	only	that.	For	example,	
in	the	field	of	hearing	aids	for	very	young	people,	professionals	argue	that	the	gap	between	prices	and	tariffs	
allows	for	payment	for	hearing	aid	professionals	whose	intervention	is	needed	to	adapt	the	equipment	for	their	
patients,	and	could,	depending	on	the	case,	represent	a	great	number	of	consultations	for	very	young	people	or	
multi-impaired	persons.	Indeed,	the	resulting	out-of-pocket	sum	was	mostly	reimbursed	either	by	the	CMU-C,	
or	by	complementary	 insurances	and	in	other	cases	by	means	of	regional	or	 local	assistance	bodies,	and	was	
often	requested	by	hearing	aid	professionals	themselves.	The	difficulty,	even	the	impossibility,	in	these	situations	
to	determine	a	bounded	price	of	sale	according	to	rational	references	and	existing	finance	possibilities	have	led	
the	Committee	to	postpone	the	fixation	of	a	ceiling	price	for	sales	for	these	hearing	aids	that	would	be	superior	
to	the	tariff”,	CEPS	(2015),	p.142.		
34	In	these	particular	cases,	technical	support	equipment	is	reimbursed	at	a	coinsurance	rate	of	60%	for	prices	
ranging	between	900	and	1,400	euros,	depending	on	the	device	classification.	In	the	case	of	a	chronic	disease	or	
‘long-term	 affliction’	 (“Affection	 de	 longue	 durée”,	 ALD)	 or	 in	 the	 case	 of	 invalidity	 allowance,	 the	 rate	 of	
reimbursement	is	100%	of	the	LPPR	tariff.	Cf.	www.ameli.fr	accessed	24	February	2016.		
35	The	reimbursement	rate	dropped	from	65%	to	60%	in	2011.		
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hearing	aid	professional,	as	well	as	the	follow-up	which	has	to	be	planned	on	an	indicative	
basis	 for	 the	 3rd,	 6th,	 and	 12th	 month	 and	 then	 twice	 a	 year	 thereafter.	 Renewal	 of	 the	
equipment	is	possible	at	any	moment,	only	one	limit	is	imposed	on	CMU-C	beneficiaries	(cf.	
infra).	A	fee	for	annual	maintenance	is	also	covered	(rising	to	21.96	euros	per	unit,	that	is	60%	
of	the	LPPR	tariff	of	36.59	euros)	on	evidence	payment	receipt	(batteries,	spare	parts,	or	for	
repairs	with	labour	included)36.	
	
Coverage	by	complementary	insurances	(apart	from	CMU-C)	
	
According	 to	 Garnero	 and	 Le	 Palud	 (2014),	 the	 coverage	 of	 the	 cost	 of	 hearing	 aids	 by	
complementary	health	 insurance	 is	very	variable,	depending	on	the	nature	of	 the	contract	
(individual	 or	 collective)	 and	 on	 the	 type	 of	 insurance	 (mutual	 fund,	 provident	 society	 or	
private	 for-profit	 insurance).	 In	 general,	 the	 complementary	 health	 insurance	 bodies	
(“organismes	complémentaires	d’assurance	maladie”,	OCAM)	cover	not	only	the	residual	co-
insurance	(40%	of	the	reference	tariff)	but	also	take	on	a	supplementary	financing	(for	89.3%	
of	OCAM).	This	supplementary	funding	is	more	often	insured	by	collective	contracts	(94.7%)	
and	by	provident	societies	(98.6%)	than	by	individual	contracts	(85.2%)	(table	15).			
	
Table	15	–		Complementary	insurance	reimbursement	for	hearing	aids	in	2010		
in	%	of	beneficiaries	(covered	people)	
	
Source:	DREES,	2014	
	
In	 2010,	 the	 complementary	 health	 insurance	 bodies	 (OCAM)	 declared	 an	 average	
reimbursement	 rate	 of	 30.5%	 for	 2009	 against	 a	 reference	 price	 of	 3,000	 euros	 inc.	 VAT	
relative	 to	 two	 hearing	 aids	 (914	 euros,	 at	 457	 euros	 per	 unit),	 with	 collective	 contracts	
offering	more	generous	coverage	(41.7%	in	comparison	to	22.1%	for	individual	contracts).	Half	
those	insured	people	received	less	than	851	euros	for	two	hearing	aids	(the	median	value	for	
reimbursement	equal	to	28.4%	of	the	reference	price).	Provident	societies	offered	the	best	
coverage	and	private	for-profit	insurance	the	weakest	(table	16).	
	
	
	 	
																																																								
	
36	Spare	parts	listed	in	the	LPPR	may	give	rise	to	extra	reimbursement.		
Not any 
refunding/RT
Partial 
refunding/RT
Total 
refunding/RT
Extra refunding 
/ RT
Overall
Collective contracts 4.3 0 9.9 85.8 100
Individual contracts 2.1 0.8 7.8 89.3 100
Overall contracts 2.7 0.6 8.4 88.3 100
Collective contracts 0.7 0 0 99.3 100
Individual contracts 0 1 5.9 93.1 100
Overall contracts 0.7 0.1 0.6 98.6 100
Collective contracts 0 0 0 100 100
Individual contracts 2.3 3.3 19.3 75.2 100
Overall contracts 1.5 2.1 12.4 84.1 100
Collective contracts 1.8 0 3.5 94.7 100
Individual contracts 2.1 1.5 11.2 85.2 100
Overall contracts 2 0.9 7.9 89.3 100
RT : reference tariff of National Health Insurance (200 euros) associated with a coinsurance rate fo 60%
Types of CHI and types of contract
Mutual funds
Provident societies
Private for-profit insurances
Overall insurance bodies
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Table	16	–		Distribution	of	the	reimbursement	for	a	pair	of	hearing	aids	in	2010	
(reference	amount	for	two	numerical	devices:	3000	euros	VAT)	
	
Source:	DREES,	2014	
	
Finally,	after	public	and	private	coverage	(AMO	and	AMC)	and	on	an	average	amount	of	3,000	
euros	for	two	hearing	aids,	the	net	out-of-pocket	sum	for	the	owner	would	be	either	1,846	
euros	 (923	 euros	 per	 ear)37	starting	 from	 the	mean	 reimbursement	 value,	 or	 1,909	 euros	
(954.5	euros	per	ear)	starting	from	the	median	reimbursement	value	.	This	estimation	takes	
into	account	the	distribution	of	beneficiaries	by	type	of	insurance	and	by	type	of	contract38.		
	
This	estimation	of	AMC	coverage	is	slightly	higher	than	those	found	in	the	literature:		
- 330	euros	per	ear	for	the	Court	of	Accounts	(Cour	des	comptes,	2013);		
- 395	euros	per	ear	for	the	IGAS	(2014);	
- 300	to	400	euros	per	ear	in	Alcimed-DSS	(2011).		
Thus,	 it	 is	 possible	 that	 OCAM	 have	 slightly	 increased	 the	 coverage	 rate,	 which	 can	 be	
interpreted	as	the	effect	of	competition	on	contracts	(but	the	“adverse	selection”	effect	limits	
the	relevancy	of	this	explanation)	or	as	a	“forced”	role	in	risk	management	by	the	withdrawal	
of	National	Health	Insurance	on	this	item.	However,	complementary	insurance	remains	very	
weak	for	optics	(68%)	or	dental	care	(38%)39.		
	
	
																																																								
	
37	Calculation:	3000	euros	minus	240	euros	(AMO)	minus	914	euros	AMC.		
38 	Adverse	 selection	 refers	 to	 a	 situation	 in	 economic	 theory	 according	 to	 which	 if	 insurances	 offer	 better	
coverage	for	goods	that	are	associated	with	higher	risk	(here,	hearing	aids	associated	with	older	age),	they	will	
capture	 the	 people	 likely	 to	 have	 other	 health	 troubles,	 and	 then	 they	 capture	 adversely	 high	 risk	 people.	
Moreover,	in	the	table	19,	collective	contracts	represent	42.7%	of	those	insured.	Their	distribution	is	of	66.6%	in	
mutual	funds,	3.7%	in	provident	societies	and	29.6%	in	private	for-profit	insurances.	Estimations	of	mean	and	
median	reimbursement	take	into	account	this	distribution	of	those	insured	between	the	three	different	types	of	
complementary	 insurances	 and	 the	 different	 types	 of	 contracts	 (collective	 or	 individual).	 Hence,	 these	 are	
weighted	estimations.	Moreover,	quartile	analysis	shows	that	25%	of	those	insured	are	reimbursed	at	most	for	
350	euros	for	two	ears,	whereas	25%	of	them	are	reimbursed	at	least	1,220	euros.		
39	Data	HCAAM,	2013b,	p.	111.		
Mean First quartile Median Third quartile
Collective contracts 1 032 539 939 1 398
Individual contracts 800 440 799 1 020
Overall contracts 865 445 840 1 039
Collective contracts 1 487 1 138 1 538 1 997
Individual contracts 777 578 739 1 138
Overall contracts 1 413 939 1 500 1 937
Collective contracts 1 142 939 1 198 1 338
Individual contracts 338 160 300 352
Overall contracts 626 240 390 1 038
Collective contracts 1 252 790 1 138 1 737
Individual contracts 662 260 640 976
Overall contracts 914 350 851 1 220
Types of CHI and types of contract
Mutual funds
Provident societies
Private for-profit insurances
Overall insurance bodies
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One	 consequence	of	 this	 differentiation	between	 collective	 and	 individual	 contracts	 is	 the	
evident	 phenomenon	 of	 the	 high	 take-up	 of	 hearing	 aids	 just	 before	 leaving	 collective	
contracts	by	people	reaching	retirement	age,	whence	the	shortage	effect	previously	shown.	
Indeed,	older	and	retired	people	are	financially	penalized	by	the	loss	of	social	rights	based	on	
working	status.		
	
Coverage	for	the	CMU-C	beneficiaries		
	
Hearing	 aid	 professionals	 are	 bound	 to	 offer	 hearing	 aid	 equipment	 suitable	 for	 CMUC	
beneficiaries	within	the	limits	of	applicable	tariffs,	which	were	revalued	in	2014	in	order	to	
reflect	upgrades	in	medical	devices	for	individual	use	(Cour	des	comptes,	2015).	For	a	ceiling	
price	of	700	euros	per	ear40,	the	CMU-C	beneficiaries	are	allowed	one	or	two	C-class	hearing	
aids	every	four	years,	which	the	hearing	aid	professional	must	be	able	to	supply	at	this	price.	
This	revision	of	the	reference	tariff	for	this	population	should	significantly	reduce	the	adverse	
effects	of	 the	previous	system	(the	equipment	of	 the	other	ear	postponed	until	 two	years	
later,	or	even	the	withdrawal	of	care	by	the	hearing	aid	professional)41.		
	
Coverage	for	the	beneficiaries	of	PCH	and	APA	
	
In	the	case	of	impaired	persons,	the	PCH	allows	for	an	additional	reimbursement	allocation	
fixed	by	ministerial	decree	at	a	ceiling	of	600	euros	for	a	middle	market	or	up-market	device	
(C	or	D)	in	cases	of	severe	impairment42.	Variable	allocations	are	likely	to	reduce	the	net	out-
of-pocket	amount,	and	may	even	lead	to	over-reimbursement.	In	contrast,	the	assessment	of	
elderly	dependency	does	not	allow,	in	most	cases,	for	any	supplementary	APA	(because	of	an	
overloaded	help	plan,	the	unsuitability	of	the	autonomy	grid	AGGIR,	or	lack	of	awareness	of	
the	field).		
	
Finally,	 it	 is	 arduous	 to	 estimate	 the	 real	 value	 of	 financial	 subsidies,	 and	 requires	 better	
knowledge	of	 equipment	 life	 span.	 The	entire	 statement	of	 the	 IGAS	 (2013)	 is	of	 a	 strong	
inequity	 in	 access	 and	 rights,	 	 and	 is	 as	 follows	 :	 “	for	 the	 same	 impairment	 or	 the	 same	
deficiency,	 older	 people	 in	 dependency	 and	 impaired	 people	 do	 not	 have,	 at	 this	 time,	 an	
equivalent	access	 to	 technical	 support	equipment”	and,	among	 the	 latter,	hearing	aids	are	
brought	to	the	forefront	of	this	criticism,	since	“it	is	for	this	type	of	support	equipment	that	
the	elderly	declare	their	technical	device	needs		to	be	the	less	well	satisfied”43.		
	
	 	
																																																								
	
40 	Current	 reimbursement	 rule	 in	 February	 2016,	 www.ameli.fr.	 Reimbursement	 for	 two	 devices	 is	 then	
guaranteed	at	a	price	of	1,400	euros	by	the	CMU-C.	Reimbursement	levels	are	highest	for	people	aged	under	20	
years	or	in	cases	of	cumulative	hearing	loss	and	blindness.		
41	Before	this	tariff	revision,	the	CMU-C	beneficiaries	were	offered	a	total	reimbursement	of	443.63	euros	for	
only	one	ear,	the	other	ear	being	reimbursed	at	the	reference	tariff,	so	there	was	an	observable	gap	in	two-ear	
equipment	and	a	low	performant	access	to	hearing	aids.		
42	16%	of	people	with	moderate	to	total	AFL	benefit	from	administrative	recognition	likely	to	be	associated	with	
an	additional	allowance	(Haeusler	et	Mordier,	2014).		
43	p.5,	IGAS	(2013).		
	 35	
1.2.1.3 Estimations	of	out-of-pocket	payment	and	healthcare	renouncement		
	
Estimations	of	out-of-pocket	payment	(OOP)	
	
Gross	out-of-pocket	(or	out-of	pocket	before	AMC)	
Apart	from	optical	devices,	hearing	aids	represent,	in	the	field	of	medical	devices,	the	greatest	
proportion	 of	 gross	 OOP	 payment	 before	 complementary	 health	 insurance	 intervention,	
representing	40%	of	the	gross	OOP	payments	(CESE,	2015).		
	
As	shown	previously,	the	National	Health	Insurance	(AMO)	covers	120	euros	per	adult	ear,	
independently	 of	 the	 apparatus	 class:	 this	 sum	 includes	 the	 service	 of	 the	 hearing	 aid	
professional	and	VAT	at	5,5%.	In	2011,	if	one	uses	the	study	reference	price	–	based	on	the	
Court	of	Accounts	(2013)	estimate	of	1,535	euros	per	hearing	aid	-		the	gross	OOP	payment	
rises	to	around	1,400	euros	per	item,	namely	a	gross	OOP	payment	of	91%,	or	even	97%	for	
an	upmarket	hearing	aid.	This	gross	OOP	payment	remains	high	in	particular	cases	(younger	
people	under	20	years	old,	and	the	blind)	that	represent	5%	of	hearing	aid	owners	(the	gross	
OOP	payment	varies	from	54%	to	59%).		
	
Such	a	situation	raises	questions.	It	is	due	to	the	base	for	reimbursement	being	frozen	since	
1986,	when	hearing	aids	were	obviously	less	efficient	and	when	they	were	implicitly	classified	
as	“low	risk”	and	a	minor	medical	service,	resulting	in	social	reimbursement	funding	(AMO)	of	
6%	to	9%	of	the	device.	It	is	also	due	to	the	withdrawal	of	National	Health	Insurance	(AMO)	in	
relation	to	the	role	of	complementary	health	insurances	which	played	a	greater	financing	role,	
but	also	created	more	 inequalities	 in	 the	system	(optional	purchase,	and	differentiation	of	
contracts).	 Finally,	 it	 is	 also	 due	 to	 the	 wait-and-see	 attitude	 of	 public	 authorities,	 and	
particularly	to	the	“paralysis	of	the	reviewing	of	generic	lines”	of	the	LPPR,	which	has	the	effect	
of	“penalising	many	patients	as	well	as	manufacturers	who	propose	innovative	solutions”44.	In	
any	case,	tariffs	have	not	been	reviewed	for	more	than	10	years45.	However,	one	noteworthy	
advance	in	2002	was	made	with	the	adoption	of	reimbursement	for	stereo	devices	(while	only	
one	mono	device	was	reimbursed	before),	resulting	in	strong	growth	for	this	item	in	the	same	
year46.		
	
	 	
																																																								
	
44	Cour	des	comptes	(2013),	p.407.	Thus,	an	examination	of	hearing	aids	in	2006	was	planned	by	a	decree	of	July	
2005,	 but	 this	 opinion	 was	 only	 given	 in	 2008	 by	 the	 ‘commission	 for	 products	 and	 benefits	 assessment’	
(“Commission	d’évaluation	des	produits	et	prestations”	–	CEPP-,	today	CNEDIMTS	since	2009)	which	proposed	a	
new	classification	and	a	revision	of	technical	prescriptions,	a	proposition	which	has	not	been	followed	by	any	
obvious	results	at	the	time	of	this	report.	The	main	recommendations	of	the	CEPP	were:	prescription	supervision	
by	 an	 ENT	 specialist;	 a	 minimum	 real-life	 probationary	 period	 of	 15	 days	 for	 the	 prosthetic;	 standardised	
feedback	 to	 be	 given	 to	 the	 prescriber	 post-equipment;	 a	 5-year,	 non-curtailable	 period	 before	 a	 new	
reimbursement,	except	when	supported	by	the	prescriber;	classification	based	on	the	impairment	level	with	a	
minimal	requirement	for	technical	performance	by	digital	hearing	aids.	However,	the	CEPP	maintained,	given	the	
literature,	 the	 generic	 prescription	 and	 did	 not	 discuss	 the	 indivisible	 character	 of	 the	 device	 and	 the	
performance	of	the	provision.	
45	Cour	des	comptes,	2014,	p.	311.		
46	Decree	of	23	April	2002.	Cf.	HCAAM	(2008).		
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Net	out-of-pocket	payment	(OOP)	(or	out-of-pocket	payment	after	reimbursement	by	AMC)	
	
Despite	the	improvement	in	hearing	aid	reimbursement	by	complementary	health	insurances	
(AMC)	and	despite	the	positive	evolution	of	the	system	for	CMU-C	beneficiaries,	there	remains	
weak	coverage	for	those	insured	in	this	field.	Depending	on	the	policy	holder’s	situation,	and	
in	particular	regarding	his/her	complementary	 insurance	contract,	the	net	OOP	payment	 is	
likely	to	be	high,	around	62%	after	coverage	of	AMO	and	AMC	(8%	+	30%)47,	and	ranging	on	
average	from	45%	for	a	downmarket	device	to	72%	for	an	upmarket	device,	given	that	this	
range	rises	relative	to	the	lower	price	of	the	downmarket	device	and	the	higher	price	of	the	
upmarket	device,	the	nature	of	the	complementary	insurance	and	the	type	of	contract	(table	
17).		
	
Table	17	–		Estimation	of	the	net	out-of-pocket	sum		
as	a	function	of	the	average	or	the	median	reimbursement	by	complementary	insurance	(AMC)	
	
Source:	Authors	on	basis	on	Alcimed-DSS	data	(2011),	DREES	data	(2014)		
and	the	reference	price	of	the	study		
	
On	 the	 basis	 of	 this	 study’s	 reference	 price,	 the	 expense	 for	 an	 adult	 covered	 by	 a	
complementary	health	insurance	policy	apart	from	CMU-C	rises	to	an	average	of	950	euros	
per	ear.		In	the	literature,	the	rough	estimates	are48	:	
- 1,040	euros/ear	(Alcimed,	2011);	
- 1,100	euros/ear	for	the	Court	of	Accounts	(Cour	des	comptes,	2013);	
- 1,000	euros/ear	(HCAAM,	2013);	
- 940	euros/ear	for	the	IGAS	(2014).	
	 	
The	presumptive	evidence	of	the	weak	public	and	private	coverage	of	hearing	aid	expenditure	
is	the	rate	of	healthcare	renunciation,	which	can	take	the	form	either	of	a	delay	in	access	to	
care	regarding	needs	and/or	of	social	inequalities	in	access	to	hearing	aids	(depending	on	the	
socio-economic	 category,	 the	 status	 of	 the	 need	 (illness,	 impairment,	 dependency),	 the	
ownership	of	complementary	health	insurance	and	its	type).	The	literature	does	not	provide	
a	concrete	estimate	for	care	renunciation	due	to	inability	to	pay,	because	the	withdrawal	of	
care	access	is	the	result	of	several	factors:	financial,	psychological,	and	lack	of	information.	It	
would	be	incorrect	to	use	the	rate	of	access	to	hearing	aids	to	directly	deduce	the	renunciation	
rate	due	to	inability	to	pay.		
	
																																																								
	
47	Estimated	shares	based	on	a	hearing	aid	priced	at	1,535	€,	minus	120	€	AMO,	minus	457	€	AMC	following	the	
previous	data	of	the	DREES	(2014).		
48	No	estimation	exists	for	OOP	impact	on	the	household	budget,	given	the	occasional	character	of	the	purchase.		
	 37	
The	 proportion	 of	 people	 eligible	 for	 hearing	 aids	 is	 usually	 taken	 at	 50%	 of	 the	 hearing	
impaired	population.	There	are	several	ways	to	demonstrate	its	relevancy:		
- first,	 by	 referring	 to	 the	 Alcimed-CNSA	 (2009)	 study	 which	 gathered	 expert	
recommendations	in	order	to	determine	this	reference	rate	of	50%;	
- by	studying	the	survey	data	from	‘Handicap-Santé’	2008:		
o using	the	direct	approach	of	hearing	loss	(cf.	table	3):	in	this,	1.8%	of	the	whole	
population	declares	themselves	to	be	hearing	aid	users,	3.2%	declare	a	need	to	
use	hearing	aids	without	owning	one,	thus	5%	of	eligible	people	declaring	for	a	
hearing	loss	prevalence	of	11.2%.	This	means	that	44.6%	of	hearing	impaired	
people	are	eligible	to	hearing	aids	(5%/11.2%);	
o or	by	the	indirect	approach	of	moderate	to	total	AFL	(cf.	table	8):	20.4%	of	this	
population	use	hearing	aids,	37%	declare	a	need	without	owning	one,	namely	
57.4%	of	the	population	with	disabling	hearing	loss	eligible	to	hearing	aids;	
- by	 analysing	 the	 access	 rate	 in	 countries	 where	 this	 access	 to	 hearing	 aids	 is	 free	
(complete	 financial	 coverage	 of	 the	 device),	 as	 in	 Denmark	 (cf.	 section	 1.3.1):	 the	
access	rate	is	of	48%	of	the	hearing	impaired	population;	
- by	studying	the	survey	data	in	Eurotrak	(2015)	which	illustrates	(for	France)	the	course	
taken	by	hearing	impaired	persons	until	owning	hearing	aids	(“the	route	to	the	hearing	
aid”):	of	100%	of	hearing	impaired	people,	26%	do	not	see	their	physician.	Therefore	
74%	of	people	have	a	medical	consultation	related	to	hearing	loss.	In	this	population,	
36%	do	not	 receive	advice	about	hearing	aid	equipment.	Thus,	only	48%	of	people	
receive	guidance	about	hearing	aids.	After	renunciation	of	hearing	aids,	34%	of	these	
people	get	hearing	aids.		
The	expert	assessments	and	the	empirical	analysis	of	access	to	hearing	aids	are	sufficiently	
robust	 to	maintain	 the	 reference	 target	 for	 people	 eligible	 to	 hearing	 aids	 of	 50%	 of	 the	
hearing	impaired	population.		
	
By	revisiting	the	chronological	data	of	surveys	which	estimate	the	access	rate	to	hearing	aids,	
by	taking	into	account	the	rate	of	hearing	loss	prevalence,	then	by	introducing	the	population	
INSEE	data	and	considering	for	each	year	that	50%	of	the	hearing	impaired	people	should	be	
equipped	(target),	it	is	possible	to	directly	estimate	the	people	being	equipped	and	the	people	
(who	are	not	owners)	able	to	be	equipped	per	year	(table	18).	This	estimation	allows	us	to	
observe	 a	 noteworthy	 growth	 in	 the	 equipment	 rate,	 despite	 the	 differences	 in	 data	
depending	on	sources.		
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Table	18	–		Estimation	of	the	population	being	equipped	in	function	of	the	sources	–	2008-2015		
	
Source:	Authors,	on	basis	on	Alcimed-DSS	data	(2011),	others	available	survey	data	and	INSEE.		
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All	data	converge	at	this	time	towards	a	current	size	of	one	million	people	able	to	be	equipped	
(and	not	already	owning	a	hearing	aid)	in	France.		
	
This	case-by-case	review	is	beneficial	 in	order	to	put	the	estimations	of	grey	literature	into	
perspective,	since	these	estimations	become	quickly	dated	given	the	rapid	development	of	
hearing	aid	access	(these	estimations	often	rely	on	the	study	of	the	DREES	(2014)	for	the	year	
2008).	As	an	example,	these	estimations	can	be	found	in	the	literature:		
- according	 to	 the	CESE	 (2015),	only	20%	of	hearing	 impaired	people	were	equipped	
because	of	care	renunciation	for	affordability	reasons;		
- according	to	IGAS	(2014),	the	equipment	rate	ranges	between	33%	and	40%	:	1.5	to	2	
million	people	remain	eligible	for	hearing	aids		(and	do	not	own	them)	for	every	one	
million	people	who	are	already	equipped49	;	
- according	to	the	Competition	Authority	(Autorité	de	la	concurrence,	2016),	there	are	
currently	1.5	million	equipped	people	for	4.4	million	people	eligible,	all	inclusive	(thus	
an	equipment	rate	of	32%);	
- according	 to	 the	 survey	 ‘UFC-Que	 Choisir’	 (2015)50,	 there	 are	 	 1.5	 million	 people	
equipped	for	an	eligible	population	not	owning	aids	of	2	million	people	in	2012.		
These	estimations	seem	to	be	very	approximate:	either	the	number	of	people	being	equipped	
is	incorrectly	assessed,	or	the	number	of	eligible	people	is	wrong,	or	confusion	persists	as	to	
the	equivalence	between	the	rate	of	hearing	loss	prevalence	and	the	rate	of	people	able	to	be	
equipped.	Whatever	the	answer,	access	to	hearing	aids	has	grown	significantly	in	a	very	few	
years	whereas	the	number	of	people	able	to	be	equipped	has	hardly	increased,	despite	the	
effects	of	demographic	growth	and	ageing.		
	
																																																								
	
49	According	to	the	IGAS,	France	is	characterised	by	an	atypical	situation,	with	a	regulation	failure	which	has	led	
to	high	prices	and	low	sales	volumes.	It	considers	that,	for	a	similar	expenditure,	the	reverse	situation	is	found	in	
English	Health	authorities:	there	is	a	high	rate	of	reimbursement	of	demands	and	control	of	prices	and	products.	
The	IGAS	advise	preferentially	the	reinforcement	of	the	National	Health	Insurance’s	role	in	the	running	of	the	
system	and	the	financing	policy	for	technical	support	equipment	and	the	reinforcement	of	the	HAS	and	CEPS’	
roles	in	the	field	of	the	technical	support	equipment	assessment.		
50	The	survey	by	UFC-	Que	choisir	first	considers	the	demand	not	being	equipped	on	the	basis	of	data	for	countries	
where	the	demand	is	totally	reimbursed	(Denmark,	United	Kingdom,	Sweden).	It	then	computes,	for	a	population	
aged	over	65,	 the	number	of	 devices	 sold	 in	 2014	and	deduces	 an	average	 for	 1,000	older	 inhabitants.	 This	
average	value	 is	 the	reference	value	from	which	a	comparison	 in	access	 is	drawn	for	 the	same	population	 in	
France.	As	this	access	is	2.41	times	less,	the	authors	estimate	that	for	the	past	five	years	the	sales	not	realised	of	
devices	 on	 the	 basis	 of	 sold	 devices,	 and	 then	 deduce	 the	 number	 of	 people	 not	 being	 equipped,	 with	 an	
assumption	of	a	binaural	equipment	rate	of	80%.	This	estimation	would	better	have	taken	into	account	several	
additional	factors	in	order	to	be	more	reliable:	the	number	of	new	buyers	of	HAs	on	the	market	each	year	(48%	
in	DK,	54%	in	UK,	68%	in	France	-	data	Eurotrak	2012);	the	median	lifespan	(4	years	in	DK	against	5	to	6	years	in	
France);	 the	 different	 rate	 of	 binaural	 equipment	 (84%	 in	 DK;	 64%	 in	 UK;	 74%	 in	 France).	 Therefore,	 this	
estimation	for	2014	–	whereas	all	studies	show	an	increase	in	access	since	2008	–	is	frail	in	terms	of	methodology.	
For	example,	if	the	same	reasoning	is	applied	to	the	same	data	for	France	and	DK,	but	includes	the	new	buyers	
on	the	market	-	142.2*48%	in	DK	and	51.5*68%	-		a	ratio	of	2	is	obtained	(and	not	2.41),	then	keeping	the	Danish	
data	for	equipment	lifespan	(4	years)	and	the	rate	of	binaural	equipment	(80%),	the	estimation	of	people	not	
being	equipped	is	about	1.2	million.	Moreover,	as	shown	previously,	the	rate	of	access	for	people	aged	over	65	
years	has	been	slightly	slower	than	this	rate	for	the	whole	population	in	France,	which	also	introduces	another	
bias	to	the	results.	Given	that	the	initial	estimation	relies	on	overall	sales	in	France	to	customers	of	all	ages,	it	
would	have	been	better	to	base	the	reasoning	on	the	whole	adult	population.	
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In	any	case,	healthcare	renunciation	–	given	the	lack	of	complementary	health	insurance	or	
insufficient	protection	-		is	likely	to	concern	people	with	low	incomes	who	may	forgo	hearing	
aid	care	because	of	impossible	costs	or	large	out-of-pocket	payments51.	Moreover,	if	hearing	
aid	 renunciation	 is	 often	 understood	 as	 a	 result	 of	 financial	 constraints,	 we	 should	 also	
consider	the	role	of	psychological	barriers,	lack	of	information	or	the	varying	effectiveness	of	
devices	particularly	among	the	elderly	(cf.	infra	2.3).		
	
1.2.2 The	hearing	aid:	a	durable	good	associated	with	a	paramedical	service	
	
The	hearing	aid	is	‘a	hearing	loss	corrective	electronic	device’	in	which	adjustment	of	output	
depends	on	the	frequency,	in	order	to	compensate	for	hearing	loss:	there	are	either	“behind-
the-ear”	hearing	aids	which	account	for	88%	of	devices	(classical	behind-the-ear	/children	and	
elderly;	 micro-sound-tube	 and	 soft	 plastic	 ear	 tip	 /	 slight	 to	 profound	 losses;	 or	 remote	
earphones	/	slight	to	profound	losses),	or	“in	the	canal”	(completely	in	the	canal,	in	the	canal	
or	in	the	ear/	moderate	loss).	They	are	digital	devices	in	nearly	100%	of	cases	(SNITEM,	2014).	
	
The	purchase	of	a	hearing	aid	is	characterised	by	a	simultaneous	purchase	of	the	apparatus	
itself	and	long	term	delivery	of	a	back-up	service	(on	average	5	years),	which	makes	hearing	
aid	professionals	different	amongst	healthcare	suppliers.	This	role	of	delivery	with	the	support	
of	the	network	connecting	the	six	manufacturers	with	central	purchasing	agencies,	and	the	
latter	with	hearing	aid	professionals52.	Hearing	aid	professionals	are	either	salaried	or	self-
employed,	depending	on	their	type	of	practice,	and	might	be	employed	by	specialised	groups	
in	 a	 	 retail	 chain	 (in	 a	 branch	 office	 or	 as	 a	 managing	 director)	 or	 they	 might	 operate	
independently,	or	as	a	member	of	a	mutual	distribution	network53.		
	
The	role	of	the	hearing	aid	professional	is	defined	by	the	Public	Health	Code	(“Code	de	la	santé	
publique”,	CSP)	and	the	Social	Security	Code	(“Code	de	la	sécurité	sociale”)	and,	since	2015,	a	
numerus	 clausus	 restricts	 access	 to	 this	 profession54.	 In	 2015,	 there	 are	 3,064	 salaried	 or	
independent	 professionals	 (table	 19).	 The	 average	 annual	 growth	 rate	 of	 the	 professional	
demography	(+5.3%	for	the	period	1999-2015)	is	close	to	what	was	observed	for	hearing	aid	
sales	(+6.2%).		
	
	 	
																																																								
	
51	The	HCAAM	(2013)	considers	that	the	stakes	are	to	determine	a	good	choice	of	complementary	health	care	
through	better	health	risk	management	(fair	and	responsible	contracts),	since	complementary	health	insurances	
are	the	main	source	of	subsidies,	and	above	all	to	question	their	ability	to	bring	under	control	device	sales	prices;	
it	supports	the	development	of	networks.	In	so	doing,	it	excludes	the	possibility	of	the	recapture	of	the	hearing	
aid	sector	by	the	AMO	and	the	adoption	of	applicable	tariffs,	because	of	the	background	of	shortfall.	Several	
scenarios	 are	 designed	 by	 the	 HCAAM,	 either	 a	 takeover	 of	 reimbursement	 by	 the	 AMO	 (by	 returning	 to	 a	
coinsurance	rate	for	the	reference	tariff	of	65%	instead	of	60%),	or	completely	transfer	to	the	AMC	the	whole	
reimbursement	charge.	At	 the	 time	of	 this	 report,	no	additional	clause	has	been	 in	negotiation	between	 the	
UNOCAM	and	the	sector	representatives.		
52	Such	vertical	integration	has	been	permitted	by	the	Competition	Authority	in	December	2015	for	the	Audika	
group	which	 is	 controlled	by	William	Demant.	Moreover,	 the	purchasing	 agencies	 -	 contrary	 to	wholesalers’	
distributors	in	the	case	of	drugs	–	play	a	referencing,	rather	than	a	distribution	role.		
53	Discount	price	being	around	15%	on	the	HAs	prices	(agreement	of	partnership	quality-price).	Cf.	IGAS	(2013).	
54	Decree	of	15	July	2015.	The	numerus	clausus	has	been	fixed	at	199	students	in	2015-2016.		
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Table	19	–		Evolution	of	the	number	and	the	density	of	hearing	aid	professional		
in	metropolitan	France	(1999-2015)	
	 	
Source:	Biennial	survey	ESPS,	data	Eco-Santé	OCDE	and	DREES	(open	data)		
(Available	in	February	2016).	
	
Once	the	hearing	loss	diagnosed	by	the	physician	leads	to	medical	advice	for	hearing	aids,	the	
hearing	 aid	 professional	 plays	 an	 advisory	 role,	 delivering	 the	 device	 and	 the	 associated	
services55.	 This	 role,	 regulated	 by	 article	 L4361-1	 of	 the	 CSP,	 is	 to	 ensure	 counselling	 of	
customers,	the	delivery	and	the	adaptation	of	hearing	aids,	and	follow-ups	during	the	lifetime	
of	the	device,	in	a	high	performance	technical	facility.	The	main	sequences	that	have	to	be	
followed	are:		
- The	 preliminary	 consultation,	 which	 leads	 to	 a	 standardised	 estimate,	 clearly	
differentiating	on	the	one	hand	the	prices	of	goods	(apparatus)	and,	on	the	other	hand,	
the	prices	of	associated	services56	;	
- The	adaptation	consultation,	in	order	to	understand	the	device	and	its	use	in	real-life	
situations,	including	a	probationary	period	of	15	days;		
- The	adjustment	consultations	(1	to	3)	dedicated	to	fine	tuning	and	counselling;	
- The	 follow-up	 consultations	 (twice	 a	 year)	 dedicated	 to	 maintenance	 and	 later	
adjustments.		
	
The	price	of	a	hearing	aid	comprises	therefore	the	cost	of	the	device	and	the	long-term	follow-
up,	including	the	apparatus,	the	hearing	aid	professional’s	time,	the	technician’s	or	assistant’s	
																																																								
	
55	The	freedom	of	counselling	leads	to	a	possible	information	asymmetry	between	the	patient	and	the	hearing	
aid	 professional,	 with	 the	 hearing	 aid	 professional	 being	 incentivised	 to	make	more	 frequent	 references	 to	
upmarket	products	because	of	a	higher	profit	margin.		
56	This	clarification	 is	 imposed	by	the	«	Macron	»	 law	of	6	August	2015.	The	costing	presents	the	pre-tax	sale	
price	and	the	service	price,	the	net	price	including	VAT	and	the	reference	tariff	fixed	by	the	LPPR	(article	L.	165-
1	of	the	social	security	Code,	title	2.		
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salaries	(administration)	and	the	technical	facilities.	The	estimated	time	devoted	to	the	user	
is	variable	in	the	literature:		
- it	ranges	between	11.5	hours	to	20	hours	according	to	the	CNC	(2000);	
- 10	hours	according	to	the	Court	of	Accounts	(Cour	des	comptes,	2013);	
- 12	hours	to	15	hours	over	5	years,	including	4	hours	for	initial	adaptation	according	o	
IGAS	(2014)57	;	
- 10	 to	 12	 hours	 according	 to	 Alcimed-DSS	 (2011).	 The	 report	 points	 out	 that	 the	
combination	of	high	manufacturers’	sales	prices	and	the	human	time	required	for	a	
high	quality	fitting	limits	the	possibility	of	cheaper	supplies	(no	“discount”	equipment).		
	
Contrary	to	some	medical	devices	which	only	require	a	short	amount	of	time	for	counselling,	
using	hearing	aids	calls	for	deeper	acquaintance	and	“cognitive”	adaptation,	depending	on	the	
capabilities	 of	 the	 auditive	 nervous	 system,	 where	 the	 stakes	 are	 compliance,	 and	 thus,	
improvement	in	the	quality	of	life	that	may	not	be	perceived	immediately.	This	adaptation	is,	
according	 to	 the	 report	Alcimed-DSS	 (2011),	 ‘a	key	phase	 for	a	 successful	equipment’,	 and	
requires	a	long-term	follow-up	and	a	confident,	sharing	relationship	between	the	patient	and	
the	hearing	aid	professional.	The	report	also	underlines	given	that	“the	psychological	stake	is	
strong	and	the	population	of	patients	mostly	older,	it	is	not	rare	that	adaptation	sessions	also	
play	a	social	role”58.			
	
This	point	of	view	is	taken	up	by	the	CESE	(2015)	for	the	whole	set	of	medical	devices,	which	
qualifies	them	as	“user-dependent”	products	to	the	extent	that	therapeutic	results	depend	on	
patient	compliance	with	recommendations	and	that	specific	patient	counselling	is	required.	
The	IGAS	(2014)	also	underlines	the	difficulty	for	assessing	the	cost	of	the	service,	which	is	a	
decisive	 factor	 in	 satisfaction	 (and	 thus	of	patients’	 compliance).	All	 this	differentiates	 this	
technical	support	equipment	from	others,	since	the	device	is	not	separable	from	counselling	
and	tune-up	on	a	long-term	basis,	and	where	the	purchase	cost	does	not	divide	device	and	
service	delivery.		
	
1.2.3 Hearing	aid	pricing	issues:	an	analytical	economic	framework		
	
In	 the	 framework	 of	 hearing	 aid	 delivery	mentioned	 above,	 is	 it	 reliable	 to	 dissociate	 the	
apparatus	and	the	service	 for	pricing?	This	 issue,	which	 is	 regularly	questioned	 in	 the	grey	
literature,	would	require	an	assessment	of	the	added-value	for	the	combination	of	apparatus-
service:		
- Arguments	 in	 favour	 of	 this	 decoupling	 suggest	 that	 pre-payment	 –	 or	 prospective	
payment	–	does	not	ensure	the	effective	fulfilment	of	the	service	(in	case	of	patient	
decease,	centre	closure	etc.59)	or	any	quality	improvement	in	the	follow-up	(as	there	
is	no	incentive	to	make	an	effort	for	the	service	provider);	
																																																								
	
57	Based	on	UNSAF	declarations,	cf.	addendum	5	p.	19.		
58	p.	42.		
59	Patient	decease	should	not	lead	to	a	charge	for	the	provider,	given	that	this	rule	doesn’t	apply	in	the	whole	
financing	situations	of	providers,	whatever	it	 is	(physician,	dentist…).	The	cases	of	a	centre	closure	or	retiring	
provider,	even	though	quite	marginal,	should	lead	to	a	transfer	rule	of	patients	between	providers,	which	could	
be	implemented	by	the	design	of	a	clearing	house.		
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- Arguments	against	this	decoupling	put	forward,	over	all,	therapeutic	efficiency,	which	
is	 linked	 to	 compliance	 and	 patient	 satisfaction,	 which	 themselves	 depend	 on	 the	
counselling	during	the	healthcare	pathway.		
These	two	classes	of	arguments	rely	on	fundamentally	different	assumptions:	in	the	first	case,	
it	is	implicitly	assumed	that	healthcare	demand	does	not	depend	on	the	quality	of	the	follow-
up	 (no	 reputation	 effect,	 no	 long-lasting	 provider-patient	 relationship,	 no	 competition	
between	providers,	providers	not	being	altruistic).	In	the	second	case,	it	is	implicitly	assumed	
that	 healthcare	 demand	 does	 depend	 on	 the	 quality	 of	 follow-up	 (reputation	 effects,	
durability	 of	 the	 provider-patient	 relationship,	 competition	 in	 quality	 between	 providers,	
altruistic	providers).		
	
This	question	of	decoupling	the	prices	of	“apparatus-service”	refers	to	a	classic	issue	in	“moral	
hazard”	 situations,	 where	 incentive	 based	 reasoning	 is	 required	 in	 a	 framework	 with	
information	asymmetry	between	the	purchaser	and	the	provider60.		
	
The	analytical	framework:		
- The	 financing	 body	 (health	 care	 insurance)	 designs	 payment	 rules	 in	 order	 to	
compensate	the	provider	(the	hearing	aid	professional),	expecting	to	pay	the	least	for	
the	best	quality;	
- The	financing	body,	which	cannot	consistently	control	provider	activity,	 is	 facing	an	
information	asymmetry	that	implies	both	efforts	to	achieve	cost	reduction	and	efforts	
to	improve	quality;		
- It	has	to	design	a	payment	rule	likely	to	incite	the	provider	to	choose	the	best	‘cost-
quality	‘pairing,	namely	the	“optimal	cost”	and	the	“optimal	quality”;		
- It	has	to	choose	between	3	pricing	rules	(or	even	a	combination	of	the	3):		
o A	global	budget	for	all	patients:	this	includes	the	cost	of	the	devices	in	order	to	
satisfy	the	demand,	and	the	provider’s	salary	which	doesn’t	depend	on	demand	
size.	 This	 is	 the	 prospective	 payment	 system	 of	 the	 United	 Kingdom	 or	 in	
Scandinavian	countries	(the	expenditure	is	forecast	ex	ante);		
o A	fee-for-service	applied	both	to	piecework	done	(sold	devices)	and	services	
(depending	on	the	provider’s	counselling	activity).	This	is	the	decoupled	system,	
which	 is	 retrospective	 (payment	 depending	 on	 sold	 devices	 and	 effective	
consultations);	
o An	overall	 payment	by	case/patient,	 being	a	pricing	both	 for	apparatus	and	
service.	This	is	the	prospective	payment	for	the	combination	apparatus-service	
in	France,	Germany	or	Switzerland.		
	
- These	three	payment	rules	do	not	present	the	same	properties	in	terms	of	cost/quality	
incentives:		
o The	global	budget	allows	expenditure	control	and	forecast.	However,	since	the	
provider’s	payment	is	not	dependent	on	quantity	and	quality	of	care,	cost	and	
quality	incentives	are	lacking.	Therefore,	he/she	reduces	his/her	effort	to	the	
minimum	 level,	 translating	 to	a	demand	 rationing	 (delays	 in	equipment	and	
moreover	 follow-up	 delays).	 In	 such	 a	 system,	 in	 general	 patients	 have	 a	
reduced	choice	of	provider	(and	thus,	cannot	make	use	of	their	sensibility	to	
																																																								
	
60	Cf.	for	exemple	Dranove	and	Satterthwaite	(2000)	or	Mougeot	and	Naegelen	(2011).		
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quality	in	order	to	stimulate	the	provider)	but	they	are	totally	subsidised.	Their	
demand	is	high	because	of	total	refunding	and	the	activity	of	providers	is	driven	
by	the	equipment	more	than	by	the	follow-up.	The	consequence	is	a	certain	
non-observance/non-compliance	 (devices	 owned	 but	 not	 worn)	 and	 finally,	
costs	 are	 higher	 because	 of	 the	 lower	 level	 of	 service	 quality	 (ratio	
salaries/effective	activity);		
	
o The	fee-for-service	payment	presents	an	opposite	set	of	incentives.	It	creates	
the	incentive	to	multiply	consultations	and	to	sell	piecework.	In	this	situation,	
the	hearing	aid	professional	 is	 incentivised	to	sell	a	great	number	of	devices	
and	a	great	number	of	counselling	and	follow-up	consultations.	The	hearing	aid	
professional’s	degree	of	freedom	depends	on	the	nature	of	demand,	regardless	
of	the	quality	of	care,	and	on	the	insurance	coverage	rules	for	the	package:		
	
§ If	patient	demand	is	independent	of	quality	of	care:	
	
• If	demand	doesn’t	depend	on	the	perceived	quality	of	care	(for	
example,	a	 totally	passive	and	manoeuvrable	demand),	and	 if	
healthcare	insurance	coverage	is	high,	the	provider	will	saturate	
its	activity	by	choosing	the	more	profitable	route:	high	sales	of	
devices	 associated	 with	 little	 follow-up,	 or	 sales	 of	 useless	
services	(induced	demand).	The	system	is	costly	for	society;		
• If	healthcare	insurance	coverage	is	low,	people	who	are	willing	
to	 pay	will	 be	 equipped	 and	will	 be	 frequently	 offered	 either	
new	devices,	or	a	great	number	of	services,	whereas	people	who	
are	not	 able	 to	pay	will	 renounce	 care	 (at	 least	 for	 follow-up	
services,	even	for	devices).	The	level	of	quality	will	be	optimal	
for	the	people	who	are	willing	to	pay,	but	this	system	is	likely	to	
be	costly	and	is	unfair;	
	
§ If	patients’	demand	depends	on	quality	of	care:	
	
• If	 patients	 are	 sensible	 to	 care	 quality	 (for	 example,	 well-
informed	 patients),	 the	 provider	 cannot	 manipulate	 them	
because	he	runs	the	risk	of	 losing	his	patients,	but	he	will	still	
have	 an	 incentive	 to	multiply	 follow-up	 services	 if	 healthcare	
insurance	coverage	is	high	(patient-provider	coalition):	the	level	
of	quality	is	optimal	but	the	social	cost	is	high;		
	
• If	patient	demand	is	sensible	to	quality	but	healthcare	insurance	
coverage	is	low,	then	the	renunciation	of	care	will	remain,	and	
thus	 the	equipment	 failure	 is	 likely	 to	be	higher	 (some	of	 the	
patients	will	renounce	follow-up	services,	even	for	equipment).	
The	 level	 of	 quality	 isn’t	 optimal	 because	 of	 the	 possible	
renunciation	 of	 care	 (or	 possible	 non-compliance	 in	 case	 of	
access	 to	 equipment)	 whereas	 the	 cost	 of	 follow-up	 for	 the	
others	may	be	high.	
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o The	overall	payment	by	case/patient	looks	like	the	actual	payment	for	hospitals	
in	France:	it	combines	the	act	and	service	in	an	indivisible	way	(for	example,	
hip	 replacement	 or	 cataract).	 This	 system	 presents	 the	 optimal	 incentives	
under	some	conditions	and	is	generally	more	desirable	than	the	other	payment	
systems	(this	is	why	public	authorities	have	given	up	the	global	budget	system	
for	 public	 hospitals	 and	 the	 fee-for-service	 system	 for	 for-profit	 hospitals).	
However,	this	system	isn’t	ideal	and	is	not	defect	free.	There	are	also	two	cases	
to	be	considered,	depending	on	the	nature	of	demand:		
	
§ If	patient	demand	is	independent	of	quality	of	care:	
• If	 patient	 demand	 does	 not	 depend	 on	 the	 quality	 of	 care	
(passive	 and	 manoeuvrable),	 the	 provider	 will	 have	 the	
incentive	to	propose	the	most	profitable	device	and	to	reduce	
the	services	that	are	associated	with	it.	Effort	is	reduced	to	the	
minimum	 level,	with	possible	equipment	 failure.	 If	healthcare	
insurance	 coverage	 is	 high,	 the	 provider	 will	 saturate	 the	
demand	in	order	to	bill	the	greatest	number	of	devices	with	the	
least	possible	follow-up	services;		
• If	healthcare	insurance	coverage	is	 low,	the	provider	will	have	
an	 incentive	 to	 capture	 patients	 who	 are	 willing	 to	 pay	 by	
offering	different	devices	at	different	prices	in	order	to	increase	
revenue,	while	reducing	its	quality	effort	to	the	minimum	level	
in	 terms	 of	 follow-up	 services.	 If	 the	 competition	 between	
providers	is	poor,	it	will	be	easier	for	the	provider	to	capture	the	
clientele.	This	 is	the	argument	of	critics	of	the	actual	coupling	
apparatus-service	in	France;		
	
§ If	patient	demand	depends	on	quality	of	care:	
	
• If	 patient	 demand	 depends	 on	 the	 quality	 of	 care	 (they	 are	
interested	in	the	perceived	quality	of	apparatus	and	service,	and	
are	 likely	 to	 renew	 purchases	 over	 time).	 In	 this	 case,	 the	
provider	 will	 have	 an	 incentive	 to	 propose	 an	 attractive	
combination	of	device	and	service,	namely	the	best	quality	for	
both	 dimensions	 at	 a	 profitable	 cost	 for	 him.	 If	 healthcare	
insurance	coverage	is	high,	the	provider	will	have	an	incentive	
not	to	multiply	the	follow-up	consultations	that	would	reduce	
margins,	but	he	will	have	an	incentive	to	offer	enough	services	
in	order	to	keep	his	clientele,	who	are	sensible	to	quality.	He	will	
have	also	an	 incentive	to	propose	the	most	profitable	devices	
and	 to	 replace	 them	 quickly	 in	 time	 because	 of	 the	 large	
reimbursement	 (coalition	 patient-provider),	 thus	 an	 optimal	
situation	in	terms	of	quality	and	compliance	but	not	in	terms	of	
social	costs.	In	such	a	case,	healthcare	insurance	would	be	well	
advised	 to	 set	 a	minimum	delay	 for	 device	 renewal	 as	 a	 first	
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condition	for	reimbursement	(for	example,	5	years)	and	a	ceiling	
sale	price	as	a	second	condition	for	reimbursement;	
	
• If	healthcare	insurance	coverage	is	low,	the	provider	will	have	a	
strong	incentive	to	deliver	the	optimal	quality	in	order	to	retain	
customers,	whatever	the	type	of	purchased	product	(they	will	
try	 to	 drive	 choice	 towards	 the	 more	 profitable	 upmarket	
products),	 but	 the	 issue	 of	 renunciation	 of	 care	 will	 remain.	
Particular	attention	has	 to	be	paid	 to	 the	possible	 strategy	of	
dumping	and	cream-skimming,	which	would	 introduce	bias	 to	
this	scheme	(choice	of	 less	severe	patients	as	better	from	the	
follow-up	 perspective,	 withdrawal	 of	 care	 for	 certain	 severe	
patients,	different	levels	of	quality	depending	on	the	ability	or	
willingness	to	pay).	In	this	case,	the	provider	must	be	required	
satisfy	 demand,	 whatsoever	 it	 be	 and	 to	 impose	 at	 least	 a	
minimal	follow-up	service	for	each	of	client.		
	
In	 summary,	 the	 issue	of	coupling	or	decoupling	hearing	aid	devices	and	services	 is	not	as	
mundane	as	it	would	appear.	One	of	the	difficulties	encountered	by	the	actual	prospective	
‘payment	 by	 case’	 relies	 on	 the	 specific	 role	 of	 the	 hearing	 aid	 professional,	 being	 the	
prescriber	of	the	device	and,	thus,	the	prescriber	of	the	price	of	the	device-service	pair.	To	put	
it	 simply,	 let’s	 suppose	 that,	 in	 France,	 demand	 for	 hearing	 aids	 is	 relatively	 aware	of	 the	
quality	of	care.	This	assumption	is	the	more	reliable	for	3	reasons:	1)	the	out-of-pocket	sum	is	
so	high	that	it	induces	patients	to	be	aware	of	the	expense	and	to	search	for	information	in	
order	to	realise	a	trade-off;	2)	of	the	oldest	patients,	the	relationship	between	the	provider	
and	the	patient	is	likely	to	be	long-lasting.	In	a	context	of	competition,	quality	and	reputation	
are	likely	to	play	a	noteworthy	role	in	maintaining	a	satisfying	relationship	for	the	user,	for	an	
“experience	service”	whose	quality	is	only	known	after	the	purchase	(and	where	the	follow-
up	 is	 one	 of	 the	 judgement	 criteria)61 	;	 3)	 a	 positive	 reputation	 effect	 derived	 from	 the	
counselling	and	the	follow-up	allows	the	provider	to	increase	his	own	demand.		
	
The	 different	 providers’	 behaviour	 in	 the	 three	 cases	 of	 payment	 systems,	 under	 the	
assumption	of	total	refunding	of	patients’	demand	(an	alternative	scenario	in	comparison	to	
the	current	situation	in	France),	would	be	characterised	as	follows:		
	
-	Providers	paid	on	the	basis	of	a	global	budget	or	salaries	will	reduce	their	activity	and	quality	
effort	and,	as	long	as	their	own	activity	doesn’t	depend	on	perceived	quality	by	the	patient,	
the	effort	is	set	at	the	minimum	level,	but	the	expenditure	for	equipment	is	controlled.	This	
system	 is	 not	 conceivable	 in	 France	 since	 it	 would	 imply	 for	 healthcare	 insurance	 a	 free	
delivery	of	devices	and	a	wage	system	for	hearing	aid	professionals;	
																																																								
	
61	In	 economics,	 an	 experience	 good	 or	 service	 is	 a	 good	 or	 service	 whose	 quality	 is	 only	 known	 after	 the	
purchase.	A	confidence	good	or	service	is	a	good/service	whose	quality	is	never	known	by	the	purchaser.	A	search	
good	or	 service	 is	 a	 good/service	whose	 quality	 is	 known	before	 the	 purchase.	On	 this	 topic	 of	 information	
searching	by	the	patient,	it	should	be	noted	that	the	IGAS	(2014)	considers	that:	“attempts	by	the	person	before	
the	technical	support	equipment	purchase	is	in	itself	non-	compulsory.	However,	such	an	obligation	would	be	
particularly	reliable	for	technical	support	equipment	requiring	strong	personalisation	and/or	a	high	cost	(hearing	
aids	constitute	a	good	example	of	these)”.	p.	76.		
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-	Providers	paid	on	the	basis	of	piecework	and	consultation	fees	will	increase	their	efforts	in	
quantity	and	quality,	but	this	system	would	be	costly	for	healthcare	insurance;	
	
-	The	prospective	payment	by	case/patient	offers	the	advantage	of	providing	better	incentives	
for	 cost	 reduction	 (not	 multiplying	 consultations)	 and	 in	 quality	 improvement	 (patient	
satisfaction	and	reactivity).	Moreover,	it	covers	the	provider	under	the	risk	of	a	distribution	of	
heterogeneous	cases	(severity),	costly	cases	being	compensated	by	non-costly	ones	(as	in	the	
hospital	 pricing	 case),	 under	 the	 condition	 that	 the	 provider	 does	 not	 select	 the	 patients	
(withdrawal	from	severe	cases)	or	does	not	discriminate	against	them	(by	differentiating	the	
levels	 of	 quality).	 The	 health	 insurance	 expenditure	 is	 controlled	 under	 the	 condition	 of	
determining	a	ceiling-price	for	sales	and	a	minimum	delay	of	use.		
What	are	the	options	for	National	Health	Insurance	in	the	case	of	a	prospective	payment	per	
case	and	a	total	reimbursement?		
- Option	1	–	To	cover	the	total	price	of	the	equipment	by	fixing	a	ceiling	price	depending	
on	the	range:	in	this	case,	all	the	prices	will	be	bounded	by	the	maximum	price	of	the	
best	 range,	 and	 so	 the	 system	would	be	 costly	with	 an	optimal	 quality	 and	a	 total	
coverage	of	needs;		
- Option	 2	–	 To	 cover	 the	 total	 price	 of	 the	 equipment	 by	 fixing	 a	 bottom	 price	
corresponding	to	 the	downmarket	or	middle	market	price,	by	 letting	 the	purchaser	
choose	the	devices	and	pay	the	costs	out	of	his	own	pocket:	the	cost	is	controlled,	the	
quality	 is	 optimal,	 and	with	 a	 coverage	 of	 needs	 (this	 system	 is	 similar	 to	 the	 fee	
reference	tariff	applied	to	drugs);		
- Option	3	–	To	organise	the	market	 into	networks	of	contracted	providers:	this	gives	
the	best	control	of	tariffs	but	also	a	risk	of	equalisation	between	a	drop	in	the	product	
price	and	an	implicit	increase	in	quality	price	(i.e.	a	reduction	of	follow-up	quality	that	
would	 result	 from	 the	 patient’s	 captive	 status	 because	 of	 his	 insurance	 contract,	
except	if	the	insurance	companies	made	the	provider-networks	compete	each	year	on	
the	basis	of	patient	satisfaction,	that	is	according	to	a	quality/price	ratio,	in	order	to	
conclude	agreements).	This	option	is	conceivable	but	is	costly	in	terms	of	information	
searching	and	regulation.		
Starting	from	an	efficiency	point	of	view,	and	assuming	that	the	issue	of	equity	is	solved	by	
social	subsidising	of	equipment,	option	2	appears	to	be	more	desirable,	or	a	combination	of	
options	2	and	3.		
	
International	comparisons	show	that	in	general	the	goods	and	the	service	are	indivisible,	but	
that	compliance	and	patient	satisfaction	are	quite	variable,	depending	on	financing	rules,	the	
range	of	prosthesis	and	the	follow-up	service	(which	is	related	to	access	rules	and	payment	
rules	 in	 the	 health	 system).	 As	 will	 be	 shown,	 this	 comparative	 analysis	 for	 people	 being	
equipped	with	hearing	aids	seems	to	demonstrate	the	existence	of	a	link	between,	on	the	one	
hand,	compliance/patients’	satisfaction	and,	on	the	other	hand,	hearing	aid	financing	schemes	
and	types	of	hearing	aid	professional	follow-up.					
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1.3 Hearing	loss	prevalence,	hearing	aid	access	and	pricing	in	comparable	
countries	to	France		
	
The	aim	of	this	section	is	to	complete	the	previous	overview	with	some	key	references	and	for	
several	comparable	countries.	The	access	rate	to	hearing	aids	is	studied	in	particular,	on	the	
basis	of	cross-referenced	data	relating	to	the	observed	access	rate,	the	compliance	rate	and	
the	real	rate	of	eligibility	for	hearing	aids.		
	
1.3.1 Hearing	loss	prevalence,	equipment	rate	and	access	rate	to	hearing	aids		
	
International	comparisons	rely	on	Eurotrak	data	(EHIMA,	2015)	gathered	from	panel	surveys	
(table	19).	In	France,	it	should	be	underlined	that	the	estimated	prevalence	rate	of	hearing	
loss	 is	 very	 close	 to	 the	 previous	 data:	 Eurotrak	 survey	 assess	 it	 to	 be	 at	 10.4%	 in	 2009	
(whereas	the	DREES	estimation	in	2008	ranged	between	11.2%	as	for	‘disabling	hearing	loss’	
and	8.6%	as	for	moderate	to	total	AFL.	In	contrast,	the	rate	of	hearing	aid	owners	was	higher	
in	2009	(3.1%)	compared	to	the	DREES	estimation	(1.8%	in	2008)	and	lower	in	2012	(2.8%)	
compared	to	the	ESPS	survey	(3,7%).	The	access	rate	to	hearing	aids	is	estimated	to	be	34.1%	
in	2015	(cf.	supra	regarding	the	variability	of	estimations).		
	
Hearing	loss	prevalence	rate	across	the	compared	countries	is	very	similar,	ranging	from	8%	
(Switzerland)	to	12.1%	(Germany).		
	
	
Table	20	–		Estimations	for	hearing	loss	prevalence	rate,	equipment	rate,	and	access	rate	to	hearing	aids	–		
Eurotrak	triennial	surveys	(2009,	2012,	2015)	
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Source:	Authors	on	basis	of	EHIMA	data,	2015	
However,	the	hearing	aid	equipment	rate	varies	by	a	factor	of	1	to	3,	Japan	being	the	least	
well	equipped	country	(1.5%)	and	Denmark	the	best.	This	variation	is	also	found	in	the	hearing	
aid	access	rate	for	hearing	impaired	people,	it	is	particularly	low	in	Japan	(13.5%),	quite	weak	
in	Italy	and	the	USA	(around	25%),	mid-point	in	France	and	Germany	(about	34%)	and	high	in	
the	United	Kingdom,	Switzerland	and	especially	in	Denmark	(47.8%).	Thus,	Denmark	will	be	
used	in	this	study	as	the	reference	value	target,	even	if	this	is	only	based	on	one	year’s	data	
(2012).	Moreover,	the	share	for	binaural	equipment	is	high	as	the	access	rate	is	high.		
	
The	analysis	of	Godinho	(2016)	compares	observed	sales	in	nine	European	countries,	gathered	
in	2011	from	the	European	market,	with	the	demographic	data62.	He	identifies	3	groups	of	
countries:		
- Those	where	the	equipment	rate	is	lower	than	5/1000	inhabitants	(Italy,	Spain).	The	
OOP	does	not	suffice	to	explain	the	poor	access	level,	cultural	factors	also	play	a	part;			
- Those	where	the	equipment	rate	ranges	between	5	and	11/1000	inhabitants:	Belgium,	
France,	Switzerland,	Germany.	The	coverage	for	hearing	aids	is	quite	similar	in	these	
countries	 (if	 we	 consider	 the	 additional	 role	 of	 complementary	 health	 insurances	
which	is	not	included	in	the	French	financing	reference	chart).	It	should	be	noted	that	
these	health	systems	are	predominantly	Bismarck	organisations	(i.e.	Social	Insurance)	
except	in	Switzerland	(regulated	liberal	organisation);	
- Those	where	the	equipment	rate	ranges	between	18	and	23/1000	inhabitants	(United	
Kingdom,	Norway,	Denmark),	namely	countries	under	National	Health	Systems	with	a	
total	or	nearly	total	refunding	for	hearing	aids.		
																																																								
	
62	The	market	analysis	relies	on	a	survey	which	is	available	online	(Grant-Salmon,	2013)	and	demographic	data	
are	extracted	from	the	European	database	Eurostat.		
Eurotrack Surveys
% Binaural 
equipment
Country/Year 2009 2012 2015 2009 2012 2015 2009 2012 2015 last year available
France 10.4 9.4 9.3 3.1 2.8 3.2 29.8 30.4 34.1 70
United Kingdom 9.5 9.1 9.7 3.7 3.7 4.1 38.6 41.1 42.4 61
Switzerland nd 8.8 8 nd 3.4 3 nd 38.8 41.4 72
Italy nd 11.6 11.7 nd 2.9 3 nd 24.6 25.2 57
Japan nd 10.9 11.3 nd 1.5 1.5 nd 14.1 13.5 46
Germany 13.1 12.5 12.1 4.2 4.2 4.2 31.8 34 34.9 75
Denmark nd 10 nd nd 4.8 nd nd 47.8 nd 82
USA 11.3 nd nd nd nd nd 24.6 nd nd nd
Norway nd 8.8 nd nd 3.7 nd nd 42.5 nd 74
HL prevalence rate (in % of 
total population)
Equipment rate (in% of 
total population)
Access rate for HAs (in % of 
hearing impaired people)
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Figure	1	–		Sales	of	hearing	aids	for	1,000	inhabitants	in	2011	
	
Source	:	Godinho,	2015/2016	
These	strong	differences	demand	an	in-depth	study	of	hearing	aid	access.		
	
1.3.2 Estimation	of	the	real	access	rate	for	hearing	aids	depending	on	the	eligible	
population	and	on	compliance		
	
Starting	from	the	former	previous	data	(section	1.1	and	1.2),	from	the	Eurotrak	survey	data	
and	 using	 the	 same	 assessment	 methodology	 as	 Alcimed-CNSA	 (2009),	 it	 is	 possible	 to	
propose	an	estimation	for	the	real	access	rate	depending	on	the	eligible	population	and	on	
compliance	in	the	compared	countries.		
	
The	 Alcimed-CNSA	methodology	 is	 as	 following:	 given	 the	 existing	 different	 definitions	 of	
hearing	loss	in	European	countries,	the	study	applies	a	uniform	rate	of	hearing	impairment	of	
12%,	 in	 order	 to	 deduce	 the	 eligible	 population	 (the	 rate	 of	 50%	of	 the	 hearing	 impaired	
population	is	the	consensual	reference	according	to	experts)	and,	then,	to	estimate	the	rate	
of	hearing	aid	owners	(here,	“effective	access	rate”).		In	the	Alcimed-CNSA	study,	two	methods	
are	compared,	taking	(or	not)	 into	account	the	real	rate	of	users	(excluding	the	number	of	
people	owning	hearing	aids	but	not	wearing	them)63.	 In	our	study,	we	combine	both	these	
previous	methods	used	by	the	Alcimed-CNSA	in	order	to	realise	an	estimation	of	the	equipped	
population,	 who	 wear	 their	 hearing	 aids	 (more	 than	 one	 hour	 a	 day),	 as	 these	 data	 are	
available	in	the	Eurotrak	survey	2015	(cf.	tables	21	and	22).	However,	we	do	not	normalise	
the	prevalence	rate	at	12%,	but	we	retain	the	observed	prevalence	rate	 in	each	country	 in	
order	to	better	 integrate	the	national	definitions	of	hearing	 loss	and	hearing	aid	eligibility.	
These	estimations	are	presented	in	table	21.		
	
Table	21	–		Estimation	of	the	effective	access	rate		
																																																								
	
63	Estimated	equipment	rates	 (out	of	compliance)	were:	69%	 in	Sweden,	84%	 in	 the	United	Kingdom,	50%	 in	
Germany,	16%	in	Spain,	27%	in	Italy.	The	study	underlines	that	these	rates	don’t	take	into	account	compliance	
whereas	a	rate	of	45%	is	observed	in	the	United	Kingdom	among	owners	who	do	not	wear	their	hearing	aids.		
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*	In	Germany,	the	compliance	rate	(not	available)	is	estimated	on	the	basis	of	its	main	survey	(2015)	and	is	normalised	at	the	
same	level	as	for	France,	given	similar	data	and	given	the	compliance	rate	in	2009	(15%	of	the	equipped	population).		
Source:	Authors	on	basis	of	EHIMA	data,	2015	
	
Results	of	this	estimation	which	should	be	noted:		
- Effective	access	rates	that	are	notably	high	in	United	Kingdom	(85%),	Denmark	(96%)	
and	Norway	(85%)	approach	the	total	coverage	of	needs,	which	can	be	explained	by	
free	 access	 (or	 almost	 free	 access	 in	 Sweden)	 for	 downmarket	 or	 middle-market	
hearing	aids,	where	prices	are	slightly	lower	than	those	in	France;	
	
- The	 effective	 access	 rate	 in	 France	 rises	 to	 68%:	 it	 means	 that	 2/3	 of	 the	 eligible	
population	is	equipped,	and	thus	the	remaining	number	of	people	who	should	have	
access	to	hearing	aids	is	around	1	million	(based	on	previous	estimations),	a	mid-rate	
level	which	can	be	explained	by	the	financial	barrier;	
	
- Nevertheless,	 the	 compliance	 rate	 (estimated	 as	 the	 rate	 of	 people	 wearing	 their	
hearing	aids	more	than	an	hour	a	day)	is	second-rate	in	the	3	countries	associated	with	
a	high	effective	access	rate	(compliance	/	UK:	80%,	DK:	81%	and	NW:	76%),	hence	the	
real	access	rates	are	obviously	lower:	69%,	76%	and	65%.	These	countries	lose	15%	to	
20%	of	hearing	aid	owners	 in	 the	estimated	 real	 access	 rate	because	of	 this	quasi-	
renouncement	of	equipment	wear;		
	
- At	the	same	time,	the	compliance	rate	is	particularly	high	in	France	(90%),	Switzerland	
(88%)	and	Germany	(90%).	These	high	rates	have	less	impact	on	the	real	access	rate	in	
comparison	to	the	previous	countries;		
	
- As	a	consequence,	real	access	rates	tend	to	converge,	but	for	different	reasons:	on	the	
one	hand,	higher	access	–	because	free	access	-		but	which	is	associated	with	lower	
compliance,	on	the	other	hand,	lower	access	–	because	costly	access	–	but	which	is	
associated	 with	 higher	 compliance.	 These	 rates	 range	 between	 61%	 to	 76%	 of	
equipped	 and	 compliant	 patients,	 France	 has	 the	worst	 score	 (apart	 from	 peculiar	
cases	such	as	Japan	and	Italy).		
	
- If	France	had	Denmark’s	effective	access	rate	(96%),	its	real	access	rate	would	be	86%,	
which	would	give	it	the	best	observable	rate	of	all	the	countries	thanks	to	compliance;	
	
- Only	Switzerland	combines	a	high	access	rate	and	a	satisfactory	compliance	rate;	
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- As	for	Japan,	it	combines	a	low	access	rate	and	a	poor	compliance	rate64,	whereas	Italy	
combines	a	middling	access	rate	with	a	very	satisfactory	compliance	rate.		
	
Taken	thus,	France	presents	a	real	 rate	of	use	close	to	61%	(combining	the	rate	of	eligible	
people	for	hearing	aids	and	the	rate	of	effective	use),	a	rate	similar	to	those	of	the	United	
Kingdom,	Germany	and	Norway	and	starting	from	very	different	situations	in	terms	of	financial	
access	to	equipment.		
If	there	is	room	for	improvement	in	France	regarding	the	need	for	hearing	aid	equipment	–	
due	to	financial	impediment	-	there	is	also	room	for	growth	in	countries	where	hearing	aids	
are	(almost)	freely	delivered	but	where	the	compliance	is	insufficiently	performant.	A	review	
of	financial	rules	relating	to	hearing	aids	has	to	consider	the	compliance	factors	determining	
the	effective	use	of	equipment	and,	 thus,	 the	 level	of	 satisfaction	 for	hearing	aid	users.	A	
trade-off	has	to	be	undertaken	between,	on	the	one	hand,	financial	access	and,	on	the	other	
hand,	suppliers’	and	users’	commitment	to	hearing	aid	use.		
	
	
1.3.3 Determinants	of	access	to	hearing	aids	
	
The	Eurotrak	survey	allows	 for	a	more	precise	analysis	of	 the	 reasons	 leading	 to	access	or	
renouncement	of	hearing	aids	(table	22),	based	on	qualitative	statements.	It	should	be	noted	
that:		
	
	
	
	
	
	
	
	
	
	
	
	
	 	
																																																								
	
64	This	could	be	explained	by	a	combination	of	device	quality	(downmarket	products)	and	follow-up	quality	(often	
poor):	indeed,	one	third	of	purchases	were	made	by	mail	ordered	in	opticians’	shops	(Eurotrak	Japan,	2012).	It	
must	be	noted	that	since	the	decree	of	13	August	2014	(modifying	the	decree	of	15	February	2002)	fixing	the	
goods	that	pharmacists	are	allowed	to	dispense;	they	are	entitled	to	sell	“assistants	for	hearing”	pre-set	at	a	
maximum	power	of	20	dB.	This	equipment	is	then	sold	freely	in	pharmacies	over-the-counter,	at	a	lower	price	of	
500	euros	(in	general	300	euros).	They	are	useful	for	patients	with	a	slight	hearing	loss	and	ought	to	be	used	
occasionally	according	to	the	General	Directory	for	competition,	consumption	and	fraud	repression	(“Direction	
générale	de	 la	concurrence,	de	 la	consommation	et	de	 la	 répression	des	 fraudes”	 (www.economie.gouv.fr	 -	8	
March	2016).		
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Table	22	–		Analysis	of	the	access	factors	–	Triennial	data	Eurotrak	(2009,	2012,	2015)	
	
- Source:	Authors	on	basis	of	EHIMA	data,	2015	
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- The	 financial	 barrier	 predominantly	 affects	 France	 (30%	 of	 people	 consider	 that	
hearing	aids	are	poorly	reimbursed,	that	is,	the	highest	rate	in	European	statements)	
while	 the	main	 argument	 for	non-access	 is	 the	 level	 of	 hearing	 loss	 (considered	as	
slight),	then	the	discomfort	or	even	infrequent	noisy	situations;		
	
- Factors	 leading	 to	 access	 are	 shared:	 hearing	 degradation,	medical	 or	 paramedical	
advice,	advice	from	close	relatives.	This	last	factor	underlines	the	fact	that	it	is	above	
all	a	subjective	assessment	of	hearing	 loss	by	people	close	to	the	persons	suffering	
hearing	 loss	 which	 leads	 to	 access	 more	 than	 the	 self-assessment	 by	 the	 person	
him/herself.		
	
- Compliance	(inversely	proportional	to	the	sum	of	people	who	never	wear	their	hearing	
aids	and	people	who	wear	them	for	less	than	an	hour	a	day)	varies	strongly:	it	is	quite	
low	 in	 Japan,	 the	United	 Kingdom,	Denmark	 and	Norway	where	 either	 the	 rate	 of	
equipment	being	given-up	or	only	occasionally	used	concerns	19%	to	24%	of	equipped	
people.	It	is	better	in	France,	Italy	and	Switzerland	(with	a	10%	to	11%	attrition	rate	
among	equipped	people);		
	
- In	 Japan,	 the	 rejection	 feeling	when	wearing	hearing	 aids	 is	 stronger	 than	 in	other	
countries,	even	if	this	feeling	appears	to	be	less	important	for	hearing	aid	wearers	than	
for	hearing	impaired	people	without	hearing	aid	equipment	(isolation).		
	
Eurotrak	 data	 2012	 relating	 to	 the	 effective	 access	 rate	 have	 given	 rise	 to	 further,	
complementary	analysis	by	Godinho	(2015b),	who	considers	the	following	indicators:		
1. The	metropolitan	population	referenced	in	Eurostat	(in	2012);	
2. Devices	sold	in	2011;	
3. Binaural	equipment	rate	in	2012;	
4. Hearing	loss	prevalence	in	2012.	
Thus,	the	number	of	people	who	purchased	equipment	in	2011	is	estimated	in	each	country	
on	the	basis	of	the	number	of	sold	devices	related	to	the	binaural	equipment	rate	(=	(sold	
devices	number)/	 (2*binaural	equipment	 rate	+	1*monaural	equipment	 rate)).	The	 rate	of	
people	having	purchased	an	equipment	(or	buyer	rate)	in	2011	can	be	deduced	(number	of	
buyers/hearing	impaired	people	number).		
	
Figure	2	–		Estimations	of	several	access	rates	in	the	hearing	aid	market	in	2011	
	
Source:	Godinho,	2015b	
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The	author	estimates	the	ratio	between	the	observed	access	rate	given	by	Eurotrak	(number	
of	 users/number	 of	 hearing	 impaired	 people)	 to	 the	 buyer’s	 rate,	 in	 order	 to	 deduce	 a	
compliance	index.		
	
	
Figure	3	–		Estimation	of	a	compliance	index	
	
Source:	Godinho,	2015b	
	
This	 compliance	 index	 is	 equal	 to	 the	 inverse	 of	 the	 new	 purchases	 rate	 for	 the	 whole	
population	of	hearing	impaired	people	owning	hearing	aids.	The	implicit	assumption	of	the	
author	is	the	following:		if,	as	in	Denmark,	25%	of	hearing	aids	owners	purchase	new	devices	
in	2011,	and	given	the	average	lifespan	of	a	device	(5	years),	the	whole	eligible	population	
should	be	equipped,	even	including	new	buyers	on	the	market.	Yet,	the	hearing	aid	access	
estimated	 by	 Eurotrak	 shows	 that	 the	 latter	 is	 less	 than	 forecast	 regarding	market	 device	
penetration.	The	author	deduces	that	a	portion	of	population	renounces	its	equipment,	and	
doesn’t	even	state	that	it	owns	them	(maybe	after	having	been	equipped	and	given	up).	The	
same	reasoning	applies	in	the	United	Kingdom	where	withdrawal	would	be	high	compared	to	
the	 French	 compliance	 index.	 This	 reasoning	 brings	 into	 light	 another	 explanation	 of	 the	
compliance	issue,	since	it	considers	that	a	rapid	rotation	rate	of	devices	is	a	reliable	indicator	
of	compliance	by	including	‘desertion’:	a	high	rate	would	result	not	only	from	a	total	refunding	
of	hearing	aids	but	also	from	significant	desertion.		
	
From	 our	 point	 of	 view,	 other	 factors	 might	 be	 behind	 this	 explanation:	 free	 provision	
encourages	 rapid	 replacement	 of	 hearing	 aids,	 especially	 if	 they	 are	 downmarket	 devices,	
users	being	willing	to	access	a	presumed	better	quality	new	devices;	and	even,	free	provision	
creates	a	demand	for	which	hearing	aids	are	not	suited,	an	assumption	to	be	investigated.		
	
1.3.4 The	role	of	health	systems	in	hearing	aid	access	and	perceived	efficiency	by	
users		
	
The	price	of	a	hearing	aid	on	the	western	European	market	is	very	similar,	but	coverage	in	
France	is	remarkably	poor	(table	23).	The	average	price	on	the	French	market	is	slightly	higher	
than	in	other	countries,	the	average	bottom	of	the	range	price	is	similar	and	the	average	top	
of	the	range	price	is	lower,	so	there	is	a	strengthening	of	sales	prices	between	the	3	lines	in	
regard	to	other	countries.		
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Table	23	–		Scale	of	price	levels	for	a	hearing	aid	in	several	European	countries	
	
Source:	Authors	on	basis	of	Alcimed-CNSA	data	(prices	of	2009)		
and	Competition	Authority	in	France	(price	of	2014)	
	
Countries	that	cover	the	total	price	of	hearing	aids	or	a	fixed	price	in	general	offer	bottom-of-
the-market	 or	midmarket	 devices.	 Apart	 from	Spain,	 systems	do	not	 reimburse	 on	 age	or	
disability	criteria.	Countries	where	hearing	aid	professionals’counselling	 is	considered	 ‘low’	
(United	Kingdom)	are	characterised	by	reduced	compliance:	“45%	of	users	benefiting	from	an	
NHS	hearing	aid	do	not	wear	it,	because	it	is	badly	tuned	or	badly	adjusted	to	their	type	of	
hearing	loss”65.	The	out-of-pocket	amount	varies	between	countries	according	to	two	models	
:	either	the	health	system	directly	delivers	the	hearing	aid	and	the	owner	cannot	opt	for	a	
more	expensive	device,	not	included	on	the	list	of	approved	products	(no	OOP),	or		the	health	
system	 pays	 a	 fixed	 price	 corresponding	 to	 bottom	 of	 the	 market	 devices	 (no	 OOP),	 the	
purchaser	then	choosing	the	market	line	on	the	basis	of	his	willingness	to	pay	any	supplement	
beyond	the	basic	fee	(such	a	system	based	on	willingness	to	pay	is	similar	to	‘reference	price’	
or	 ‘standard	 tariff	 of	 responsibility’	 systems).	 Patient	 satisfaction	 is	 higher	 in	 the	 case	 of	
possible	choice,	while	 the	others	are	able	 to	opt	out	 towards	 the	private	market	as	 in	 the	
United	Kingdom.		
	
	
In	 1999,	 although	 the	 average	 French	 price	 for	 a	 hearing	 aid	 was	 the	 lowest	 among	 the	
comparable	countries,	hearing	aid	access	was	also	one	of	the	lowest	of	developed	countries	
(by	a	factor	of	2	to	4	times).	France,	along	with	Italy,	appeared	amongst	countries	where	social	
financing	was	 lowest,	 reimbursing	 only	 one	 ear	 (partial	 reimbursement),	while	 only	 Spain	
provided	no	coverage.		
	
	
	
	
	 	
																																																								
	
65	Alcimed-CNSA	(2009),	p.	10.		
Country
Price inc. VAT Euros/HA OOP Euros/HA OOP Euros/HA OOP Euros/HA OOP Euros/HA OOP Euros/HA OOP
Basic na na na na 640 0% 400 0% na na na na
Downmarket 979 0%
570 to 
1300
0%
700 to 
800
0% 1100 0%
1100 to 
1600
100% 950 87%
Middle market
979 to 
1879
100%
1800 to 
2300
100%
1000 to 
2000
Price 
minus fee
1100 to 
1300
Price 
minus fee
1700 to 
2100 
100% 1550 92%
Upmarket 2792 100%
2700 to 
2800
100% 3900 3300
2400 to 
2600
2000 to 
2400
2200 to 
3100
100% 1850 94%
na : not available
FranceSweden United Kingdom Italy Germany Spain
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Table	24	–		Comparison	of	the	price	and	reimbursement	rules	for	a	digital	hearing	aid		
in	several	comparable	countries	in	1999	(in	francs)		
	 	
Source:	Conseil	national	de	la	consommation,	2000	
	
The	price	level,	the	degree	of	coverage	and/or	the	market	line	of	devices	could	have	an	impact	
on	 its	 median	 lifespan,	 although	 this	 only	 appears	 as	 a	 trend	 and	 is	 not	 systematically	
observable	 (table	 25).	 	 In	 France,	 the	 median	 lifespan	 is	 6	 years,	 whereas	 in	 the	 United	
Kingdom	and	Denmark	it	is	4	years.	For	actual	hearing	aid	users,	the	daily	time	of	use	is	8	to	9	
hours.	 It	 should	be	noted	 that	 this	daily	 time	 in	Denmark	 is	 in	contrast	 to	 the	given-up	or	
occasional	rate	(20%):	the	distribution	analysis	of	the	time	of	use	in	hours	shows	that	2	types	
of	 population	 are	 concentrated	 at	 the	 extremes,	 the	 non-compliant	 users	 and	 the	 very	
compliant	users	(cf.	Eurotrak	DK,	2012,	p.	56).		
	
Table	25	–		Comparison	of	indicators	of	equipment	lifespan	and	on	daily	length	of	use	
	
Source:	Authors	on	basis	of	EHIMA	data,	2015	
	
	
As	 regards	 overall	 satisfaction,	 the	 survey	 shows	 that	 France	 has	 the	 best	 rates	with	 84%	
satisfied	users	(comparable	rates	to	Switzerland’s).	These	rates	are	clearly	better	than	those	
of	Germany,	the	United	Kingdom,	Denmark	and	Norway,	and	they	are	also	reliable	with	the	
compliance	rate	stated	in	our	study66.		
	
																																																								
	
66	Our	study	further	exploits	the	more	detailed	results	of	the	Eurotrak	survey	regarding	satisfaction	and	quality	
of	life.		
Netherland 11	390 Social	security	:	3	800	F	(2	ears)
Switzerland 13	500 75	%	for	retired	people,	100	%	for	
working	people	(2	ears)
USA 21	000 Private	insurances
Germany 11	200 80	%	(2	ears)
Spain 12	400 No	reimbursement
Italy 12	400 670	F	(1	ear)
France 9	000	to	10	000 1	310	F	(1	ear)
Countries
Price	for	a	
hearing	aid	in	
francs
Reimbursement	rules
Indicators Median lifespan of a HA
Average age of equipment (at the 
time of the survey) 
Daily length of use in hours 
Country Last year available Last year available Last year available
France 6 2.9 8.6
United Kingdom 4 2.1 8.1
Switzerland 6 2.1 9,0
Italy 4 2.5 8.4
Japan 5 4.1 6.8
Germany 5 na na
Denmark 4 4.1 9.2
Norway 6 2.7 7.9
na : not available
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Table	26	–		Overall	satisfaction	of	users	(7	possible	answers,	from	‘very	unsatisfied’	to	‘very	satisfied’:	
satisfaction	=	total	of	3	satisfaction	groups	–	enough,	well,	very	well)		
	
Source:	EHIMA,	2015	
	
As	 underlined	 by	 the	 IGAS	 (2013),	 it	 is	 best	 to	 remain	 careful	 when	 interpreting	 this	
satisfaction	 score,	which	also	 reflects	 socio-cultural	differences	and	collective	preferences.	
Similarly,	 a	 score	 function	 cannot	 be	 transposed	 from	one	 country	 to	 another,	 and	 in	 the	
framework	of	a	quality	of	life	assessment	which	relies	on	a	preference-based	questionnaire	
(such	 as	 EQ-5D	 or	 HUI3),	 it	 is	 tricky	 to	 compare	 these	 rates	 that	 do	 not	 cover	 the	 same	
collective	 preferences	 regarding	 health	 status.	 It	 would	 be	 more	 interesting	 to	 observe,	
country	by	country,	preference	variations,	but	data	are	insufficient	to	state	a	trend.		
		
Empirically,	it	is	however	interesting	to	underline	the	presumed	link	between	the	compliance	
index	 (inverse	 of	 equipment	 rotation	 rate	 for	 the	 eligible	 hearing	 aid	 population)	 and	 the	
satisfaction	rate	(Godinho,	2015b).	The	author	linked	this	index	with	the	overall	satisfaction	
rate	in	2012.	Apart	from	Italy,	he	observed	a	close	relationship	between	satisfaction	rate	and	
compliance	 rate:	 where	 the	 satisfaction	 rate	 drops	 from	 80%	 (France)	 to	 72%	 (United	
Kingdom),	the	compliance	 index	 is	2	times	 lower.	Two	groups	of	countries	are	 identifiable:	
Switzerland-France-Germany	 characterised	 by	 both	 a	 performant	 satisfaction	 rate	 and	
compliance	index;	and	the	group	Norway-Denmark-United	Kingdom	where	a	less	performant	
satisfaction	rate	is	associated	with	less	compliance.	Italy	has	a	unique	position	(with	a	high	
compliance	index	and	middling	satisfaction).	This	position	is	due	to	a	bias	in	the	comparison,	
because	the	binaural	equipment	rate	is	low	(44%)	and	the	access	rate	particularly	low.	The	
compliance	 would	 remain	 high	 for	 equipped	 people,	 because	 of	 insufficient	 access	 (OOP	
remaining	high);	the	choice	would	be	driven	towards	basic	or	downmarket	devices	given	the	
coverage	(zero	OOP	in	these	cases),	explaining	only	middling	satisfaction.	As	regards	the	two	
criteria	(compliance/satisfaction),	the	best	group	is	Switzerland-France-Germany:	this	analysis	
reinforces	the	previous	approach	in	terms	of	real	access	rate.		
	
The	 international	 comparison	 of	 Alcimed-CNSA	 (2009)	 which	 focused	 on	 traditionally	
‘Beveridge-type’	countries	(Sweden,	the	United	Kingdom,	Italy,	and	Spain)	and	a	‘Bismarck-
type’	country	(Germany)	showed	moreover	that	equipment	rates	were	not	only	dependent	
on	 the	 financing	 system	 but	 also	 on	 cultural	 factors	 (southern	 countries	 more	 often	
renouncing	 equipment	 which	 is	 seen	 as	 a	 disability	 indicator),	 or	 else	 on	 users’	 lack	 of	
information	or	the	device	type	(downmarket	etc.).		
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Starting	from	their	statements	and	from	our	analysis,	the	main	elements	to	be	underlined	are	
the	following:		
	
- The	optimal	equipment	rate	in	each	country	is	not	as	standardised	as	in	the	previous	
estimations	 (for	 example	 50%	 of	 hearing	 impaired	 people,	 because	 of	 cultural	
differences	 between	 countries,	 or	 medical	 advice	 or	 social	 disability	 perceptions).	
Moreover,	this	rate	is	likely	to	change	over	time.	This	statement	slightly	restricts	the	
significance	of	our	estimations;		
	
- A	refunded	access	in	France	would	involve	changing	the	system	in	a	politically	radical	
direction	 and,	moreover,	 it	 has	 been	 observed	 that	 free	 access	 in	 National	 Health	
Systems	is	associated	with	a	lower	compliance	and	so	to	a	lower	efficiency	(a	weaker	
result):	 it	 is	 not	 possible	 to	 state	 if	 this	 is	 a	 consequence	 arising	 from	 lower	 user	
commitment,	or	if	it	is	an	effect	of	integrated	systems	which	associate	free	access	with	
access	rationing	(it	is	a	possible	explanation	of	insufficient	adaptation	and	follow-ups	
by	 hearing	 aid	 professional),	 or	 even	 if	 it	 is	 an	 impact	 of	 hearing	 aid	 quality	
(downmarket	and	mid-market	ones).	The	assumption	of	a	lack	of	interest	in	follow-ups	
by	hearing	aid	professionals	and/or	organisational	barriers	to	follow-up	access	should	
-be	favoured	here67	;	
	
- The	issue	of	decoupling	the	device	and	the	service	by	means	of	separate	pricing	cannot	
be	discussed	regarding	other	countries	included	in	the	comparison.	Indeed,	it	would	
be	necessary	to	investigate	this	question	by	itself.	In	general,	both	activities	are	not	
dissociated	 in	 western	 European	 countries	 (Alcimed-CNSA,	 2009).	 If	 they	 were	
separated,	 the	 compliance	 rate	 would	 be	 affected	 since	 the	 follow-up	 service	 is	
associated	to	an	OOP	for	patients.	Moreover,	it	would	probably	generate	an	extra	cost	
in	terms	of	business	activity	(relaunches,	induced	demand),	that	would	be	passed	on	
in	prices,	associated	with	a	risk	of	activity	deviating	from	various	patient	needs	and	
which	focused	instead	on	their	ability	to	pay.	A	conventional	bounded	minimal	price	
for	 middle-market	 hearing	 aids,	 identical	 in	 every	 place,	 including	 the	 service,	 is	
probably	a	more	desirable	pathway	for	users;		
	
- The	device	lifespan	varies	between	countries,	which	has	an	impact	on	the	overall	cost	
for	several	years.	This	 lifespan	certainly	depends	on	financing	rules	(it	 is	reduced	 in	
countries	where	coverage	is	large)	or	on	the	initial	investment	cost	(the	choice	of	an	
upmarket	device	may	be	associated	with	a	longer	lifespan	as	in	France);	
	
- Overall	user	satisfaction	varies	between	countries	yet	is	quite	comparable	(apart	from	
Japanese	people	for	whom	subjective	assessment	of	health	status	is	structurally	lower	
than	those	in	other	countries	–	OCDE,	2015).	This	satisfaction	rate	seems	to	be	linked	
to	the	compliance	rate,	and	so	probably	to	the	hearing	aid	professionals’	counselling	
service,	 since	 the	 device	 performances	 are	 likely	 to	 be	 similar	 according	 to	 what	
experts	say	(cf.	infra,	section	4).	The	market	line	of	devices	may	also	play	a	role;		
	
																																																								
	
67	In	accordance	with	our	previous	analysis	on	hearing	aid	pricing.		
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- It	is	important	that	the	user	can	in	fine	choose	their	preferred	device	in	order	to	sustain	
a	better	compliance	(thanks	to	a	fixed	price,	users’	preferences	and	their	willingness	
to	pay).	A	higher	reimbursement	of	downmarket	or	middle	market	devices	ensures	
user	solvency	and	allows	for	this	trade-off;	
	
- Compliance	depends	closely	on	device	suitability	to	needs,	which	relies	on	the	hearing	
aid	professional’s	role	(however,	bias	in	this	counselling	and	advice	is	possible	in	the	
case	independent,	non	state-salaried	practitioners);		
	
- Compliance	depends	closely	on	adaption	and	follow-up	and,	thus,	impose	to	deliver	
information	next	 to	 the	user,	 about	 the	device	and	 the	added-value	of	hearing	aid	
professional’s	 counselling	 (that	are	more	often	billed	on	an	ex	ante	 basis	 in	all	 the	
countries);	
	
- the	 added-value	 of	 upmarket	 devices	 should	 be	 more	 fully	 discussed	 in	 scientific	
literature,	in	order	to	dissociate	the	effect	‘high	technology’	and	the	effect	‘quality	of	
service’	in	patient	satisfaction.	According	to	the	different	hearing	aid	market	lines,	the	
issue	 of	 lack	 of	 information	 about	 added-value	 is	 a	 major	 impediment	 in	 the	
assessment	of	their	relative	utility;		
	
- geographical	accessibility	of	hearing	aid	centres	as	well	as	access	delays	to	follow-up	
appointments	have	to	be	analysed	through	the	issues	of	compliance	and	counselling.	
It	 is	also	necessary	to	study	access	via	references	from	prior	consultations	with	ENT	
physicians	and	general	practitioners	(and	particularly	the	medical	demography);	
	
- the	 lack	 of	 information	 and	 monitoring	 a	 posteriori	 of	 ENT’s	 or	 GP’s	 medical	
recommendations	 and	 advice	 is	 a	 common	 feature	 in	 countries,	 which	 limits	 the	
possible	field	for	equipment	assessment.		
	
The	 significant	 growth	 of	 equipment	 rate	 in	 France	 during	 the	 last	 few	 years	 seems	 to	
demonstrate	the	impact	of	technological	improvement	on	the	preferences	of	eligible	people	
for	hearing	aids:	
- they	increasingly	access	hearings	aids	despite	the	price	to	pay;	
- hearing	aid	miniaturisation	and	their	low-visibility	leads	to	better	access	and	make	it	
commonplace,	even	for	younger	people	with	the	spread	of	connected	hearing	aids.		
	
The	 main	 obstacle	 to	 hearing	 aid	 access	 in	 France	 (financial	 barrier)	 questions	 current	
financing	rules,	and	particularly	the	public	trade-offs	that	have	led	hearing	aids	to	be	classified	
in	the	‘low	risk’	category	and	practically	pushed	out	of	socialised	health	care.	This	classification	
implicitly	indicates	that	the	hearing	aid	is	a	luxury	product	whose	medical	added-value	is	very	
low:	 in	comparison	to	the	trade-offs	for	drug	classification,	the	hearing	aid	medical	added-
value	ranges	between	‘low’	and	‘insufficient’,	since	its	observed	reimbursement	rate	is	under	
15%.			
Yet,	wide	access	to	hearing	aids	(2/3	in	terms	of	‘real	access’	of	the	eligible	population)	shows	
clearly	that	demand	elasticity	is	low:	they	are	a	necessary	item.	In	general,	the	public	choice	
of	 coinsurance	depends	on	 the	 combination	of	 ‘low	 risk’	 and	 ‘commitment’.	 There	 is	 only	
partial	reimbursement	in	relation	to	‘low	risk’,	or	even	totally	exclusion	from	the	social	health	
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care	basket	when	it	does	not	depend	on	the	collective	responsibility	and	implies	an	individual	
judgement	on	the	trade-off	between	consumption-price	(in	order	to	avoid	over-consumption	
or,	in	economics,	the	‘moral	hazard’	risk).	Yet,	not	only	is	access	significant	despite	the	OOP	
payment,	but	moreover	–	contrary	to	optics	–	its	health	consequences	as	well	as	its	economic	
impact	 are	 likely	 to	be	major.	 The	 cost	 to	 society	of	 hearing	 aid	 renunciation,	 in	 terms	of	
quality	 of	 life,	 expenditure	 and	 social	 inequalities	 is	 in	 total	 opposition	 to	 the	 objectives	
assigned	to	the	French	health	system.		
	
The	survey	of	scientific	literature	which	follows	in	the	next	section	will	shed	light	on	the	link	
between	hearing	loss	and	people’s	morbidity-mortality	rate,	allowing	to	estimate	the	burden	
of	illness.		
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2 Health	and	economic	consequences	of	hearing	loss:	impact	
study	
	
Nowadays,	hearing	loss	is	considered	as	a	major	public	health	issue	in	the	scientific	literature	
and	by	international	health	agencies.	The	World	Health	Organisation	(WHO,	2016)	estimates	
that	the	burden	of	illness	actually	concerns	more	than	5%	of	the	global	population,	namely	
360	million	people,	and	one	third	of	the	population	aged	over	65,	with	a	dominant	prevalence	
in	low-	and	middle-income	countries68.	Since	hearing	loss	prevalence	is	rising	with	age,	actual	
ageing	 of	 the	 global	 population	 would	 else	 increase	 this	 prevalence,	 with	 an	 over-
representation	of	moderate	to	total	hearing	loss.		
	
It	 is	 the	most	 frequent	sensory	deficiency,	 leading	to	a	great	degradation	of	quality	of	 life,	
which	is	associated	with	substantial	economic	and	societal	costs.	The	main	consequences	of	
hearing	loss	are	due	to	the	decrease	in	communication	and	human	interaction,	which	has	an	
impact	upon	mental,	psychological	and	cognitive	dimensions	of	 the	person’s	health	status.	
These	 consequences	 have	 been	 known	 for	 a	 long	 time,	 as	 in	 2006	 Shield	 reviewed	 them,	
showing	 that	 psycho-social	 effects	 were	 already	 being	 referred	 to	 in	 1979.	 The	 main	
dimensions	of	well-being	 (in	 the	 actual	 assessable	 sense,	 namely	health	 state,	wealth	 and	
education/qualification	 level)	 affected	 by	 hearing	 loss	 and	 referenced	 by	 the	 author	 are:	
global	 quality	of	 life;	 loneliness,	 social	 isolation	 and	exclusion;	 psychiatric	 disturbance	and	
depression;	 family	 relationships;	 stigma	 and	 low	 self-esteem;	 education;	 difficulties	 in	
particular	 environments;	 general	 health	 estimated	 in	 terms	 of	 doctor’s	 consultations;	
cognitive	 skills	 and	 dementia;	 memory	 loss;	 intimate	 relationships;	 prejudice	 and	 abuse;	
employment;	all	these	dimensions	are	also	associated	with	denial	for	a	fraction	of	impaired	
hearing	people.		
	
Causal	relationships	between	hearing	loss	and	each	of	these	dimensions	are	better	recognised	
and	quantified	in	the	recent	literature.	Given	that	this	this	literature	is	abundant,	we	propose	
a	 survey	 of	 the	 main	 papers	 on	 this	 topic	 (and	 not	 a	 systematic	 review	 of	 the	 scientific	
literature).	Moreover,	we	have	selected	papers	specifically	focused	on	the	elderly,	but	with	a	
specific	 inclusion	 of	 papers	 questioning	 the	 link	 between	 hearing	 loss	 and	 professional	
situations	for	the	adult	workforce.		
	
2.1 Observed	 scientific	 connections	 between	 hearing	 loss	 and	 morbi-
mortality	in	adults	and	elderly	populations	
	
In	the	international	literature,	numerous	papers	study	the	connection	between	hearing	loss	–	
one	 of	 the	most	 frequent	 chronic	 health	 status	 for	 elderly	 –	 and	 several	morbi-mortality	
indicators.	 Thus,	 hearing	 loss	 is	 independently	 associated	 with	 mortality,	 heart	 attack,	
ischemic	heart	disease,	diabetes,	 and	 smoking69.	Also,	 it	 is	 established	 that	hearing	 loss	 is	
																																																								
	
68	The	WHO	(2016)	defines	hearing	loss	as	an	impairment	implying	at	 least	a	 loss	of	40	dB	in	the	best	ear	for	
adults	and	30	dB	for	children.		
69	The	independent	association	means	here	that	age	impact	effect	is	controlled.		
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associated	with	functional,	physical	and	psychosocial	deficiencies,	or	else	with	a	lower	quality	
of	life,	an	increased	risk	of	institutionalisation,	falls,	cognitive	decline,	car	crashes,	and	even	
less	ability	in	relation	to	personal	health	empowerment70.	In	other	words,	the	burden	of	illness	
is	 likely	 to	 be	 heavier	 for	 hearing	 impaired	 people,	 not	 only	 because	 of	 the	 hearing	
degradation	 which	 decreases	 communication	 capacities,	 but	 also	 for	 associated	 morbi-
mortality.	In	the	literature,	the	connections	that	are	mostly	recorded	for	the	elderly	and	for	
which	a	presumed	causality	is	stated,	concern	mortality	risk,	mental	health	degradation	and	
cognitive	decline.	Hence,	our	review	will	be	primarily	focused	on	these	issues.	Secondly,	we	
will	 bring	 up	 the	 connection	 between	 hearing	 loss,	 labour	 market	 integration	 and	 social	
relationships/leisure	activities.		
	
2.1.1 Hearing	loss	and	associated	limitations	in	France	
	
In	 order	 to	 assess	 the	extent	 to	which	 activity	 restrictions	 (daily,	 professional	 and	 leisure)	
depend	on	auditive	functional	limitations	(AFL,	cf.	supra),	it	is	important	to	differentiate	the	
latter	 from	other	 associated	deficiencies	 and	 functional	 limitations.	 This	 analysis	 has	been	
driven	by	the	DREES	(Haeusler	et	al.,	2014;	Haeusler	et	Mordier,	2014),	which	distinguishes,	
on	 the	 one	 hand,	 deficiencies	 associated	 with	 AFL	 and,	 on	 the	 other	 hand,	 functional	
limitations	–	apart	from	auditive	ones	-	related	to	these	deficiencies.		
	
2.1.1.1 Associated	deficiencies	with	hearing	loss	
	
In	2008,	given	a	similar	age	and	sex,	77.4%	of	people	affected	by	moderate	to	total	AFL	stated	
that	 they	had	at	 least	one	another	associated	deficiency	apart	 from	auditive,	being	either	
motor,	visual,	intellectual,	cognitive,	or	other	(against	63.3%	in	the	general	population).	This	
rate	is	clearly	different	since	moderate	visual	deficiencies71	are	excluded	from	the	field,	given	
that	 they	 almost	 equally	 concern	 both	 populations	 (i.e.	 moderate	 to	 total	 AFL	 /	 general	
population):	indeed,	68%	of	people	affected	by	moderate	to	total	AFL	declared,	in	2008,	that	
they	had	an	associated	deficiency,	against	37%	of	the	general	population.		
	
The	most	significant	gaps	that	can	be	observed	regarding	the	standardised	rate	are:		
- Motor	deficiencies:	35.1%	against	20.3%;	
§ Significant	discomfort	in	joints		 	 	 (24.3%	/	14.5%);	
§ Muscular	strength	limitations		 	 	 (14.7%	/	8.3%);	
§ Balance	troubles		 	 	 	 	 (12.3%	/	5.2%);	
- Deficiencies	relating	to	speech:	8.9%	/	2.5%;	
- Psychological,	intellectual,	cognitive	deficiencies:	39.3%	/	20%	
§ Significant	memory	troubles		 	 	 (10.1%	/	4.8%);	
§ Mood	troubles		 	 	 	 	 (19.7%	/	8.7%);	
§ Anxious	troubles		 	 	 	 	 (23%	/	12.6%);	
§ Difficulties	in	relationships	with	others		 	 (10.8%	/	3%);	
§ Understanding	difficulties		 	 	 	 (7.9%	/	2%).	
																																																								
	
70	Cf.	for	example	Karpa	and	al.	(2010)	or	Archbold	and	al.	(2014).		
71	Defined	as	the	“difficulty	to	see	closer	or	further,	but	neither	blind,	nor	visually	impaired”.		
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As	concerns	motor	deficiencies	as	well	as	psychological,	intellectual	and	cognitive	deficiencies,	
the	gaps	between	both	populations	were	found	at	all	ages.	Greatly	higher	anxiety	troubles	
and	mood	troubles	are	a	notable	characteristic	for	hearing	impaired	people.		
	
2.1.1.2 Functional	limitations	associated	with	hearing	loss	
	
46%	of	people	affected	by	moderate	to	total	AFL	had	declared	another	associated	functional	
limitation	 (against	 20%	 of	 the	 global	 population).	 These	 associated	 deficiencies	 could	 be	
visual,	motor,	psychological,	intellectual	as	well	as	cognitive,	and	some	of	them	could	be	the	
direct	 consequence	of	 hearing	 loss,	 particularly	 learning	 or	 understanding	 activities:	 as	 an	
illustration,	 it	can	be	seen	that	 learning	difficulties	or	memory	troubles	were	3	times	more	
frequent	than	in	the	global	population	(table	27).		
	
Table	27	–		Prevalence	of	functional	limitations	apart	from	auditive	for	people		
affected	by	moderate	to	total	AFL	compared	to	general	population	(2008)	
	
Source:	Haeusler,	Mordier,	2014	
	
The	functional	 limitations	that	were	most	frequently	declared	are	those	related	to	exterior	
displacements.	 Psychological,	 intellectual	 or	 cognitive	 limitations	 affected	 18%	 of	 hearing	
At least one important limitation linked to eyesight 436000 8% 5% 3%
To see print characters (possibly with glasses or lenses) 353000 7% 4% 2%
To see a face at 4 meters (possibly with glasses or lenses) 243000 4% 2% 1%
At leat one important limitation linked to moving 1407000 26% 14% 8%
Able to walk 500 meters on flat ground without help or cane 838000 15% 7% 4%
Able to go up and down a floor of stairs without help or cane 940000 17% 7% 5%
Able to carry a 11 pds bag of supplied for 10 m without help 1140000 21% 11% 7%
At least one important limitation affecting the upper body 618000 11% 6% 3%
Raise the arm 601000 11% 4% 2%
Use his/her hands and fingers in order to take an object 537000 10% 2% 1%
Take an object with his/her hands without technical help 195000 4% 2% 1%
Other important motor limitation
To bend down or to kneel down without help 1310000 24% 11% 7%
At least one important psychological, mental or cognitive 999000 18% 17% 8%
Not able to remember what time of day it is 145000 3% 2% 1%
Memory lapses during the day 303000 6% 5% 2%
Difficulties to concentrate for more than 10 minutes 230000 4% 6% 2%
Difficulties in daily life (find his/her bearings on an itinerary, add up money) 331000 6% 5% 2%
Difficulties to learn new knowledge or know-how 440000 8% 7% 3%
Difficulties to understand  others or to be understood 217000 4% 6% 1%
Imperilment (apart from that caused by eyesight problems) 146000 3% 3% 1%
Too impulsive or agressive 259000 5% 6% 3%
At least one another important limitation 1126000 21% 9% 7%
To bite and chew hard foodstuffs 984000 18% 8% 6%
To control his/her stool and urines 333000 6% 3% 2%
At least one important functional limitation 2507000 46% 32% 20%
Overall 5433000
Number of 
persons 
concerned 
among the 
people affected 
by moderate to 
total AFL 
Gross 
rate
Standardi
sed rate
Overall 
Population
Key : 363,000 persons, 6.7% of people affected by moderate to total AFL have many difficulties or cannot 
see at all printed characters of a newspaper. Standardised by age and sex, i.e. eliminating the differences 
due to demographic structure, this rate is at 4.1% against 2.1% for the whole population
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impaired	people,	often	occurring	through	memory	lapses,	concentration	difficulties,	learning	
new	knowledge	or	know-how	difficulties,	or	else	difficulties	to	make	themselves	understood	
or	to	understand	others.		
	
2.1.1.3 Activity	restrictions	and	social	involvement	associated	with	hearing	loss	
	
For	France,	the	study	of	Haeusler	and	Mordier	(2014)	showed	that	involvement	in	social	life	is	
only	 reduced	 for	 people	 affected	 by	 heavier	 AFL,	 and	 in	 general	 activity	 restrictions	were	
mostly	related	to	non-hearing	limitations:	of	19	daily	restrictions,	the	two	main	situations	–	
for	severe	or	total	AFL	–	were	the	independent	use	of	a	phone	and	calling	for	the	emergency	
services.	For	people	aged	over	60,	access	for	assistance	in	daily	activities	is	higher	when	people	
are	 affected	 by	 moderate	 to	 total	 AFL	 (35%	 against	 22%	 for	 people	 not	 being	 hearing	
impaired),	 but	 the	 accumulation	 of	 several	 health	 troubles,	 functional	 limitations	 and	 the	
ageing	effect	makes	 it	arduous	to	highlight	a	causal	 relationship	between	hearing	 loss	and	
autonomy	loss:	very	severe	to	total	AFL	are	associated	with	an	autonomy	loss,	itself	leading	
to	a	more	important	access	to	assistants.	However,	this	access	is	not	only	due	to	AFL	severity	
but	also	to	associated	functional	limitations.		
	
People	with	AFL	who	are	in	the	work	force	differed	from	those	in	the	general	population	by	
having	 a	 lower	 level	 of	 qualifications:	 the	 more	 severe	 the	 limitation,	 the	 lower	 the	
qualification.	 As	 for	 employment	 access,	 the	 activity	 rate	 of	 people	 being	 affected	 by	
moderate	 to	 total	 AFL	 was	 similar	 to	 that	 in	 the	 general	 population,	 indicating	 an	
improvement	in	occupational	integration	over	a	decade.	However,	the	severity	level	of	AFL	
had	an	impact	on	the	opportunities	to	aim	for	managerial	positions.		
	
Moreover,	the	same	study	showed	that	social	relationships,	being	estimated	by	the	likelihood	
to	live	as	a	couple,	were	not	impacted	by	the	hearing	trouble	except	in	very	severe	or	total	
AFL,	and	nor	were	social	relationships,	being	estimated	by	the	frequency	of	familial	or	friendly	
meetings:	 the	 frequency	of	 friendly	meetings	 reduces	with	age,	 independently	of	 involved	
AFL.	Nevertheless,	these	favourable	results	have	to	be	considered	with	caution,	to	the	extent	
that	the	quality	of	conversation	and	their	dependency	on	AFL	level	could	not	be	measured.		
	
The	French	study	also	showed	that	the	boundary	of	leisure	activities	for	people	affected	by	
AFL	is	reduced,	with	a	notably	lower	involvement	compared	to	the	general	population	(81%	
for	AFL	comprising	all	severity	levels,	55%	for	moderate	to	total	AFL	and	90%	for	the	general	
population).	 The	 impact	was	 particularly	 clear	 on	 activities	 such	 as	 “listen	 to	music”	 (62%	
against	83%)	and	“go	to	the	cinema”:	the	probability	of	going	to	the	cinema	was	reduced	by	
30%	 in	 cases	 of	moderate	 AFL	 and	 by	 50%	 in	 cases	 of	 severe	 to	 total	 AFL	 (Haeusler	 and	
Mordier,	2014).	It	should	be	underlined	that	“for	people	over	60	years,	hearing	troubles	do	not	
have	an	impact	on	the	number	of	leisure	activities	practiced”72.		
	
	 	
																																																								
	
72	p.	15.		
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2.1.2 Main	findings	in	medical	scientific	literature		
	
The	main	recent	findings	in	medical	scientific	literature	have	shown	the	association	between	
hearing	loss	and	risks	of	mortality,	many	mortality	risk	markers,	falls,	degradation	of	mental	
health,	 and	 cognitive	 decline	 for	 older	 people	 over	 50.	 They	 have	 also	 highlighted	 the	
difficulties	 encountered	 on	 the	 labour	 market	 for	 working	 people.	 Finally,	 they	 have	
demonstrated	the	positive	impact	of	hearing	aids	on	the	risk	of	health	status	degradation.		
	
2.1.2.1 An	increased	risk	of	mortality		
	
For	people	aged	50	and	over,	 studies	have	 shown	an	 increased	 risk	of	mortality	 for	 those	
affected	by	moderate	to	severe	hearing	loss	compared	to	the	general	population.		
	
In	2010,	Karpa	et	al.	demonstrated,	on	the	basis	of	statistical	analysis	of	2,956	Australians	aged	
50	and	over,	followed	for	13	years,	that	hearing	loss	(hearing	thresholds	greater	than	25	dB)	
was	associated	with	increased	risk	all-cause	mortality	after	adjustment	for	age	and	sex73.	This	
risk	was	mediated	by	cognitive	impairment,	walking	disability	and	self-assessments	of	health,	
that	 increased	mortality	directly	and	 indirectly.	The	study	was	however	unable	 to	 reveal	a	
connection	between	the	degree	of	hearing	loss	severity	and	an	increased	risk	of	mortality.		
	
The	 observation	 of	 a	 connection	 between	 hearing	 loss	 and	 increased	 risk	 of	 all-causes	
mortality	is	also	stated	by	Fisher	et	al.	(2014),	on	a	population-based	cohort	study:	the	aim	of	
the	study	was	to	analyse	the	link	between,	on	the	one	hand,	hearing	impairment	only,	visual	
impairment	only,	both	associated	impairments	and,	on	the	other	hand,	all-causes	mortality	
and	cardio-vascular	diseases.	The	population	involved	4,926	Icelandic	people	aged	over	66,	
followed	 on	 the	 basis	 of	 their	 examinations	 between	 2002	 and	 2006	 and	 then	 followed	
prospectively	 by	 survey	 until	 2009	 for	 mortality.	 Impairments	 ranged	 from	 moderate	 to	
greater.	 Hearing	 loss	 prevalence	 is	 estimated	 at	 25.4%	 in	 the	 sample.	 The	 main	 results	
showed:	1)	an	all-causes	mortality	 significantly	greater	 for	hearing	 impaired	persons	 (after	
adjustment	 by	 age),	 particularly	 for	 men	 and	 particularly	 from	 cardio-vascular	 causes 74 .	
Mortality	rates	for	women	were	not	significant,	although	they	were	greater	than	those	in	the	
general	population.	2)	Men	and	women	being	fitted	with	hearing	aids	tend	to	be	older	and	
more	severely	impaired	than	others.	However,	their	risk	of	mortality	is	lower,	and	this	has	an	
impact	upon	 the	global	 result	 for	all	 the	people	with	hearing	 impairment	 (in	other	words,	
hearing	 aid	 access	 reduces	 the	mortality	 risk,	 and	 this	 reduction	 reduces	 itself	 the	 gap	 in	
mortality	risk	compared	to	the	general	population).	The	assumption	made	by	the	authors	is	
the	 following:	 hearing	 aid	 equipment	 reduces	 social	 isolation	 and	 increases	 neurosensory	
stimulation.			
	
The	 study	 of	 Genther	 et	 al.	 (2015)	 strengthens	 these	 results,	 by	 analysing	 an	 American	
population-based	cohort	of	1,958	older	people	aged	over	69	during	8	years	after	audiometric	
																																																								
	
73	Two	statistical	models	used	by	the	authors	confirm	the	association:	in	the	Cox	model,	the	OR*	is	1.39,	(CI95%	
1.11-1.79);	in	the	structural	equations	model,	the	OR*	is	2.58	CI95%	(1.64-4.05).	
74	On	the	basis	of	two	statistical	models,	the	OR*	for	men	is	1.74	(CI95%	1.21-2.49)	and	1.93	(IC95%	1.30-2.87).		
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examination.	With	control	of	demographic	and	cardiovascular	risk	factors,	they	showed	that	
hearing	impairment	(>	25	dB	in	the	better	ear)	was	associated	with	a	20%	increased	mortality	
risk	 compared	 with	 normal	 hearing75 .	 The	 authors	 suggested	 investigating	 the	 pathways	
leading	 to	 this	 association	 and	 in	 order	 to	 determine	 the	 impact	 of	 rehabilitation	 hearing	
strategies.		
	
All	these	papers	recommend	taking	into	account	this	association	between	hearing	impairment	
and	mortality	risk	in	medical	follow-ups,	which	implies	that	a	part	of	this	risk	is	preventable	
and	causes	loss	of	life	in	years.		
	
2.1.2.2 An	increased	risk	of	falls		
	
The	INSERM	recommendations	(2014)	for	preventing	falls	amongst	the	elderly	estimated	that	
a	hearing	loss	of	at	least	25	dB	was	associated	with	a	threefold	increase	of	risk	for	falls,	due	to	
the	deterioration	of	sensory	function,	the	loss	of	sound	marks	contributing	to	balance,	and	
the	reduction	in	cognitive	resources	ensuring	balance	and	attention.		
	
This	possible	link	has	been	studied	by	Viljanen	et	al.	in	2009	and	by	Lin	and	Ferrucci	in	2012.	
Viljanen	 et	 al.	 (2009)	 analysed	 the	 predictive	 value	 of	 hearing	 impairment	 as	 a	 fall	 factor	
through	a	sample	of	217	pairs	of	female	Finnish	twins	–	monozygotic	and	dizygotic	–	aged	63-
76	years.	They	showed	that	people	with	poor	hearing	acuity	(loss	of	at	least	21	dB	in	the	better	
ear)	have	a	higher	fall	risk,	because	of	their	poorer	postural	control	among	other	factors.		
 
Lin	and	Ferrucci	(2012)	studied	a	population	of	2,017	persons	aged	40-69	years,	from	2001	to	
2004,	based	on	the	American	register	NHANES.	They	showed	that	hearing	 loss	(>	25	dB)	 is	
significantly	 associated	 with	 the	 risk	 of	 reported	 falls.	 Moreover,	 this	 risk	 increased	 with	
hearing	 loss	 severity	 (1.4	 fold	 by	 10	 dB	 classes),	 independently	 of	 demographic	 factors,	
cardiovascular	factors	and	vestibular	balance.		
	
2.1.2.3 A	degradation	in	mental	health	
	
The	connection	between	hearing	 loss	and	mental	distress	has	been	highlighted	by	a	great	
number	of	studies.		
	
The	 analysis	 proposed	 by	 Fellinger	 et	 al.	 (2007)	 of	 373	members	 of	 the	 German	 Hard	 of	
Hearing	Association	of	all	ages	showed	that	people	affected	by	moderate	to	severe	hearing	
loss	 (even	 total)	 had	 worse	 psychological	 scores	 in	 contrast	 to	 a	 non-hearing	 impaired	
population:	using	the	WHO’s	brief		quality	of	life	scale	(WHO-QOL)	the	scores	are	similar	in	
both	 populations;	 through	 the	 scale	 ‘BSI’	 (Brief	 symptom	 inventory),	 people	 affected	 by	
moderate	to	severe	hearing	loss	suffer	from	greater	anxiety,	somatization,	paranoid	ideation,	
and	depression	(the	level	of	degradation	depends	on	severity).	This	study	also	showed	that	
these	people	have	worse	social	 relationships	compared	 to	 the	signing	deaf	 (evident	 in	 the	
both	the	WHO-QOL	and	BSI	scales).	The	authors	compared	the	levels	of	psychological	distress	
and	quality	of	life	and	suggested	two	main	conclusions:	on	the	one	hand,	general	psychiatrists	
																																																								
	
75	OR*	1.20	95%IC	(1.03-1.41).		
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should	 consider	 the	 increasing	 risk	 of	 isolation	 and	 quality	 of	 life	 degradation	 for	 hearing	
impaired	 people	 who	 have	 communication	 difficulties	 or	 who	 lip-read	 (compared	 to	 the	
signing	deaf);	on	the	other	hand,	the	benefit	of	hearing	aid	equipment	could	be	substantial	
since	they	would	improve	their	communication	capacities	(for	more	profound	hearing	loss,	
the	benefit	would	rely	on	cochlear	implants).		
	
Moreover,	the	study	of	Bernabei	et	al.	(2011)	has	shown	that	the	accumulation	of	a	hearing	
impairment	 and	 vision	 impairment	 in	 an	 Italian	 study	 population	 (7,389	 older	 people)	 is	
associated	with	depression	and	anxiety.	More	recently,	through	research	in	the	United-States,	
Li	et	al.	(2014)	have	estimated	the	prevalence	and	risk	factor	in	depression	for	adults	older	
than	69	and	being	affected	by	hearing	loss	(among	18,318	persons	participating	in	a	national	
survey).	Depression	was	assessed	on	the	basis	of	a	customised	scale,	and	results	showed	a	
significant	 association	 between	 hearing	 loss	 and	 depression,	 particularly	 for	 women,	 and	
especially	in	the	case	of	moderate	hearing	loss.	At	the	same	time,	Acar	and	al.	(2011)	analysed	
the	results	of	a	study	involving	34	Turkish	people	older	than	65	in	order	to	estimate	the	impact	
of	hearing	aid	equipment	on	mental	health:	they	showed	that	the	use	of	hearing	aids	for	3	
months	significantly	improved	psycho-social	health	state,	as	described	by	the	MMSE	scale.			
	
In	the	same	perspective,	in	2013,	Mener	et	al.	worked	on	the	cohort	NHANES	data,	for	two	
periods	(2005-2006)	and	(2009-2010),	including	a	population	aged	70-79	to	whom	a	specific	
questionnaire	assessing	depression	was	proposed	(PHQ-9).	They	studied	the	impact	of	hearing	
aid	use	(at	least	5	hours	a	day)	and	showed	a	significant	reduction	of	symptoms	of	depression	
and	major	depressive	troubles.	This	favourable	impact	was	appreciable	starting	from	the	first	
3	months	of	equipment.	However,	the	authors	underlined	that	it	wasn’t	possible	to	state	if	
this	association	would	result	 in	a	 larger	 inclination	of	people	without	depressive	trouble	to	
access	for	hearing	aids,	or	if	their	perception	of	their	own	psychological	frailty	would	have	led	
them	to	access	for	hearing	aids.	Hence,	the	authors	suggest	future	scientific	investigation	in	
order	to	question	the	link	between	hearing	aids	and	the	reduction	in	depressive	symptoms.		
	
For	France,	the	studies	of	the	InVS	and	the	INPES	(Sitbon	and	al.,	2015)	undertaken	as	part	of	
the	framework	of	the	«	Baromètre	santé	sourds	et	malentendants	»	(BSSM	–	‘Barometer	for	
the	health	of	deaf	and	hard	of	hearing	people’)	in	2011-2012	underlined	the	degradation	of	
mental	 health	 for	 people	 affected	by	deafness	 and	hearing	 troubles.	 They	highlighted	 the	
more	frequent	rate	of	suicidal	thoughts	than	in	the	general	population	(Baromètre	santé	2010,	
BS):	 suicidal	 thoughts	 occurring	 during	 the	 last	 12	 months	 were	 5	 times	 more	 frequent	
(affecting	 indeed	22%	of	people	 in	 the	NSSM	survey	against	4%	of	 the	general	BS	survey),	
whereas	the	number	of	suicide	attempts	during	the	life	course	were	3	times	higher	for	men	
and	 twice	 for	 women.	 The	 analysis	 by	 sex	 and	 age	 groups	 showed	 a	 decrease	 in	 suicidal	
thoughts	with	age:	15%	of	men	and	17.2%	of	women	aged	55-75	had	these	thoughts	against	
35.4%	of	men	and	25.3%	of	women	aged	15-24.	Retired	people	(13.4%)	were	less	affected	
than	 professionally	 active	 people.	 Moreover,	 the	 comparisons	 between	 the	 two	 surveys	
showed	 that	 indicators	 relative	 to	 physical	 violence	 (6.7%	 against	 2.8%),	 dismissive	 or	
humiliating	 looks	 or	words	 (26.4%	 /	 14.9%)	 or	 sexual	 violence	 (20.4%	 /	 8%)	 are	 obviously	
higher.	 The	 research	 of	 the	 causes	 leading	 to	 psychological	 suffering	 resulted	 from	 tiring	
communication	 situations	 and	 hardness	 of	 hearing	 troubles.	 Situations	 of	 psychological	
violence	can	also	participate	in	the	deterioration	of	psychological	health.	Indeed,	everyday	life	
characterised	by	a	deterioration	in	communication	quality	and	social	relationships	because	of	
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impairment	 would	 be	 likely	 to	 generate	 ‘conflictual	 interactions’,	 ‘isolation,	 feelings	 of	
exclusion	and	discrimination’.		
	
Vulnerability,	 which	 is	 linked	 to	 physical	 and	 psychological	 suffering,	 led	 the	 authors	 to	
recommend	reflection	concerning	access	conditions	for	technical	and	human	assistance,	as	
well	as	an	awareness	campaign	for	hearing	impaired	people	and	for	the	general	population	in	
order	 to	 promote	 positive	 change	 of	 representations	 and	 prejudice,	 or	 even	 for	 health	
professionals	(dealing	with	pain,	and	dealing	with	psychological	suffering).		
	
2.1.2.4 Deterioration	in	cognitive	capacities		
	
The	papers	of	Lin	et	al.	(2011a;	2011b;	2013;	2014)	are	among	the		most	cited	articles	in	the	
field	of	research	into	the	link	between	hearing	loss	and	cognitive	decline.	In	2011(a),	Lin	et	al.	
tested	the	assumption	in	which	hearing	loss	is	associated	with	all-causes	dementias	and	with	
Alzheimer’s	 disease.	 They	 based	 their	 study	 on	 a	 population	 of	 639	 Americans	 followed	
prospectively	 since	 1990-1994	 (inclusion	 period)	 when	 they	 didn’t	 have	 dementia,	 with	 a	
follow-up	of	11.9	years	 (median	time)	during	which	58	cases	of	dementia	were	diagnosed,	
including	37	cases	of	Alzheimer’s	disease.	The	authors	showed	that	dementia	risk	increases	
significantly	and	linearly	with	hearing	loss	severity.	The	risk	of	Alzheimer’s	disease	increased	
at	such	a	confidence	interval	that	it	was	not	possible	to	validate	the	association	assumption.	
They	 concluded	 that	 hearing	 loss	 is	 associated	 independently	 with	 all-causes	 dementia,	
without	being	able	to	say	if	hearing	loss	is	an	early	marker	or	is	a	modifiable	risk	factor.		
	
The	studies	also	released	in	2011	(b)	by	Lin	et	al.	analysed	the	link	between	hearing	loss	and	
cognitive	decline	on	the	basis	of	a	cohort	of	347	persons	aged	55	and	over,	who	were	in	the	
same	panel	cohort	BLSA	(Baltimore	Longitudinal	Study	of	Aging),	and	who	had	neither	hearing	
loss	nor	dementia	during	the	inclusion	period	1990-1994.	The	authors	showed	that	the	more	
hearing	loss	increases,	the	more	the	scores	on	the	mental	health	scale	(MMSE)	deteriorate,	
as	well	as	memory	and	cognitive	function:	when	hearing	performance	is	reduced	by	25	dB,	
the	scores	converge	to	those	of	a	population	without	hearing	loss	who	are	older	by	6.8	years.	
In	other	words,	hearing	loss	accelerates	the	cognitive	ageing	process.			
	
The	 study	 of	 2013	 assumed	 that	 hearing	 loss	 was	 independently	 associated	 with	 an	
accelerated	cognitive	decline.	There	were	1,984	American	adults,	aged	on	average	44.4	years,	
followed	since	their	inclusion	in	1977-98	for	6	years.	Hearing	loss	concerned	1,162	persons,	
for	whom	cognitive	decline	rate	–	measured	through	2	adapted	scales	–	appeared	to	be	41%	
or	32%	according	to	the	2	scales.	Finally,	the	authors	stated	that	people	with	hearing	loss	have	
an	increased	risk	of	cognitive	deficiency	of	24%76,	these	latter	rates	and	this	risk	being	linearly	
associated	 with	 the	 severity	 level	 of	 hearing	 loss.	 They	 concluded	 that	 hearing	 loss	 is	
independently	 associated	 with	 accelerated	 cognitive	 decline	 and	 they	 then	 suggested	 an	
assessment	of	the	impact	of	auditive	rehabilitation	on	these	results.		
	
In	2014,	Lin	et	al.	estimated	the	association	between	hearing	loss	and	brain	volume	changes	
for	the	older	people	included	in	BLSA	panel	and	they	confirmed	the	independent	association	
																																																								
	
76	OR*:	1.24	CI95%	(1.05-1.48).		
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between	the	two	measures:	hearing	loss	beyond	25	dB	led	to	an	accelerated	atrophy	of	the	
whole	brain	and	in	particular	the	regional	volumes	concentrated	in	the	right	temporal	lobe.		
	
The	 very	 recent	meta-analysis	 of	 Schmulian	 Taljaard	 et	 al.	 (2015)	 on	 the	 issue	of	 a	 causal	
relationship	 between	 hearing	 loss	 and	 cognitive	 decline	 included	 33	 studies	 related	 to	 40	
population	samples.	It	concluded	(with	some	reserve	on	the	sample	size	and	on	the	lack	of	
control	on	risk	factors)	that:		
- Cognitive	capacities	are	significantly	lower	for	people	with	non-treated	hearing	loss,	
and	remain	lower	for	hearing	aid	equipped	people	regarding	people	without	hearing	
loss;	
- The	degree	of	cognitive	decline	is	significantly	associated	with	the	level	of	hearing	loss	
for	both	people	being	equipped	and	not	being	equipped	with	hearing	aids;	
- Auditive	intervention	significantly	improves	cognitive	capacities;	
- Hearing	loss	has	an	impact	upon	all	cognitive	domains.		
	
If	 several	 papers	 have	 stated	 a	 significant	 connection	 between	 hearing	 loss	 and	 cognitive	
decline,	 the	 analysis	 of	Amieva	et	 al.	 (2015)	 showed	 the	 favourable	 impact	 of	 hearing	 aid	
equipment	 in	reducing	this	adverse	effect.	The	study	was	based	on	the	prospective	cohort	
(‘Personnes	âgées’	QUID),	whose	population	was	studied	from	1989-90.	The	cohort	involved	
3,670	older	people	(65+)	at	the	moment	of	the	study.	Hearing	loss	was	assessed	through	a	
perception	 questionnaire	 recording	 the	moderate	 or	major	 difficulties	 relating	 to	 hearing	
capacity.	 Cognitive	 decline	 was	 assessed	 by	 the	 MMSE	 scale,	 recorded	 during	 follow-up	
consultations.	The	authors	also	showed	an	independent	and	significant	association	between	
hearing	loss	and	cognitive	decline.	Above	all,	they	showed	that	decline	depends	on	the	use	or	
not	 of	 hearing	 aids,	which	 can	 delay	 it:	 indeed,	 people	 using	 hearing	 aids	 have	 the	 same	
cognitive	decline	as	people	without	hearing	loss.		
	
In	a	similar	perspective,	Dawes	et	al.	(2015)	examined,	on	the	basis	of	English	data	(164,770	
persons	aged	40-69	whose	hearing	capacities	were	recorded)	the	impact	of	hearing	aid	use	
on	cognitive	performances,	social	isolation	and/or	depression).	Using	a	model,	they	showed	
that	hearing	aids	are	associated	with	a	better	cognitive	performance,	independently	of	social	
isolation	and	depression;	these	hearing	aids	are	not	here	stated	factors	of	improved	cognitive	
capacity,	 but	 thanks	more	 to	 direct	 improvement	 in	 hearing	 and	 personal	 efficiency.	 The	
authors	suggest	supporting	access	to	hearing	loss	treatment	in	order	to	reduce	the	burden	of	
disease	related	to	cognitive	decline	and	quality	of	life.		
	
Meanwhile,	the	paper	of	Hung	et	al.	(2015)	focused	on	Alzheimer’s	disease	and	relied	on	a	
controlled	study	including	a	sample	of	Taiwanese	over	a	13	year	period	and	where	488	persons	
aged	 over	 65,	 with	 a	 diagnosis	 of	 Alzheimer’s	 disease,	 were	matched	with	 1,952	 persons	
without	Alzheimer’s	disease	in	the	control	group.	The	aim	was	then	to	compare	comorbidity	
factors	(including	hearing	loss)	with	the	risk	of	having	Alzheimer’s	disease	in	both	groups.	The	
statistical	analysis	showed	that	hearing	loss	is	associated	with	an	increased	risk	of	Alzheimer’s	
disease	in	an	older	population	with	an	odds-ratio	of	1.3977.		
																																																								
	
77	Interpretation:	individuals	who	are	affected	by	hearing	loss	have	1.39	times	greater	risk	of	having	Alzheimer’s	
disease,	as	the	confidence	interval	does	not	comprise	the	value	1	(1.05-1.84).	However,	the	association	does	not	
prove	the	causality,	even	a	presumption	exists	today.		
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2.1.2.5 Health	at	work		
	
In	France,	the	recent	analysis	of	Sitbon	et	al.	(2015)	of	BSSM	have	provided	some	key	data	on	
the	impact	of	hearing	loss	on	health	at	work:		
- Hearing	 impaired	 people	 more	 frequently	 suffer	 at	 work,	 as	 34%	 of	 this	 working	
population	 is	 in	 a	 psychological	 distress	 situation	 due	 to	 working	 conditions	 (in	
contrast	to	5.4%	of	general	working	people),	10.3%	of	them	have	thought	of	suicide	
during	the	last	past	12	months	because	of	their	working	situation	(1.4%	for	the	general	
population)	and	3.5%	have	attempted	to	kill	themselves	during	their	lives	for	the	same	
reasons	(0.6%	for	the	general	population).	Moreover,	comprehension	difficulties	are	
frequent,	 in	 the	 double	 sense	 of	 being	 understood	 by	 and	 to	 have	 understood	
colleagues;	
- 2/3	 of	 this	 population	 have	 asked	 for	 a	 recognition	 of	 their	 impairment	 (‘RQTH’	
benefit).		
	
Although	 the	 ‘Handicap-Santé’	 survey	2008	did	not	 reveal	 any	major	difficulty	 in	 terms	of	
professional	integration	(cf.	supra)	–	which	could	be	interpreted	as	the	result	of	social	progress	
over	a	decade-	the	observed	results	 in	developed	countries	are	more	mixed:	 in	the	United	
Kingdom	it	can	be	observed	that	the	person’s	situation	in	the	labour	market	is	affected	in	the	
case	 of	 hearing	 loss	 with	 regard	 to	 career	 opportunities,	 the	 loss	 of	 employment,	 and	
difficulties	to	get	back	to	work	(Archbold	et	al.,	2014).	Access	to	hearing	aids	would	alleviate	
this	negative	impact.		
	
	
Whether	mortality	or	morbidity,	French	as	well	as	international	scientific	literature	highlights	
the	consequences	of	hearing	loss,	which	are	likely	to	be	substantial	for	the	hearing	impaired	
persons	 themselves,	 not	only	 in	 terms	of	 quality	 and	quantity	of	 life,	 but	 also	 in	 terms	of	
economic	and	societal	impact	(burden	of	illness):	if	hearing	loss	is	independently	connected	
to	other	health	state	dimensions		-	physical,	psychological,	cognitive,	and/or	social	-		it	is	then	
associated	with	an	economic	burden	in	terms	of	direct	medical	and	non-medical	costs,	indirect	
costs	(productivity)	and	intangible	costs.	Access	to	hearing	aids	would	reduce	this	burden	–	
recent	 scientific	 studies	 increasingly	 tend	 to	demonstrate	 this	 assumption.	 The	aim	of	 the	
following	section	is	to	explore	this	issue.		
	
2.2 Economic	impact	of	hearing	loss	
	
As	shown	in	the	first	section	of	this	report,	most	French	agencies	(HAS,	2008;	HCAAM,	2008;	
CEPP,	 2008;	 IGAS,	 2014)	 have	 pointed	 out	 the	 lack	 of	 global	 assessment	 of	 hearing	 aid	
expected	service	(particularly	on	the	possible	differences	of	quality	rendered	by	hearing	aids	
according	to	their	characteristics).	However,	the	HAS	(2008)	specified	that	“the	benefit	of	the	
prosthesis	is	linked	to	its	suitability	with	the	audiometric	characteristics	and	the	patient’s	way	
of	life,	as	well	as	the	quality	of	its	adaptation	performed	by	the	hearing	aid	professional”78.	
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The	HCAAM	(2008)	estimated	on	its	side	that	the	question	of	medical	devices	recorded	on	the	
LPPR	is	tricky	to	the	extent	that	“the	rendered	service	is	hardly	assessable”	because	it	depends	
both	on	the	apparatus	and	the	service79.		
	
Moreover,	the	continuous	innovation	concerning	hearing	aids	leads	to	a	rapid	replacement	of	
the	products	on	 the	market,	upmarket	products	becoming	 five	years	 later	downmarket	or	
middle	market	products,	whereas	the	least	performant	exit	the	market,	resulting	in	a	100%	
digital	supply	(Alcimed-DSS,	2011).	In	this	way,	device	assessment	is	increasingly	complex,	in	
terms	of	separating	added-value	from	marketing	innovation.	As	underlined	in	this	report,	such	
an	assessment	is	still	necessary	to	put	in	perspective	reimbursement	rules	for	hearing	aids.		
	
This	 question	 is	 also	 raised	 in	 the	 international	 literature:	 two	 systematic	 reviews	 were	
undertaken	in	2015	by	the	Cochrane	Library,	but	their	results	were	not	yet	released	at	the	
time	of	this	report.	The	research	protocol	of	Ferguson	et	al.	 (2015)	specifies	that	the	main	
medical	action	 in	 the	 face	of	hearing	 loss	 is	compensation	with	hearing	aids,	but	we	don’t	
know	 their	 exact	 performance,	which	 is	 ‘user	 dependant’,	 to	 use	 the	 CESE’s	 term	 (2015),	
although	11	million	hearing	aids	were	sold	in	one	year.	The	main	objective	of	hearing	aid	users	
affected	by	moderate	to	severe	hearing	loss	is	obviously	to	reduce	the	sensory	impairment,	
but	also	to	reduce,	 indirectly,	associated	 limitations.	 If	 it	 is	possible	 to	assess	 the	patient’s	
hearing	capacities	by	means	of	physical	measures	(audiometric	ones),	the	consequences	 in	
terms	 of	 associated	 limitations	 could	 be	 assessed	 by	 using	 questionnaires	 specific	 to	 the	
associated	 disease/limitation	 (for	 example,	 MMSE	 in	 the	 case	 of	 mental	 health)	 or	 by	
preference-based	generic	questionnaires	for	quality	of	life.	However,	the	latter	may	not	allow,	
in	general,	the	demonstration	of	the	real	benefits	of	hearing	aids	because	of	the	low	impact	
multiple	 consequences	 have	 on	 them.	 This	 is	 apart	 from	 the	 HUI3	 questionnaire	 which	
includes	a	question	directly	linked	to	hearing	loss	level	(cf.	infra).	Ferguson	et	al.	point	out	the	
lack	of	scientific	consensus	on	this	issue	and,	further,	the	lack	of	a	measure	reference	on	the	
benefit	in	terms	of	quality	of	life,	and	even	the	lack	of	systematic	review	of	recent	literature	
(particularly	that	which	would	highlight	results	of	prospective	randomised	controlled	trials).	
All	this	considerably	limits	health	policies	towards	a	roadmap	for	hearing	aid	regulation	and	
delivery,	and	it	also	limits	the	possibility	of	defining		guidelines	for	their	prescribers.		
	
Taking	into	account	this	statement,	our	analysis	will	propose	an	assessment	scenario	which	
does	not	pretend	to	be	an	efficiency	analysis	and	which	must	be	read	with	caution,	but	that	
would	 give	 some	 general	 orientation	 on	 this	 issue.	 Before	 beginning,	 we	 propose	 a	 brief	
overview	of	several	papers	focused	on	the	link	between	hearing	loss	and	health	care	access.		
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2.2.1 Economic	assessments	in	scientific	literature	of	hearing	loss:	health	care	access,	
expenditure	and	screening		
	
On	 the	 basis	 of	 previous	 articles	 which	 have	 demonstrated	 an	 independent	 connection	
between	hearing	 loss	and	 the	morbi-mortality	of	older	people,	 some	papers	have	 tried	 to	
estimate	the	impact	of	health	degradation	related	to	hearing	loss	on	health	care	access	and	
expenditure	level.	Others	papers	have	considered	the	benefit	that	would	be	expected	of	an	
earlier	screening	of	hearing	loss.		
	
2.2.1.1 Higher	health	care	access	and	expenditure	level	
	
Two	recent	papers,	relying	on	results	from	previous	international	studies,	have	focused	on	the	
economic	impact	of	a	degraded	health	state	for	hearing	impaired	older	people	to	health	care	
access	and	expenditure.		
	
Genther	and	al.	 (2013)	have	 identified	an	association	between	hearing	 loss,	hospitalisation	
and	burden	of	 illness	 for	older	people	aged	over	69	 (representing	2/3	of	hearing	 impaired	
people	and	1,140	people	who	were	matched	with	529	persons	without	hearing	loss)	for	two	
different	 periods:	 2005-06	 and	 2009-10.	 The	 statistical	 analysis	 showed	 a	 significant	
association	between	hearing	 loss	and	 several	markers	of	health	 care	pathways	and	health	
states:	the	occurrence	of	hospitalisation,	the	number	of	hospitalisations,	and	the	number	of	
days	with	worsened	physical	and	mental	health.	However,	the	connection	with	an	inactivity	
related	to	health	state	was	not	stated.	It	showed	that	hearing	loss	is	independently	associated	
with	hospital	 access	 and	 so	with	an	 increased	use	of	health	 care	 services,	which	 could	be	
explained	 by	 social	 isolation,	 and	 by	 the	 effects	 of	 hearing	 loss	 on	 cognitive	 decline	 and	
dementia	(these	factors	were	controlled	in	the	analysis	of	healthcare	pathways).	The	authors	
suggested	 that	 an	 analysis	 should	 be	 pursued	 of	 the	 effect	 of	 auditive	 rehabilitation	 on	
hospitalisation	reduction	and	self-assessment	of	health	state.		
	
In	Foley	et	al.	(2014),	the	question	was	to	investigate	the	nature	(independent	or	not)	of	the	
connection	between	hearing	loss	and	the	higher	level	of	health	expenditure.	The	study	used	
expenditure	figures	for	34,981	persons	aged	over	64,	who	had	completed	the	Short	Form	12	
quality	of	life	questionnaire.	Health	expenditure	was	assessed	regardless	of	financing	type,	to	
which	was	added	a	non-monetary	estimation	for	health	state	results	(number	of	assistance	
days,	 quality	of	 life	 scores).	 The	main	 results	 in	 this	 study	 showed,	 that	 for	 a	hearing	 loss	
prevalence	ranging	around	23.7%,	the	probability	of	higher	expenditure	was	significant	(the	
extra	 amount	was	 significant	 -	 +	 39%)80,	meaning	 on	 average	 US$	 392,	 because	 of	more	
frequent	medical	visits,	outpatient	and	emergency	hospitalisations.	The	scores	for	quality	of	
life	were	lower	in	the	physical	and	mental	dimensions	compared	to	people	without	hearing	
loss.	The	authors	concluded	that	there	was	an	independent	association	between	hearing	loss	
and	a	higher	level	of	expenditure:	this	would	represent	an	extra	amount	of	US$	3.1	billion	for	
all	hearing	impaired	people	(7.91	million	people),	related	to	falls,	cognitive	decline,	depression	
and	social	isolation.	They	also	considered	that	this	estimation	was	probably	an	under-estimate	
																																																								
	
80	Extra	health	expenditure	proportion:	OR*	1.39	CI95%	(1	.12-1.71);	extra	health	expenditure	amount:	OR*392$	
CI95%	(277-513).		
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because	of	hearing	loss	denial	in	surveys.	As	with	previous	authors,	they	suggested	the	impact	
of	auditive	rehabilitation	strategies	on	health	care	expenditure	reduction	should	be	studied.		
	
These	suggested	auditive	rehabilitation	strategies	would	involve	earlier	screening	for	hearing	
difficulties	and,	thus,	an	improvement	in	access	to	hearing	aids	since	economic	studies	will	
have	demonstrated	their	favourable	cost-effectiveness	ratio.		
	
2.2.1.2 Economic	concerns	of	earlier	screening	for	hearing	loss	
	
As	 shown	 previously,	 hearing	 loss	 is	 common	 after	 the	 age	 of	 50	 years,	 with	 increasing	
prevalence	and	severity	with	ageing.	Autonomy	as	well	as	people’s	quality	of	 life	could	be	
jeopardised	if	hearing	loss	is	not	compensated.		
	
The	English	literature	has	shown	that	individuals	often	wait	for	10	to	15	years	before	accessing	
hearing	aids,	because	they	consider	that	their	hearing	level	is	not	particularly	bad	and	because	
they	 don’t	 envisage	 themselves	 with	 a	 hearing	 aid	 until	 their	 hearing	 has	 seriously	
deteriorated.	This	is	also	a	result	of	the	misreading	of	the	connection	between	hearing	loss	
and	 long	 term	 health	 state:	 indeed,	 it	 is	 actually	 stated	 that	 hearing	 aids	 improve	 social	
integration	and	quality	of	life,	even	in	the	case	of	moderate	hearing	loss,	and	mainly	when	
they	are	used	earlier	by	individuals.		
	
Is	secondary	prevention	of	hearing	loss	economically	reliable?	In	order	to	justify	a	systematic	
screening	 process,	 this	 hearing	 loss	 must	 become	 a	 significant	 public	 health	 priority,	
associated	with	a	precise	knowledge	of	the	‘natural’	history	of	hearing	loss	and	the	evidence-
based	 efficiency	 of	 earlier	 screening.	 Yet,	 the	 previous	 statements	 highlight	 not	 only	 the	
significant	prevalence	of	this	health	state	problem,	but	also	its	adverse	consequences	since	
the	 link	 between	 severity	 and	 age	 has	 been	 demonstrated.	 Screening	 aims	 to	 reduce	 the	
hearing	impairment	impact	timeline	and	its	severity	impact	in	a	patient’s	life.	Furthermore,	
this	 raises	 questions	 about	 the	 cost	 of	 such	 systematic	 screening:	 indeed,	 a	 secondary	
prevention	 campaign	 could	 require	 significant	 financial	means.	 The	 financial	 requirements	
would	 depend	 on	 the	method,	 as	 a	 systematic	 screening	 during	 the	GP’s	 consultations	 in	
France	would	represent	little	financial	outlay	to	be	efficient.	Indeed,	on	the	basis	of	Amieva	et	
al.	 (2015),	 screening	 of	 the	 PAQUID	 cohort	 was	 realised	 over	 the	 course	 of	 follow-up	
consultations,	by	recording	a	very	short	questionnaire	allowing	hearing	 loss	screening.	The	
questionnaire	comprised	two	questions:	
- Do	you	have	hearing	trouble?	(possible	responses:	“I	do	not	have	hearing	trouble”/	“I	
have	trouble	following	the	conversation	with	two	or	more	people	talking	at	the	same	
time	or	in	a	noisy	background”/	“I	have	major	hearing	loss”);		
- Do	you	use	a	hearing	aid?	(possible	responses:	yes/no)	
Such	a	questionnaire	is	easy	to	carry	out	during	a	general	consultation	without	burdening	the	
GP’s	 time.	 That’s	 why	 a	 reflection	 about	 this	 screening	 method	 in	 general	 consultation	
deserves	to	be	studied,	linked	with	the	‘ROSP’	system	(the	French	payment	for	performance	
system).		
 
In	 the	 literature,	most	 analysis	 suggests	 the	 implementation	 of	 hearing	 loss	 screening	 for	
adults	aged	50-65,	i.e.	an	audience	who	are	sufficiently	old	to	represent	an	important	target	
regarding	prevalence	but	young	enough	 to	benefit	 from	earlier	 screening.	However,	 these	
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recommendations	are	rarely	assessed	regarding	efficiency	and	the	economic	literature	is	still	
sporadic	 on	 this	 issue.	We	 present	 the	main	 results	 of	 two	 studies	 on	 this	 topic,	 but	 we	
underline	that	other	efficiency	studies	do	exist	on	the	specific	economic	impact	of	cochlear	
implants	(not	part	of	this	discussion).		
	
1-	 The	 study	of	Davis	 et	 al.	 (2007):	 hearing	 loss	 screening	 is	 acceptable	 and	beneficial	 for	
people	aged	55-74,	and	a	target	screening	of	people	aged	60-70	for	a	bilateral	hearing	loss	of	
at	least	35	dB	is	the	most	appropriate.		
	
The	authors	have	considered	adult	bilateral	hearing	loss,	having	consequences	on	hearing	and	
communication	 (1/5	 of	 this	 population),	 associated	 with	 difficulties	 hearing	 in	 a	 noisy	
background.	If	they	assess	that	one	in	ten	people	would	benefit	from	hearing	aids,	one	in	six	
hearing	aid	equipped	persons	did	not	benefit	from	them	(no	efficacy).		Moreover,	individuals	
whose	hearing	capacities	were	assessed	admitted	to	having	hearing	trouble	for	at	 least	10	
years,	were	aged	75	on	average	and	had	hearing	loss	considered	as	severe.	This	later	access	
leads	to	greater	difficulties	in	terms	of	their	own	adaptation	because	of	impairment	severity	
and	is	associated	with	reduced	communication	capacities.		
		
The	study	of	Davis	et	al.	aimed	to	assess	the	reliability	of	hearing	loss	screening	by	efficient	
and	acceptable	methods,	in	order	that	this	screening	be	linked	to	a	measurable	result	in	terms	
of	quality	of	life.		
	
Their	preliminary	study	demonstrated	that	people	aged	54-74	are	greatly	affected	by	hearing	
loss	 and	would	 benefit	 from	 referred	 to	 screening.	 The	 amplification	 obtained	 from	using	
hearing	 aids	 clearly	 improved	 the	 health	 state	 of	 people	 affected	 by	moderate	 to	 severe	
hearing	loss	(at	least	35	dB)	when	they	are	screened	at	least	10	years	before	the	‘natural’	point	
of	self-referral	for	hearing	aids.	They	estimated	that	the	cost-utility	incremental	ratio	ranged	
around	£800	to	£1,000	by	QALY	(Quality	adjusted	life	years,	see	infra).		
	
	
2)	Early	screening	efficiently	improves	the	quality	of	life	of	older	people:	the	study	of	Morris	
et	al.	(2012)	
	
The	study	of	Morris	et	al.	(2012)	was	largely	based	on	the	initial	analysis	of	Davis	et	al.	(2007)	
and	followed	its	recommendations.	In	order	to	set	up	an	economic	assessment	of	screening,	
the	authors	compared	3	programs	following	the	English	population:	
- A	one-step	screening	program,	which	targets	eligible	adults	for	screening	aged	60-70	
and	invites	them	to	be	screened;	
- A	two-step	screening	program,	which	targets	eligible	adults	for	screening	aged	60-70,	
firstly	 by	 posting	 them	a	 questionnaire,	 then	 inviting	 to	 screening	 those	who	have	
signalled	hearing	troubles	in	their	answers;	
- The	 self-referral	 rates	 through	 the	 GP	 (comparator),	 who	 would	 refer	 the	 patient	
towards	an	audiometric	assessment.		
	
If	hearing	loss	is	confirmed	(>35	dB),	the	patient	was	offered	one	or	two	hearing	aids,	taking	
into	account	that	individuals	could	renounce	them	or	might	not	use	them.	The	model	is	built	
around	these	different	scenarios:	the	framework	is	a	Markov	model	where	cycles	last	for	5	
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years,	and	where	cost	and	utility	dimensions	are	included	(utilities	are	estimated	in	QALYs,	
and	these	values	are	given	in	the	study	of	Davis	et	al.).			
	
Map	1	–	Transitions	between	health	states	(Markov	cycle	–	5	years)	
	
	
Source:	Morris	and	al.,	2012.		
	
The	main	results	showed	that:		
- The	one-step	screening	scenario	dominates	(it	generates	better	results	than	the	two-
step	screening	scenario),	thus	this	scenario	is	chosen;		
- The	 incremental	 cost-effectiveness	 ratio	 between	 the	 one-step	 scenario	 and	 the	
comparator	(self-referral	to	a	GP)	is	estimated	to	be	£1,461	/QALY:	it	is	the	price	to	
pay	for	having	one	year	of	good	health.	It	is	calculated	as	the	ratio	of	cost	variation	and	
utility	variation	between	the	two	strategies;	
- The	differently	simulated	scenarios	linked	with	a	probabilistic	analysis	show	that	the	
dominant	strategy	is	that	of	one-step	bilateral	screening	of	hearing	loss	from	the	age	
of	60,	and	a	delivery	of	hearing	aid	equipment	starting	from	35	dB	
	
The	table	of	parameters	and	costs	presented	in	the	following	pages	shows	estimation	ranges	
related	to	access	to,	and	the	use	of	hearing	aids,	as	well	as	cost	and	utility	associated	with	
screening	(with	a	utility	scale	ranging	between	0	–	worse	health	state-	to	1	–	best	health	state).		
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Table	28	–	Morris	and	al.	study	results	of	screening	efficiency	of	HL	for	the	English	population	aged	60-70		
	
Source:	Morris	and	al.,	2012	
	
On	 the	 basis	 of	 these	 assumptions	 and	 results,	 the	 screening	 strategy	 appears	 to	 be	 very	
efficient:	the	following	map	illustrates	the	acceptability	of	this	strategy	from	a	financing	point	
of	view.	Usually,	the	NICE	(National	Institute	of	Clinical	Excellence)	determines	a	willingness	to	
pay	threshold	ranging	from	£20,000	to	£30,000	for	each	year	of	good	health	gained.	It	can	be	
seen	that	the	probability	of	being	below	such	a	threshold	is	close	to	1	(map	2).		
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Graph	1	–	Acceptability	curve	of	one-step	screening	strategy	vs	comparator	in	Morris	et	al.	
	
Source:	Morris	and	al.	(2012)	
	
	
We	should	note	that	these	results	probably	have	underestimated	intangible	costs	(or	quality	
of	life	score)	related	to	hearing	loss	consequences	on	other	health	state	dimensions,	since	the	
analysis	 relied	on	QALYs	gained	 in	 the	case	of	 screening	and	earlier	hearing	aid	access	 for	
people	 who	 did	 not	 have	 severe	 impairment.	 In	 this	 study,	 the	 quality	 of	 life	 gain	 was	
estimated	to	range	between	0.035	and	0.105.	However,	these	values	are	useful	for	the	next	
analysis,	where	our	reference	values	for	quality	of	life	gains	are	close.	Moreover,	it	should	be	
underlined	that	prices	of	hearing	aids	are	very	low:	this	limit	is	mentioned	by	the	authors,	who	
specified	that	the	follow-up	cost	was	probably	underestimated.	Hearing	aids	delivered	at	this	
price	are	basic	ones81.		
	
2.2.2 Economic	impact	of	hearing	loss	in	France:	scenarios	and	approximations	
	
The	 literature	survey	of	Shield	 (2006)	conducted	 ten	years	ago	allowed	us	 to	measure	 the	
expected	impact	of	hearing	aids	on	quality	of	life,	particularly	the	psycho-social	dimensions,	
at	a	time	when	technical	devices	were	not	as	performant	as	today,	even	if	this	measure	was	
not	quantified	in	a	robust	way:		
- Greater	 self-confidence,	 self-image	 and	 better	 communicative	 function	 resulting	 in	
overall	higher	self-esteem,	although	these	results	are	less	obvious	for	older	people;	
- Less	degradation	of	psychological	health;	
- Less	functional	difficulties	for	the	elderly	in	the	first	three	months	of	use;	
- Improvements	in	psycho-social	health	perceptible	in	better	quality	of	life	scores	after	
a	couple	of	weeks;	
- Less	depression	related	to	hearing	loss;	
- Improvements	in	social	and	familial	activity;	
																																																								
	
81	Cf.	www.fdp.org.uk	for	an	idea	of	the	different	choices	and	prices	(refunded	or	not),	depending	on	the	nature	
of	access	to	hearing	aids:	public	sector	(NHS)	or	private	sector	(£300	to	£2500	per	ear).	For	an	idea	of	the	price	
range	in	the	private	sector,	see	http://www.specsavers.co.uk/hearing/hearing-aids/hearing-aid-range.	Internet	
sites	consulted	in	March	2016.		
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- Increasing	relationship	between	satisfaction	related	to	hearing	aids	and	hearing	loss	
severity:	the	greater	the	severity	of	the	hearing	loss,	the	greater	the	satisfaction	(apart	
from	very	severe	cases);	
- Level	of	satisfaction	independent	of	age;	
- Less	social	isolation;	
- Less	feelings	of	stigmatisation	for	hearing	aid	users	than	for	non-users;	
- Better	emotional	life.		
Hearing	aid	users	bear	their	impairment	more	easily	than	non-users	(who	are	more	often	in	
denial)	and	are	more	aware	of	security.	Their	families	estimate	that	wearers	of	hearing	aids	
have	 improved	 cognitive	 capacities	 in	 comparison	 to	 non-users,	 and	 wearers	 are	 less	
introverted.	 Hearing	 aid	 users	 have	 in	 a	 better	 overall	 health	 state,	 particularly	 for	
relationships,	self-esteem,	mental	health	and	this	is	especially	true	for	more	severe	hearing	
impaired	 people.	 This	 body	 of	 evidence	 –	 highlighted	 on	 the	 basis	 of	 Shield’s	 scientific	
literature	survey	released	before	2006	-	 	seems	to	be	reinforced	by	our	previous	 literature	
survey	of	2005-2015	 in	which	 statistical	 investigations	have	also	 supported	 the	 favourable	
impact	of	hearing	aids	on	health	state.				
The	 consequences	of	 hearing	 loss	on	 all	 dimensions	of	 health	 status,	 impose	 the	use	of	 a	
quality	of	life	framework.	However,	for	lack	of	reliable	data	on	health	referenced	scores,	we	
propose	a	few	scenarios	and	approximations	in	order	to	assess	the	potential	economic	impact	
of	hearing	loss	in	France.		
	
Investigating	socio-economic	costs	related	to	hearing	loss	(‘economic	burden’),	Shield	(2006),	
the	London	economics/RNID	(2010)	and	Archbold	(2014)	propose	methods	that	we	combine	
according	to	available	data	for	France.	Ideally,	the	main	objective	would	be	to	estimate:		
- Avoidable	health,	social	and	long-term	direct	costs	related	to	hearing	loss;	
- indirect	 costs	 (loss	 of	 productivity,	 selection	 in	 the	 labour	market,	 impact	 of	 noisy	
professional	backgrounds…);	
- a	direct	assessment	of	utility	score	benefits,	or	an	 indirect	assessment	of	 intangible	
costs	–	greater	ones	–	estimated	by	 the	quality	of	 life	degradation	with	or	without	
hearing	 aids.	 Intangible	 costs	 are	 estimated	 on	 the	 whole,	 by	 combining	 average	
quality	of	 life	scores	and	statistical	values	of	human	life,	but	these	methods	remain	
controversial.		
	
In	our	approach,	it	is	obvious	that	a	precise	analysis	of	each	line	is	not	possible.	The	estimation	
that	will	be	proposed	is	therefore	partial	–	not	including	all	the	costs	and	not	assessing	the	
utility	scores	–	and	approximate	(relying	on	a	certain	number	of	assumptions).	It	consists	of	a	
rough	estimate,	to	be	compared	to	other	available	estimations	in	the	literature.	The	first	step	
of	this	economic	reckoning	is	to	give	a	possible	value	for	intangible	costs.		
	
2.2.2.1 Quality	of	life,	preference-based	scores,	QALYs	and	statistical	value	of	a	human	
life:	a	framework		
	
In	 health	 economics,	 cost-utility	 analysis	 consists	 of	 comparing	 at	 least	 two	 strategies	
regarding	their	costs	(direct	medical,	direct	non-medical,	indirect)	and	their	consequences	in	
terms	of	quality	of	life.	Quality	of	life	is	estimated	through	validated	scales;	in	France,	the	HAS	
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suggests	using	either	 the	EQ-5D-3L	 (Euroqol)	or	 the	HUI3	 (Health	utilities	 index	mark	3)82.	
Quality	of	 life	 scores	 are	obtained	 through	a	patient	questionnaire	 and	a	 scoring	 formula.	
Average	scores	–	in	general	–	can	be	reported	on	0-1	scale	(0=state	equivalent	to	death	and	
1=state	equivalent	 to	perfect	health)	which,	when	combined	with	 the	 length	of	 life	 in	 this	
state,	allow	us	to	convert	years	of	life	in	this	state	into	healthy	years	of	life,	with	the	help	of	
QALYs83.		
	
When	there	are	two	strategies	for	which	costs	and	utility	scores	are	assessed,	it	is	possible	to	
compute	the	incremental	cost-utility	ratio	by	comparing	cost	variation	to	utility	variation:	we	
thus	obtain	 the	 cost	 to	 pay	 for	 one	 year	 in	 a	 perfect	 state	of	 health.	 The	 issue	 is	 then	 to	
question	if	this	cost	is	affordable	from	a	social	point	of	view	or	not.	It	depends	on	the	collective	
willingness	to	pay.		
	
The	threshold	for	such	a	willingness	to	pay	for	one	year	in	perfect	health	is	not	revealed	in	
France	by	the	HAS.	However,	it	is	known	for	the	United	Kingdom,	and	this	threshold	ranges	
between	£20,000	and	£30	000,	i.e.	in	euros	€25,840	and	€38,760.	This	threshold	reveals	the	
upper	collective	willingness	to	pay	for	a	year	in	perfect	health	and	has	indeed	a	connection	
with	the	statistical	value	of	a	human	life.	Although	this	range	represents	the	lower	value	class	
for	an	extra	QALY	(Shiroawa	et	al.,	2010),	we	propose	to	take	as	a	reference	€40,00084.	We	
draw	the	reader’s	attention	to	the	methodological	precautions	with	this	assumption,	requiring	
us	to	deduce	the	value	of	statistical	life	(VSL)	from	the	threshold	of	willingness	to	pay	for	one	
additional	QALY	gained	(and	so	on	the	value	of	one	year	of	human	life	VHL)	(Commissariat	
général	de	la	stratégie	et	de	la	prospective,	2013).	As	stated,	the	main	objective	is	to	propose	
a	framework	and	our	assessment	is	based	on	short	periods	of	time	(without	taking	account	of	
value	of	human	life	related	to	age).	Moreover,	we	use	the	assessment	method	found	in	the	
literature,	in	order	to	compare	rough	values	for	lack	of	possibility	to	set	up	a	cost-effectiveness	
analysis.		
	
Economic	evaluations	abound	for	cochlear	implants,	for	which	it	is	possible	to	compare	two	
strategies	(implants	vs	traditional	care)	and	to	infer	an	incremental	cost-effectiveness	ratio	
(cost	variation/utility	variation).	However,	it	is	trickier	to	find	in	the	literature	a	reference	scale	
for	average	utility	scores	related	to	each	age	group	and	each	level	of	hearing	loss	severity,	
especially	 as	 these	 scores	 themselves	 depend	 on	 the	 assessment	 tool	 (EQ-5D,	 HUI3…).	
Therefore,	several	reference	values	have	been	taken	as	references	from	the	study	of	quality	
																																																								
	
82	Cf.	www.euroqol.org	and	www.healthutilitiesindex.com		
83	Example:	if	the	loss	in	utility	associated	with	a	profound	hearing	loss	was	estimated	at	-0.46	over	10	years,	the	
person	would	get	a	score	of	0.54	for	health	state,	so	it	can	be	deduced	that	this	health	state	would	represent	5.4	
QALYs	instead	of	10	QALYs	if	he/she	were	in	perfect	health	(in	other	words,	the	degradation	of	health	state	has	
resulted	in	a	loss	of	4.6	years	in	perfect	health).	If	hearing	aid	equipment	allowed	the	person	a	reduction	in	utility	
loss	with	a	score	of	0.74	(loss:	-0.26)	then	the	person	would	get	a	health	state	estimated	to	be	at	7.4	QALYs	for	
10	years	of	life,	meaning	a	gain	of	2	QALYs	thanks	to	hearing	aids.	In	fact,	this	assessment	should	take	into	account	
the	discount	rate	(time	preference)	but	it	won’t	be	necessary	to	apply	it	in	our	estimation	as	far	as	it	relies	on	
the	economic	burden	in	2014	(one	year).		
84	The	authors	estimated	for	example	the	Australian	threshold	to	be	at	€43,112,	and	the	American	threshold	to	
be	at	€56,374,	but	these	thresholds	would	be	several	million	euros	in	Asian	countries.	Shield	(2006)	has	taken	on	
the	value	of	€44,000,	as	defined	by	the	European	commission	for	the	Environment	in	2003.		
	 81	
of	 life	 led	 by	 Shield	 (2006)85,	 who	 has	 proposed	 a	 frame	 of	 reference	 for	 the	 European	
population	(table	29).		
	
Table	29	–	Frame	of	reference	for	utility	scores	in	hearing	loss	
	
Source:	Authors	on	basis	of	Shield	(2006)	and	applying	a	€40,000	value	for	one	additional	QALY	gained	
	
More	 than	 the	 absolute	 value	 of	 scores,	 these	 score	 variations	 are	 meaningful	 here.	 For	
example,	 if	 we	 were	 applying	 the	 HUI3	 questionnaire	 which	 includes	 a	 question	 directly	
related	to	hearing	dimension:	
- A	person	would	have	a	score	of	0.788	if	he/she	has	declared	no	limitation	other	than:		
o “able	to	hear	what	is	said	in	a	conversation	with	another	person	in	a	quiet	room	
with	a	hearing	aid,	and	able	to	hear	what	is	said	in	a	group	conversation	with	
at	least	three	other	people	with	a	hearing	aid”;	
o “somewhat	happy”.	
	
- As	for	the	EQ-5D-3L	questionnaire,	a	decrease	 in	the	score	would	happen	for	these	
illustrative	cases:	
o A	 person	who	 has	 “some	 problems	with	 performing	 usual	 activities”	would	
have	a	loss	in	their	score	of	0.117	(if	no	other	limitation);	
o A	person	who	declares	 “moderate	pain	or	discomfort”	would	have	a	 loss	 in	
score	of	0.204	(if	no	other	limitation);	
o A	person	who	cumulates	these	two	limitations	would	have	a	 loss	 in	score	of	
0.24	(if	no	other	limitation);	
	
	
2.2.2.2 Annual	cost	of	hearing	loss	(2014)	according	to	the	quality	of	life	perspective		
	
Starting	from	the	data	collected	in	the	first	section	as	well	as	analyses	related	to	economic	
burden	and	quality	of	life,	we	propose	an	estimation	of	the	economic	cost	of	non-equipped	
hearing	loss.		
	
The	components	of	costs	are	tricky	to	evaluate	since	we	do	not	know	direct	medical	and	non-
medical	costs,	including	costs	relating	to	the	social	domain,	nor	do	we	know	the	indirect	costs	
(loss	of	productivity).	As	concerns	the	economic	burden	of	illness,	we	estimate	it	by	quality	of	
life	method.		
	
																																																								
	
85	The	second	estimation	method	consists	of	an	assessment	of	lost	revenues	because	of	hearing	loss.	This	method	
seems	to	be	less	advisable	to	the	extent	that	a	large	proportion	of	hearing	impaired	people	are	older	and	also	
because	this	human	capital	approach	is	less	used.	Moreover,	the	quality	of	life	approach	presents	the	advantage	
of	covering	all	the	dimensions,	including	occupational	ones	(particularly	in	HUI3	questionnaire).		
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This	method	requires	definition	of	the	following	variables:		
- The	French	adult	population	affected	by	hearing	loss	according	to	the	different	levels	
of	severity;	
- The	French	adult	population	who	are	not	hearing	aid	equipped	and	who	should	be	
(eligible	population	but	not	owning	hearing	aids);	
- The	French	adult	population	which	is	equipped	but	not	using	its	hearing	aids;	
- The	quality	of	life	associated	with	the	different	levels	of	severity;	
- The	monetary	value	associated	with	a	healthy	year	of	life.		
	
The	survey	Handicap-Santé	2008	presented	charts	of	hearing	loss	prevalence	according	to	of	
severity	levels,	but	without	releasing	the	precise	occurrences.	As	we	do	not	know	these	values	
by	age	groups,	we	have	retained	those	of	the	1998	survey	in	order	to	estimate	hearing	loss	
prevalence	for	the	adult	population	in	2014	according	to	severity	levels	(remember	that	these	
data	have	remained	steady	over	time,	as	shown	in	the	first	section):		
	
Table	30	–	Reference	rates	for	hearing	loss	prevalence	according	to	severity	levels		
	
Source:	Survey	Handicap	santé	1998	
	
On	the	basis	of	demographic	data	for	the	year	2014	(database	Eco-santé	OCDE),	we	deduce	
headcounts	by	age	groups	in	mainland	‘metropolitan’	France	and	for	all	French	possessions	
(‘the	whole	of’	France)	(table	31).		
	
Table	31	–	Estimation	of	French	adult	population	in	2014	affected	by	disabling	hearing	loss	
(moderate	to	total	AFL	following	the	definition	of	the	DREES	2014)	
	
Source:	Authors,	data	pop.	Eco-Santé	2016,	data	prevalence	HS1998		
	
	
As	mentioned	above,	and	by	hypothesis,	the	average	health	score	for	an	adult	in	Europe	is	
0.85	and:		
- A	moderate	hearing	loss	leads	to	a	0.05	loss	in	utility	(score	of	0.8);	
- A	severe	hearing	loss	leads	to	a	0.15	loss	in	utility	(score	of	0.7);	
- And	a	very	severe	hearing	loss	leads	to	a	0.15	loss	in	utility	(score	of	0.6).		
The	monetary	value	for	a	healthy	year	is	fixed	at	40,000	euros.		
	
If	hearing	impaired	people	in	France	couldn’t	access	any	hearing	aid	equipment	in	order	to	
compensate	for	their	impairment	(i.e.	if	nobody	were	equipped),	intangible	costs	associated	
Prevalence 
rate/1000 
people
Slight to 
moderate
Moderate to 
severe
Very severe to 
total
<20 12.3 0.7 1.3
20-39 18.3 2.7 1
40-59 51.5 17.6 2.8
60-74 157 56.6 8.8
75 and over 229.6 158.7 37.3
Overall 50.4 24.6 5.2
Stat. Eco 
santé year 
2014
Stat. Eco-
santé year 
2014
Group age Moderate Severe
Very severe to 
total
Metrop. 
France
Overall France Moderate AFL Severe AFL
Very severe to 
total AFL 
Moderate AFL Severe AFL
Very severe to 
total AFL 
20 à 39 ans 1.83% 1,0% 0.1% 15 551 014 16 001 614 284 584 155 510 15 551 292 830 160 016 16 002
40 à 59 ans 5.15% 1.76% 0.28% 17 180 853 17 709 879 884 814 302 383 48 106 912 059 311 694 49 588
60 à 74 ans 15.7% 5.66% 0.88% 9 720 665 9 941 571 1 526 144 550 190 85 542 1 560 827 562 693 87 486
75 ans ou plus 22.96% 15.87% 3.73% 5 875 312 5 976 043 1 348 972 932 412 219 149 1 372 099 948 398 222 906
AFL severity
Metropolitan France 2014 - Number of 
people
Overall France 2014 - Number of people
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to	AFL	would	amount	to	23.3	billion	euros	in	metropolitan	France	and	24	billion	euros	for	the	
whole	of	France	(table	32).		
	
Table	32	–	Economic	burden	of	hearing	loss	under	assumption	of	no	hearing	aid	equipment	access.	
	
Source:	Authors.		
	
As	a	comparison,	for	Europe	in	2006,	and	with	a	reference	value	of	€44,000,	the	economic	
burden	of	hearing	 loss	 rose	 to	€284	billion	 (Shield,	2006).	 If	we	don’t	 include	 the	value	of	
Swedish	willingness	to	pay	(€70,000),	the	economic	burden	would	amount	to	41	billion	euros.	
	
It	is	now	possible	to	estimate	the	costs	saved	by	access	to	hearing	aids	in	France.	In	order	to	
start	this	estimation,	let’s	assume	that	equipped	persons	do	not	recover	a	health	state	similar	
to	those	without	hearing	loss,	but	recover	75%	of	the	degraded	quality	of	life.	This	assumption	
should	 be	 linked	 to	 the	 appraised	 satisfaction	 through	 qualitative	 surveys	 (for	 example,	
Eurotrak	2015)	and	 the	 literature	survey.	Let’s	also	assume	that	 the	data	 for	people	being	
equipped	at	every	adult	age	group	in	the	Eurotrak	survey	2015	are	reliable	(these	data	were	
convergent	with	those	of	French	surveys).	These	frequencies	are	represented	in	graph	8.			
	
Graph	8	–	Hearing	aid	access	by	age	groups		
	
Source:	Eurotrak,	2015	
	
Group	ages	only	partially	match	with	those	of	table	32.	Moreover,	we	have	applied	the	rate	
of	29.5%	to	the	age	group	{20-39};	the	rate	of	23.2%	to	the	age	group	{40-59};	and	the	rate	of	
42%	to	the	older	groups.	Table	33	shows	the	gain	obtained	from	actual	hearing	aid	equipment,	
which	would	allow	6.6	billion	euros	of	intangible	costs	to	be	saved:	this	is	the	monetary	value	
associated	to	additional	quality	of	life	gained.	Intangible	costs	amount	to	16.7	billion	euros:	
Severity Moderate AFL Severe AFL
Very severe to total 
AFL
Overall
Metrop. France 4 044 514 1 940 495 368 348 6 353 357
Overall France 4 137 814 1 982 801 375 982 6 496 597
Cost Metrop. France 8 089 027 052 € 11 642 968 837 € 3 683 483 920 € 23 415 479 809 €
Cost Overall France 8 275 628 849 € 11 896 805 719 € 3 759 815 039 € 23 932 249 607 €
Hypothesis : no hearing aid equipment at all in France
27,6% 
23,7% 
35,7% 
29,3% 
29,8% 
23,6% 
21,2% 
39,0% 
30,4% 
30,4% 
29,5% 
23,2% 
42,0% 
33,6% 
34,1% 
0% 10% 20% 30% 40% 50% 
<=44 
45-64 
65+ 
Total 18+ 
Total 
EuroTrak 2015 
Base: 1'548 
EuroTrak 2012 
Base: 1'599 
EuroTrak 2009 
Base: 1'622 
	 84	
this	is	the	loss	in	quality	of	life	related	to	hearing	loss.	In	this	table,	the	line	‘people	not	being	
equipped	with	HA’	includes	not	only	the	population	eligible	for	hearing	aids	but	not	owning	
them	but	also	the	non-eligible	population	for	hearing	aids	(50%	of	hearing	impaired	people).		
	
Table	33	–	Intangible	cost	saved	by	hearing	aid	access		
	
Source:	Authors.		
	
If	France	had	reached	the	target	rate	of	50%	of	hearing	impaired	people	owning	hearing	aids	
(as	in	the	case	of	Denmark	which	covers	the	optimal	rate	of	people),	intangible	costs	saved	
would	be	8.7	billion	euros	(table	34).		and	intangible	costs	would	amount	to	14	billion	euros.	
This	means	that	cost	savings	of	2.1	billion	euros	could	be	gained	by	a	revision	of	access	rules	
to	hearing	aids	in	order	to	reach	the	target	of	50%	(in	the	table,	by	definition,	the	number	of	
non-equipped	people	is	equivalent	to	half	the	hearing	impaired	people).		
	
Table	34	–	Avoidable	intangible	costs	by	an	improvement	in	hearing	aid	access	
	
Source:	Authors.		
	
	
However,	another	 issue	to	consider	 is	compliance.	We	saw	in	the	first	section	that	France,	
together	with	Switzerland,	presented	the	best	performance	in	the	Eurotrak	2015	survey,	with	
a	 low	 rate	 of	 owners	who	were	 non-users	 (10%),	with	 non-use	 defined	 as	 the	 number	 of	
people	owning	hearing	aids	but	not	using	 them	(never	or	 for	 less	 than	one	hour	a	day).	 If	
compliance	 were	 complete,	 this	 would	 reduce	 intangible	 costs	 by	 65	 million	 euros.	 This	
relatively	 low	 gain	 indicates	 the	 performance	 of	 France	 for	 compliance	 and	 it	 might	 be	
considered	as	a	cost	which	cannot	be	reduced.		
	
	 	
Severity Moderate AFL Severe AFL
Very severe to total 
AFL
Overall
Metrop. France 4 044 514 1 940 495 368 348 6 353 357
Not equipped people 2 547 736 1 201 774 224 630 3 974 140
Cost Metrop. France 5 843 860 475 € 8 318 724 136 € 2 605 595 568 € 16 768 180 180 €
Cost savings 2 245 166 576 € 3 324 244 701 € 1 077 888 352 € 6 647 299 629 €
Actual cost savings related to equipment in France (Hypothesis : hearing aid users gain 3/4 utility score)
Severity Moderate AFL Severe AFL
Very severe to total 
AFL
Overall
Metrop. France 4 044 514 1 940 495 368 348 6 353 357
Not equipped people 2 022 257 970 247 184 174 3 176 678
Cost Metrop. France 5 055 641 907 € 7 276 855 523 € 2 302 177 450 € 14 634 674 881 €
Cost savings 3 033 385 144 € 4 366 113 314 € 1 381 306 470 € 8 780 804 928 €
Avoidable cost / target 
50%
-788 218 568 € -1 041 868 613 € -303 418 118 € -2 133 505 299 €
Target for cost savings (Hypothesis : all egilible people is equipped)
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Table	35	–	Avoidable	intangible	costs	by	an	improvement	in	compliance		
	
Source:	Authors.		
	
Hence,	this	cost	reduction	target	relying	on	compliance	improvement	seems	to	be	difficult	to	
meet	 since	 the	French	performance	 is	 in	 itself	 a	 reference	point	 compared	 to	 some	other	
countries	(Norway,	Denmark,	and	the	United	Kingdom).	Conversely,	let	us	study	the	intangible	
costs	 saved	 in	 France	 due	 to	 its	 better	 compliance	 in	 comparison	 to	 these	 countries.	 For	
example,	if	we	take	the	Danish	rate	there	are	20%	of	non-complying	patients:		
	
Table	36	–	Avoided	intangible	costs	in	France	(if	target	50%	was	reached)		
in	comparison	to	the	Danish	compliance	rate	
	
Source:	Authors.		
	
If	in	France	20%	of	patients	were	non-	compliant	(instead	of	10%),	intangible	costs	(or	value	
of	the	loss	of	quality	of	life)	would	be	increased	by	1	billion	euros	if	the	target	‘50%	of	hearing	
impaired	adults	are	equipped’	was	reached.	This	statement	has	to	be	placed	in	perspective	
against	the	analysis	of	health	system	organisation:	free	delivery,	as	in	Denmark,	allows	almost	
total	coverage	for	the	people	eligible	for	equipment.	However,	the	weaker	patient	follow-up	
associated	 with	 this	 free	 delivery	 in	 NHS	 systems	 leads	 to	 a	 loss	 in	 effectiveness,	 which	
translates	into	a	‘loss’	of	hearing	aid	users,	and	so	into	in	additional	intangible	costs.			
	
Therefore,	 it	 is	 necessary	 to	 simultaneously	 support	 hearing	 aid	 access,	 to	 give	 strong	
incentives	to	hearing	aid	professionals	to	improve	the	quality	of	follow-up	services	and	to	give	
strong	incentives	to	patients	to	use	these	follow-up	services.		
	
	 	
Severity Moderate AFL Severe AFL
Very severe to total 
AFL
Overall
Metrop. France 4 044 514 1 940 495 368 348 6 353 357
Not equipped people 2 697 414 1 275 646 239 002 4 212 061
Cost Metrop. France 6 068 377 133 € 8 651 148 606 € 2 713 384 404 € 17 432 910 143 €
Cost savings 2 020 649 919 € 2 991 820 231 € 970 099 516 € 5 982 569 666 €
Avoidable cost / perfect 
compliance
-224 516 658 € -332 424 470 € -107 788 835 € -664 729 963 €
Target for compliance (Hypothesis : all HAs owners are users)
Severity Moderate AFL Severe AFL
Very severe to total 
AFL
Overall
Metrop. France 4 044 514 1 940 495 368 348 6 353 357
Not equipped people with 
Danish values (including 
compliance)
2 426 708 1 164 297 221 009 3 812 014
Cost Metrop. France 5 662 318 936 € 8 150 078 186 € 2 578 438 744 € 16 390 835 866 €
Cost savings / initial 
situation
2 426 708 116 € 3 492 890 651 € 1 105 045 176 € 7 024 643 943 €
Cost savings regarding the 
Danish compliance
-406 058 197 € -501 070 420 € -134 945 660 € -1 042 074 277 €
Cost savings regading the Danish rate for compliance
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2.2.2.3 Additional	health	care	costs	due	to	non-equipped	hearing	loss	and	efficiency	of	
hearing	aids	regarding	eligible	population:	approximations		
	
The	 previous	 scenario	 was	 an	 exercise	 which	 permitted	 the	 estimation	 of	 the	 impact	 of	
hearing	aid	access	and	compliance	on	additional	quality	of	 life	gain,	as	valued	 in	monetary	
terms.	It	is	also	interesting	to	design	an	assessment	scenario	in	order	to	estimate	the	size	of	
hearing	aid	costs,	of	cost	savings	related	to	equipment	and	of	quality	of	 life	benefits.	Once	
again,	we	propose	a	simulation	exercise	relying	on	some	assumptions:	
	
- The	total	number	of	people	affected	by	hearing	loss	(moderate,	severe	and	very	severe	
AFL)	in	2014	is	assessable	on	the	basis	of	prevalence	rates	by	age	groups	in	the	survey	
‘Handicap-Santé	 1998’	 (table	 30)	 and	 on	 the	 estimated	 demographic	 population	 in	
metropolitan	France	in	2014	(Eco-santé	OCDE);	
	
- The	number	of	this	hearing	impaired	population	not	accessing	hearing	aids	is	available	
in	the	Eurotrak	2015	survey,	as	well	as	the	compliance	rate	(10%	of	hearing	aid	owners	
are	not	users);	
	
- The	degradation	of	quality	of	life	according	to	impairment	severity	levels	is	assessable	
on	the	basis	of	Shield’s	references	(2006),	since	they	seem	to	be	reliable	regarding	the	
recent	literature	(table	29);	
	
- Hearing	impaired	people	eligible	for	hearing	aids	but	who	are	not	equipped	is	related	
to	an	additional	cost	in	terms	of	health	care	consumption,	because	of	the	morbidity	
linked	to	hearing	loss.	We	assume	that	this	additional	annual	cost	depends	on	the	AFL	
severity	 and	 we	 retain	 as	 monetary	 values:	 +400	 euros/moderate	 AFL,	 +1,200	
euros/severe	 AFL	 and	 +2,000	 euros/very	 severe	 AFL.	 These	 estimations	 are	 very	
debatable,	 but	 they	 rely	 on	 the	 IRDES	 study	 (Sirven	 and	 Bougueil,	 2016)	 which	
estimated	that	the	additional	health	care	cost	for	frail	people	amounted	to	2,000	euros	
a	person/year.	Moreover,	the	previous	survey	(see	Foley,	2014)	showed	an	increase	in	
health	care	expenditure	for	hearing	impaired	people	ranging	around	+39%	in	contrast	
to	 the	 same	 population	 without	 hearing	 loss:	 in	 France,	 the	 average	 health	 care	
expenditure	per	capita	amounts	to	3,000	euros	beyond	age	of	55,	therefore	an	average	
add-on	of	1,000	euros	relating	to	severe	hearing	loss	seems	to	be	reliable.	Assuming	
that	 this	monetary	add-on	 is	associated	with	 the	higher	 loss	 in	quality	of	 life	 score	
(0.25),	we	can	see	the	values	for	a	0.15	loss	of	utility	(1,200	euros)	and	for	a	0.05	loss	
of	utility	(400	euros).	This	linearity	in	costs	is	also	debatable.	Nevertheless,	taking	into	
account	the	previously	underlined	elements	concerning	hearing	loss	morbidity	effects,	
this	seems	an	appropriate	estimate;	
	
- We	assume	that	the	complying	hearing	aid	users	have	a	lower	loss	in	utility	(this	loss	
is	reduced	by	75%	because	of	satisfaction	linked	to	hearing	aids),	but	as	they	do	not	
return	to	the	same	health	state	as	the	same	people	without	hearing	loss,	we	assume	
that	 additional	 annual	 health	 care	 costs	 are,	 following	 the	 AFL	 severity	 levels:	 100	
euros;	300	euros;	500	euros	(as	a	proportional	reduction	of	health	care	costs	of	75%	in	
relation	to	hearing	impaired	people	who	are	not	equipped);	
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- We	estimate	the	additional	cost	of	hearing	aid	access	and	the	saving	cost	according	to	
population	types	(HAs	owners	and	users/	HAs	not	owners	or	HAs	owners	not	users)	
and	 according	 to	 hearing	 loss	 severity	 for	 the	 French	 population	 if	 the	 equipment	
target	of	50%	was	reached	(that	is	the	whole	eligible	population);	
	
- The	additional	cost	savings	relying	on	optimal	access	are	then	estimated	on	the	basis	
of	these	values,	taking	into	account	non-compliance	(which	is	considered	to	be	non-	
improvable).	 This	 cost	 is	 estimated	 for	 6	 years	 (the	median	 life	 span	 of	 a	 piece	 of	
equipment).	 This	 is	 then	 the	 additional	 health	 care	 cost	 born	 by	 society,	 and	 is	
attributable	to	the	lack	of	hearing	aid	access	for	the	eligible	population.		
	
Thus,	under	these	assumptions,	the	health	care	cost	savings	amounts	to	around	290	million	
euros	for	2014,	that	is,	for	6	years	and	in	constant	euros	without	discounting,	1.7	billion	euros.	
This	 is	 the	morbidity	 cost	 related	 to	 disabling	 hearing	 loss	 that	 could	 be	 saved	 by	 all	 the	
financing	 contributors	 (National	 Health	 Insurance,	 complementary	 health	 insurances	 and	
patients)	if	an	optimal	access	for	hearing	aids	were	implemented	for	eligible	people	(50%	of	
the	 whole	 hearing	 impaired	 population),	 taking	 into	 account	 a	 non-modifiable	 loss	 of	
effectiveness	related	to	a	compliance	rate	of	10%	(hearing	aid	owners	but	non-users).		
	
Next,	the	number	of	people	to	equip	(including	both	compliant	and	non-compliant	groups	as	
it	is	not	possible	to	distinguish	between	them	for	hearing	aid	access)	is	estimated	in	relation	
to	the	target.	We	assess	the	cost	of	hearing	aid	equipment	for	this	eligible	population	(797,461	
people).	On	the	basis	of	our	reference	values	–	the	unit	cost	for	a	hearing	aid	(€1,535),	average	
cost	of	an	initial	ENT	consultation	(€50)	and	annual	battery	cost	(€50/year),	we	can	estimate	
the	 total	 cost	of	hearing	aid	equipment	 for	 this	 additional	population	 for	6	 years	 (median	
lifespan	of	equipment).	This	equipment	cost	would	amount	to	1.5	billion	euros	over	6	years.	
Yet,	this	additional	equipment	cost	would	allow	us	to	avoid	over	the	same	time	(6	years)	1.7	
billion	euros	in	terms	of	health	care	expenditure	(taking	into	account	compliance),	that	is,	a	
saving	of	200	million	euros.		
	
Finally,	we	estimate	the	quality	of	 life	benefits	 for	 this	 fraction	of	people	who	were	newly	
equipped	during	the	6	years	of	equipment,	taking	into	account	compliance	rate	and	the	partial	
recovery	of	quality	of	 life	 for	people	both	equipped	and	compliant.	This	utility	gain	would	
range	around	48,000	QALYs	for	685,817	people.		
	
Under	all	these	assumptions:		
- The	total	cost	of	equipment	for	eligible	hearing	impaired	persons	(compliant	or	not),	
estimated	to	be	1.5	billion	euros	and	linked	to	a	benefit	of	48,000	QALYs	(for	compliant	
users),	leads	to	an	incremental	cost-effectiveness	ratio	of	€5,462/QALY.	It	means	that	
a	cost	of	€5,219€	gains	one	healthy	year,	which	is	a	ratio	largely	below	the	previous	
thresholds	of	willingness	to	pay.	Even	if	the	gain	in	quality	of	life	were	markedly	lower	
(for	example,	5	 times	 lower),	 this	 ratio	would	deserve	be	considered	as	a	 trade-off	
regarding	these	thresholds	(€26000/QALY);		
	
- If	we	compare	the	net	differential	cost	(additional	cost	of	equipment	minus	health	care	
cost	 savings),	 the	 incremental	 cost-effectiveness	 ratio	 (ICER)	 would	 be	 equal	 to	 -
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€830/QALY:	 in	other	words,	 the	target	strategy	of	 ‘all	eligible	people	are	equipped’	
saves	costs	and	provides	an	increased	quality	of	life,	and	is	thus	the	dominant	strategy.		
	
Under	which	assumptions	would	the	target	strategy	of	‘all	eligible	people	are	equipped’	be	
rejected?	It	would	be	the	case	if	either	the	increase	in	QALYs	gained	was	5	times	less	than	in	
this	case	study	(that	is	an	unlikely	situation	given	the	literature	on	the	association	between	
hearing	loss	and	morbidity	and	regarding	the	low	score	variations	of	utility	employed	in	the	
case	 study),	 or	 if	 the	 additional	 costs	 related	 to	 hearing	 loss	 (in	 terms	 of	 health	 care	
expenditure	impact)	were	much	lower:		
- If	we	halve	the	health	care	cost	reference	values	for	all	severity	levels	(that	is	€200;	
€600;	 €1,000	 for	 people	 being	 not	 equipped	 and	 €25;	 €75;	 €125	 for	 people	 being	
equipped)	the	ICER	would	amount	to	€9,759/QALY.		
- The	ICER	would	amount	to	€9,085/QALY	with	the	cost	reference	values	of	€0;	€600;	
1,000€	for	people	being	not	equipped	and	€0;	€150;	€250	for	people	being	equipped).		
Even	under	relaxed	assumptions	about	the	health	care	costs	for	a	hearing	impaired	person	
not	being	a	hearing	aid	owner,	the	ICER	remains	socially	acceptable.		
	
Beyond	assumptions	relating	to	this	simulation	exercise,	it	should	be	noted	that	we	have	not	
provided	 an	 estimation	 for	 indirect	 costs	 (for	 example,	 the	 impact	 of	 hearing	 loss	 on	
productivity)	or	social	costs	linked	to	dependency.	These	dimensions	would	raise	the	total	cost	
savings.		
	
This	entire	case	study,	which	relies	on	acceptable	assumptions,	underlines	the	requirement	
for	a	substantial	economic	assessment	that	would	corroborate	these	results,	that	is	the	highly	
efficient	target	strategy	that	‘all	eligible	hearing	impaired	people	are	equipped’.		
	
However,	 it	remains	to	solve	the	touchy	question	of	hearing	aid	financing	 likely	to	support	
access	to	them,	and	especially	the	question	of	the	relative	financial	contributions	of	payers,	
as	seen	 in	the	first	section	of	the	report.	Moreover,	 if	 the	National	Health	 Insurance	could	
greatly	increase	its	financial	role	in	hearing	aid	reimbursement,	we	would	anticipate	a	bounce	
effect	 for	 people	 being	 equipped	 but	 having	 postponed	 hearing	 aid	 renewing.	 This	 effect	
would	inevitably	increase	the	budget	impact	of	hearing	aid	access.		
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Table	37	–	Scenario	for	an	economic	assessment	of	the	strategy	‘all	eligible	hearing	impaired	people	are	
equipped’	
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3 Conclusion	
	
This	overview	of	hearing	loss	and	hearing	aid	access	in	France	emphasizes	four	main	lessons,	
in	the	light	of	international	comparisons	and	of	medical	scientific	literature:		
	
1) Disabling	 hearing	 loss	 (or	 moderate	 to	 total	 auditive	 functional	 limitations),	 by	
reducing	 the	person’s	 communication	 capacities,	 rebounds	 significantly	 on	broader	
dimensions	 of	 health	 state	 (mobility,	 autonomy,	 daily	 activities,	 pain/discomfort,	
anxiety/depression)	 through	 a	 succession	 of	 chain	 reactions,	 the	 main	 ones	 being	
social	isolation,	cognitive	decline,	suffering	at	work,	mental	troubles	and	falls.	Hearing	
loss	represents	a	major	impairment	which,	by	affecting	more	than	six	million	French	
(often	older)	people,	not	only	has	deleterious	effects	on	quality	of	life	but	also	leads	
to	additional	health	and	social	care	expenditures	for	society	as	a	whole;	
	
2) The	 health	 policy	 for	 secondary	 prevention,	 that	 could	 consist	 of	 screening	 and	
equipping	hearing	impaired	people	with	hearing	aids,	is	non-existent	regarding	public	
reimbursement.	National	Health	 Insurance,	 by	 covering	 only	 8%	of	 the	 hearing	 aid	
price	 for	 adults,	 has	 almost	 excluded	 hearing	 loss	 from	 its	management	 policy	 for	
health	 risk,	 leaving	 the	out-of-pocket	payment	 to	 complementary	 insurance	bodies	
and	above	all	to	patients.	In	fine,	families,	close	relatives	and	the	whole	society	bear	
the	costs	of	this	impairment,	as	well	as	for	the	loss	of	autonomy	since	one	third	of	the	
eligible	population	for	hearing	aids	don’t	get	them.	Moreover,	inequalities	relating	to	
the	 rights	 of	 those	 insured	 with	 complementary	 health	 bodies,	 their	 revenue	 and	
ability	to	pay	for	equipment	contribute	to	maintain	these	social	inequalities	in	health,	
by	the	renouncement	effect.		
	
3) As	concerning	payment	schemes	 for	hearing	aid	professionals,	 reflection	must	 take	
place	as	their	effectiveness.	In	order	to	regulate	the	hearing	aid	sector	and	to	design	
an	incentive	payment	for	hearing	aids,	a	trade-off	is	necessary	between	the	objectives	
of	expenditure	control,	health	care	quality	and	freedom	of	choice;	this	must	take	place	
in	a	hypothetic	framework	which	assumes	a	higher	coverage	of	hearing	aids.	There	are	
many	tools	which	would	allow	us	to	find	the	optimal	trade-off	for	public	financing,	but	
we	must	be	very	cautious	about	the	issue	of	a	possible	decoupling	of	the	device	and	the	
service.	This	decoupling	model	brings	up	adverse	effects	which	are	similar	to	those	of	
‘cost-plus’	payment,	leading	to	increasing	prices	and	putting	patients’	compliance	at	
stake,	that	is	the	therapeutic	efficiency	of	hearing	aids	for	some	patients.	At	the	same	
time,	recourse	to	prospective	payment	systems	is	increasingly	implemented	for	pricing	
in	health	systems,	and	as	growing	attention	 is	paid	to	patients’	empowerment,	 this	
concept	of	divisibility	of	device/service	falls	into	an	old-fashioned	economic	approach	
in	 terms	 of	 optimal	 incentives.	 International	 comparisons	 highlight	 the	 impact	 of	
coverage	and	health	care	organisation	on	hearing	aid	access,	equipment	renewal	and	
patients’	compliance.		
	
4) The	imperative	revision	of	coverage	rules	for	hearing	aids	in	France	has	to	take	into	
account	not	only	the	incentives	of	payment	schemes	for	hearing	aid	professionals,	but	
also	cost-effectiveness	studies	which	shed	light	on	the	evidence	regarding	expected	
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service	of	hearing	aids.	By	intuition,	this	expected	service	is	at	least	‘important’,	even	
extremely	so:	
	
- Adult	 hearing	 aid	 owners	 –	 that	 is	 two	 thirds	 of	 the	 eligible	 population	 for	
equipment	–	by	paying	out	of	their	own	pocket	950	euros	(one	ear)	to	1,900	euros	
(two	ears),	purchase	the	equipment	despite	the	financial	charge,	which	indicates	
the	nature	of	the	benefit	(fundamental	one);		
- The	 medical	 scientific	 literature	 unambiguously	 reports	 the	 negative	 waterfall	
effects	of	hearing	loss,	but	also	show	the	beneficial	effects	of	hearing	aid	access	(at	
least	on	cognitive	decline	and	mental	health,	since	the	systematic	reviews	on	this	
topic	are	expected	for	2016);	
- The	 simulation	 exercise	 of	 the	 cost-utility	 ratio	 that	 has	 been	 proposed	 in	 this	
report,	although	relying	on	simplistic	assumptions,	gives	some	approximate	values	
that	 lead	 one	 to	 believe	 in	 the	 efficiency	 hearing	 aid	 strategy,	 and	 even	 in	 a	
dominant	hearing	aid	strategy	for	society	as	a	whole.		
	
These	four	main	lessons	lead	to	some	proposals	for	the	regulation	of	the	hearing	aid	sector	in	
France:		
	
§ To	reinforce	public	authorities’	 information	at	all	decision	making	levels	of	the	
health	system	on	the	burden	of	hearing	loss:		
-	 on	 the	 basis	 of	 a	 systematic	 review	 of	 the	 medical	 and	 economic	 scientific	
literature;	
-	 through	 prospective	 cost-efficiency	 assessments,	 by	 collecting	 useful	 data	 in	
sequential	or	regular	surveys	based	on	the	working	and	older	population,	in	order	
to	infer	the	differential	cost-utility	ratio	between	strategies;	
-	by	estimating	the	budget	impact	of	hearing	aid	equipment	depending	on	several	
coverage	scenarios	from	the	National	Health	Insurance’s	point	of	view.		
	
§ Before	health	care	demand:		
-	 inform	 the	 whole	 population	 on	 the	 consequences	 of	 noise	 exposure	 and	
presbycusis;	
-	to	reform	access	rights	for	hearing	aids	independently	of	status	considerations	
(illness,	 impairment,	old	age)	 in	order	to	set	up	a	 level	playing	field	for	hearing	
impaired	people	in	France.		
	
§ Following	health	care	demand:		
-	To	ensure	a	sufficient	coverage	of	needs	with	a	refunding	of	cheaper	equipment,	
on	 the	basis	of	a	prospective	 fixed	price	and	a	minimum	 length	of	use,	and	 let	
willing	patients	pay	for	their	own	free	choice	in	the	face	of	differentiated	devices,	
following	the	principle	of	the	responsibly	fixed	tariff	applied	to	drugs	in	France;	
-	 To	 inform	 people	 who	 need	 equipment	 about	 the	 expected	 service	 for	 the	
different	types	of	hearing	aids,	by	disassociating	common	and	recognised	qualities	
in	auditive	rehabilitation	from	comfort	options;	
-	To	assess,	from	the	National	Health	Insurance	point	of	view,	the	budget	impact	
related	to	reimbursement	rules	revision,	 including	not	only	eligible	people	who	
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are	not	hearing	aid	owners	but	also	remediation	behaviour	for	people	equipped	
for	more	than	six	years.		
	
§ Before	health	care	supply:		
-	 To	 link,	 using	 appropriate	 incentives,	 networks	 of	 general	 practitioners	 and	
occupational	 health	 doctors	 in	 a	 secondary	 prevention	 campaign	 in	 real-time,	
during	medical	consultations	of	people	at	the	end	of	their	active	life,	aged	60-65.	
This	 screening	 could	 be	 carried	 out	 with	 little	 costs	 on	 the	 basis	 of	 a	 short	
questionnaire	comprising	two	questions	that	allow	easy	identification	of	hearing	
loss	occurrence.		
	
§ Following	health	care	supply:	
-	To	maintain	 the	principle	of	a	prospective	payment	–	 for	which	 the	 incentive	
properties	are	well-known	–	 for	hearing	aid	professionals,	 in	order	 to	promote	
both	expenditure	control	and	health	care	quality,	then	to	promote	the	compliance	
and	therapeutic	efficacy	of	hearing	aids	for	all	patients,	whatever	their	capability	
to	pay.			
	
These	overall	suggestions	have	found	their	justification	in	the	analytical	survey	of	the	recent	
literature	presented	in	this	report.	They	impose	the	need	for	an	urgent	examination	of	the	
regulatory	rules	for	the	hearing	aid	sector	in	France,	at	a	moment	where	ageing,	and	listening	
to	amplified	music	among	the	young	risks	contributing	to	aggravated	hearing	loss	prevalence	
in	France.		
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